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Abstract 
 
 
 
Glycosylation is a complex yet common form of post-translational protein/lipid modification 
in the eukaryotic cells. It is processed by glycosyltransferases (GTs), a large group of 
enzyme, that are involved in the biosynthesis of glycoprotein and glycolipid sugar chains. 
Moreover, carbohydrates represent major components of the outer surface of mammalian 
cells and there is now abundant evidence that terminal glycosylation sequences are 
involved in adhesion, immune response, and neuronal outgrowth events. Sialylated 
oligosaccharide sequences have long been predicted to be information – containing 
molecules and critical determinants, e.g. in cell-cell recognition processes, cell-matrix 
interactions and maintenance of serum glycoproteins in the circulation. Enzymes 
responsible for the terminal sialylation are sialyltransferases (STs), a subset of the GT 
family that use CMP-NeuNAc as the activated sugar donor to catalyze the transfer of sialic 
acid residues to terminal non-reducing positions of oligosaccharide chains of glycoproteins 
and glycolipids. 
The Myelin-Associated Glycoprotein (MAG), expressed in myelin of the central and 
peripheral nervous system, has been identified as one of the neurite outgrowth-inhibitory 
proteins, together with Nogo-A and the oligodendrocyte myelin glycoprotein (OMgp). 
Among all MAG physiological ligands, i.e. brain gangliosides, the GQ1bα is the most 
potent natural ligand identified so far. Moreover, only the sialic acid containing part of the 
whole GQ1bα molecule was shown to be important for MAG binding. Therefore, we 
decided to use a chemo-enzymatic approach for syntheses of the GQ1bα mimetics. For 
that purpose we expressed recombinant eukaryotic rST3Gal III (EC 2.4.99.6) and hST6Gal 
I (EC 2.4.99.1), and recombinant prokaryotic Campylobacter jejuni α-2,3/2,8 bifunctional 
sialyltransferase (Cst-II) using different expression systems. The enzymes were purified 
and biochemical characterized towards several natural and non-natural acceptor 
substrates, and used for the preparative chemo-enzymatic synthesis of different 
carbohydrate structures, e.g. [NeuNAcα(2,8)]NeuNAcα(2,3)Galβ(1,3)GlcNAc-β-OLem; 
NeuNAcα(2,3)Galβ(1,4)GlcNAc-β-OLem; NeuNAcα(2,3)Galβ(1,4)Glc-β-OLem;). 
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1 Introduction 
 
 
 
1.1 The carbohydrates 
Carbohydrates represent major components of the outer surface of mammalian cells. 
There is now abundant evidence that terminal glycosylation sequences are differentially 
expressed in cells and are subject to change during development, differentiation and 
oncologic transformation [1-10]. 
Many different theories have been advanced concerning the biological role of the 
oligosaccharide units of individual classes of glycoconjugates. The ability to accurately 
sequence the oligosaccharide units of glycoconjugates has revealed a remarkable 
complexity and diversity. However a single common theory has not emerged to explain 
this diversity [11]. 
The importance and biological role of the oligosaccharides was presented in number of 
monographs and review articles. These include a purely structural role in respect to 
conformation and stability of proteins, the provision of target structures for 
microorganisms, toxins and antibodies, the masking of such target structures, the control 
of the half life of proteins and cells, the modulation of protein functions, and the provision 
of ligands for specific binding events mediating protein targeting, cell-matrix interactions or 
cell-cell interactions [11]. The covalent addition of sugars to proteins is one of the major 
biosynthetic functions of the ER. The oligosaccharide could be transferred to the side-
chain amide group of asparagine in tripeptide consensus sequence Asn-Xaa-Ser/Thr, i.e. 
N-linked or asparagine-linked glycosylation or to the side-chain OH group of 
serine/threonine, i.e. O-linked glycosylation. 
Recently, the correlation of glycosyltransferases (GTs), more precisely, sialyltransferase 
expression with cancer formation was presented [5]. Thus, the up-regulation of a 
sialyltransferase in a cancer cell might indicate that a specific signaling pathway has been 
activated. An example is provided by the up-regulation of ST6Gal I by ras oncogene 
overexpression [12]. Distinct carbohydrate structures and antigens can be formed by 
coordinated expression of several GTs. For instance, carbohydrate structures containing 
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GalNAc or Galβ(1,3)GalNAc disaccharide O-glycosidically linked to serine or threonine, as 
well as their sialylatable forms (Table 1.1) are collectively referred to as Thomsen-
Friedenreich-related antigens (TF antigens). The biosynthesis of these and other simple 
O-linked structures depend on the expression of different GTs and has often been 
correlated with cancer prognosis [5]. 
Table 1.1 The names and structures of some common oligosaccharide structures used from 
distinct glycosyltransferases. 
Name Functional structure 
Type I Galβ(1,3)GlcNAc-R 
Type II Galβ(1,4)GlcNAc-R 
Type III Galβ(1,3)GalNAc-R 
Sialyl-Tn antigen NeuNAcα(2,6)GalNAc-O-Ser/Thr 
Sialyl-T antigen NeuNAcα(2,3)Galβ(1,3)GalNAc-O-Ser/Thr 
Sialyl-Lewisa NeuNAcα(2,3)Galβ(1,3)[Fucα(1,4)]GlcNAc 
Sialyl-Lewisx NeuNAcα(2,3)Galβ(1,4)[Fucα(1,3)]GlcNAc 
 
1.2 The eukaryotic glycosyltransferases 
Glycosylation is a complex yet common form of post-translational protein/lipid modification 
in cells. Glycosyltransferases (GTs) constitute a large group of enzyme that are involved in 
the biosynthesis of glycoprotein and glycolipid sugar chains [13,14]. The GTs catalyze 
transglycosylation reactions where the monosaccharide component of a high-energy 
nucleotide sugar donor (e.g., GDP-Fuc or CMP-NeuNAc) is transferred to an acceptor 
(Figure 1.1). The acceptor molecules for most GTs are usually oligosaccharides 
themselves (Table 1.1). 
It has been estimated that more than 100 distinct glycosidic linkages are present in the 
glycoconjugate repertoire of vertebrate species. Furthermore, it appears that there are at 
least several hundred different GT loci in the genome of vertebrates [13,15]. Most of 
eukaryotic GTs are found within the endoplasmic reticulum and Golgi apparatus [16]. The 
GTs are a very large family of enzymes of ancient evolutionary origin [17,18]. These 
enzymes are typically grouped into families based on the type of sugars they transfer (i.e. 
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Dolichol-P-(Glucose3-Mannose9-N-acetylglucosamine2)  
 
Figure 1.1 (a) Schematic illustration of the reaction catalyzed by human α-1,3-fucosyltransferase 
V. The enzyme can utilize both uncharged structures such as N-acetyllactosamine (LacNAc) or 
charged structures such as sialyl-LacNAc [20]. (b) Glycosyltransferases utilize a glycosyl donor 
and an acceptor substrate. Glycosyl donors include nucleotide sugars and dolichol-phosphate-
linked mono- and oligosaccharides. Acceptors are most commonly oligosaccharides or rarely 
monosaccharides. Proteins and ceramides are also acceptors for the glycosyltransferases that 
initiate glycoprotein and glycolipid synthesis. 
 
Glycoprotein synthesis can require an initiating attachment of a single monosaccharide to 
a threonine or serine residue (O-glycosylation) and asparagine residue (N-glycosylation) 
[21]. In this instance, a protein serves as the acceptor substrate. Finally, glycolipid 
biosynthesis begins with a galactosyltransferase or glucosyltransferase that utilizes a 
ceramide as an acceptor molecule. There are, of course, other GTs in Nature that are not 
involved in glycan biosynthesis, such as those involved in forming small sugar glycosides 
(e.g., in the detoxification of drugs by glucuronidation). 
 
1.2.1 Sequential glycosyltransferase action 
Glycosyltransferases act sequentially, such that the oligosaccharide product of one 
enzyme yields a product that serves as the acceptor substrate for the following action of 
other GTs, a characteristic known as “cooperative sequential specificity” [17,22]. The final 
result is a linear and/or branched polymer composed of monosaccharides linked to one 
another specifically [22]. This precision is a result of the very narrow acceptor substrate 
specificity exhibited by most GTs. A central dogma of glycobiology, concerning virtually all 
known vertebrate GTs, is that each glycosidic linkage is the product of a single enzyme. 
This is known as “one (glycosidic)-linkage, one enzyme” principle [17]. 
The “one (glycosidic)-linkage, one enzyme dogma” has several exceptions, i.e. it is 
becoming clear that a specific glycosidic linkage may actually be the product of one of 
several structurally and genetically related enzymes, that a few GTs (e.g., Cst-II) can 
synthesize two different glycosidic linkages, and that the acceptor specificity of an enzyme 
can be modified by another protein (e.g., α-lactalbumin) [23,24]. 
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galactosyltransferases, sialyltransferases etc.). The GT families that received the most 
attention are those that add terminal sugars to glycoconjugates and that therefore play 
major roles in recognition and signaling events, i.e. sialyltransferases and 
fucosyltransferases. Also of importance are the polypeptide: N-
acetylgalactosaminyltransferases that initiate mucin-type O-glycosylation. Despite the fact 
that many GTs recognize identical donor and acceptor substrates, few regions of enzyme 
homology have been found among the different classes of eukaryotic gylcosyltransferases. 
Therefore, the enzymes that are structurally related most often catalyze the same or 
similar reaction [19]. 
O
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Glycosyl donors Glycosyl acceptors 
CMP-Sialic acid (CMP-NeuNAc) Oligosaccharides 
GDP-Fucose Monosaccharides 
GDP-Mannose Proteins 
UDP-Galactose Lipids (Ceramides) 
UDP-N-Acetylgalactosamine  
UDP-N-Acetylglucosamine  
UDP-Glucose  
UDP-Glucuronic acid  
UDP-Xylose  
Dolichol-P-Glucose  
Dolichol-P-Mannose  
a 
b 
FucT V 
Lewisx LacNAc 
FucT V 
Sialyl-LacNAc Sialyl-Lewisx GDP-β-L-fucose 
+  GDP 
+  GDP 
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In a few cases, the underlying protein is known to specifically dictate the action of a 
particular GT (e.g., glycoprotein glucosyltransferase). 
 
1.2.2 Recombinant DNA technology of the glycosyltransferase gene 
The problem in molecular cloning of GTs can be explained by the fact that these enzymes 
are often extraordinarily difficult to purify in quantities sufficient to obtain protein sequence 
information or to generate specific antisera [16,17]. Subsequently, it has become possible 
to clone new GT loci using low-stringency cross-hybridization approaches, and methods 
involving PCR with primers derived from conserved sequences among members of a GT 
gene family [15,17,18,25-27]. Recently, expressed sequence tag (EST) databases have 
served as a rich source for finding new GTs. 
 
1.2.3 Primary sequence and secondary structure similarity of 
glycosyltransferases 
Cloned GTs clearly show similarity in the nucleotide sequence within members of some 
enzyme families [27]. However, there is relatively limited homology between members of 
different families [13,28]. These observations imply that the different GT families are 
evolutionarily very ancient and that there have been strong selection pressures 
maintaining sequence similarities within families [17,18]. Sensitive hydrophobic cluster 
analysis (HCA) of sequence similarities within families has yielded a few shared amino 
acid sequence motifs [29-31]. The first of these recognized were the "sialyl motifs" that are 
shared among different sialyltransferases [27]. 
Despite the lack of sequence homology between different families of GT, almost all of the 
Golgi enzymes do share some secondary features [17]. Early studies of the cell biology 
and biochemistry of vertebrate GTs indicated that some GT could be found as soluble 
forms in secretions and body fluids (e.g., blood, lymph, breast milk, colostrums etc.); 
others were identified as membrane-bound GTs within cells, whereas some GTs exhibited 
both properties [17,32].  
Golgi GTs share a common secondary structure: a single transmembrane domain flanked 
by a short amino-terminal domain and a longer carboxy-terminal domain. This structure is 
characteristic of type II transmembrane proteins consisting of a short amino-terminal 
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cytoplasmic domain followed by a transmembrane domain (TMD), a proteolytically 
sensitive “stem” region, and a large globular catalytic domain facing the luminal side of the 
Golgi apparatus (Figure 1.2) [17,18]. The large carboxy-terminal domain corresponds to 
the catalytic domain of the GT [13,32]. The intraluminal location of this domain allows it to 
participate in the synthesis of the growing glycans displayed by glycoproteins and 
glycolipids during their transit through the secretory pathway [33,34]. 
TMD

Stem region
Golgi lumen
Cytoplasm
NH2
Catalytic domain
 
Figure 1.2 Topology of Golgi resident glycosyltransferases. TMD corresponds to the 
transmembrane domain. Stem region sensitive to proteolytical cleavage generated by cathepsin-
like proteases (). 
 
Many Golgi enzymes are secreted by cells as soluble or membrane-bound proteins. 
Soluble forms are derived from membrane-associated forms by virtue of one or more 
proteolytic cleavage events which occur in the “stem region” [17,32]. These proteolytic 
cleavage events release a catalytically active fragment of the GT from its transmembrane 
tether and allow the cell to export this fragment to the extracellular milieu [32]. The nature 
of the signals within the GT sequence that direct proteolysis is not defined, but it appears 
that the proteolytic cleavages are relatively specific and are generated by certain 
cathepsin-like proteases functioning in the trans Golgi apparatus [13,32,35,36]. The 
production of these soluble form of GTs from cell types such as hepatocytes and 
endothelial cells can also be dramatically up-regulated under certain inflammatory 
conditions [35]. Since these circulating enzymes do not have access to adequate 
concentrations of donor sugar nucleotides, which are primarily inside cells, they are 
functionally incapable of carrying out a transfer reaction. 
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1.2.4 Topogenesis and intracellular transport of glycosyltransferases 
Studies concerning biochemical analysis of the cell indicate that GTs partially segregate 
into distinct compartments within the secretory ER-Golgi pathway, i.e. enzymes acting 
early in glycan biosynthetic pathways have been localized to cis-Golgi network and cis and 
medial cisternae of the Golgi, whereas enzymes acting later in the biosynthetic pathway 
tend to colocalize in the trans-Golgi cisternae and the trans-Golgi network (TGN) [37-42]. 
The transport of proteins through the Golgi compartments is mediated by transport 
vesicles and involves complex budding and fusion events [43-45]. These observations 
have encouraged extensive exploration of the mechanisms whereby GTs achieve this 
compartmental segregation [38,46]. Unlike the carboxy-terminal tetrapeptide KDEL 
associated with the ER-protein retention and retrieval signal, “Golgi retention motif” for 
distinct GTs are located within the cytoplasmic and transmembrane domains [13,38,46-
48]. Most information relevant to retention of GTs within specific Golgi compartments 
derives from experiments done with α-2,6 sialyltransferase (ST6Gal I), a β-1,4 
galactosyltransferase (GalT I), and an N-acetylglucosaminyltransferase I (GlcNAcT I). The 
first two enzymes tends to concentrate in the trans-Golgi compartments and the trans-
Golgi network, whereas GlcNAcT I localizes mostly to the medial-Golgi compartment 
[48,49]. 
Two types of models were proposed to explain retention of different GTs in specific Golgi 
subcompartments. The first model, the oligomerization/kin recognition model is based on 
retention of Golgi proteins through oligomerization and their inability to enter a transport 
vesicles destined for the next secretory pathway compartment, and the second model, the 
bilayer thickness model which postulates retention through differences in membrane 
thickness along the exocytic pathway [48-50]. 
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1.2.5 Regulation of glycosyltransferase gene expression 
Apart from the Golgi factors that can regulate GT functions, their actual expression can be 
controlled at the level of mRNA synthesis or turnover. The level of protein and activity is 
often directly correlated with the level of mRNA [17]. Studies have indicated that although 
the expression patterns of some glycosyltransferase mRNAs are highly regulated in a 
tissue-specific and developmental manner, others have a widespread so-called 
"housekeeping" type of distribution [17]. Examples of both can be found within any given 
family of enzymes. For the most part, it appears that differential regulation is due to the 
action of specific promoter regions in the 5’ region of the corresponding genes [51]. In the 
case of some genes (e.g., ST6Gal I), there is evidence for multiple tissue-specific 
promoters that are activated under different biological circumstances [52]. 
 
1.2.6 Glycosyltransferases as glycoproteins 
Many Golgi GTs have consensus N-glycosylation sequences, as well as serine and 
threonine residues that could be modified by glycosylation processes [13,17]. Biochemical 
analyses indicate that many mammalian GTs are indeed post-translationally modified by 
glycosylation, especially N-glycosylation [38]. Glycosylation is required for proper folding 
and/or activity, and limited studies indicate that GTs are also subject to "self-glycosylation" 
and that their activity could be modified and regulated by phosphorylation [53,54]. 
 
1.2.7 The catalytic domain: structure and mechanism 
For many years, the knowledge of the mechanism of action of GTs was hampered by the 
lack of 3D-structures particularly of eukaryotic GTs. The first X-ray crystal structure to be 
solved was the β-glucosyltransferase of phage T4, in 1994 [55]. In the past two years, 
seven crystal structures of GTs from prokaryotes and eukaryotes have been determinated. 
Furthermore, comparison of crystal structures revealed that GTs are probably comprised 
of an unexpected small number of protein folds. Although belonging to different GT 
families showing no primary sequence identity, the various 3D structures reported to date 
share a similar class of fold, consisting in the three-layer α/β/α sandwich that resembles 
the “Rossmann fold”. On a structural basis, these GT structures have been classified into 
two distinct superfamilies. The so-called GTA (glycosyltransferase A) superfamily is 
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composed of α/β proteins with a single Rossmann domain [56], a conserved DXD motif 
and two closely associated domains forming a conical shape with a large active site cleft 
on one face capable to accommodate both the donor and acceptor substrate [57-59]. The 
GTB (glycosyltransferase B) superfamily includes α/β proteins (e.g. β-GlcT and β4-
GlcNAcT) comprising two similar Rossmann domain separated by a deep substrate-
binding cleft [60,61]. The DXD motif is known to coordinate with two valencies of the cation 
(see below) involved in binding of the nucleotide sugar through interaction with the 
diphosphate moiety [62,63]. The metal cofactor is generally considered as a Lewis acid 
catalyst in the reaction mechanism by stabilization of the leaving nucleoside diphosphate. 
Mutagenesis studies of the conserved Asp (D) residue in the DXD motif of 
glysosyltransferases from various species have shown that the removal of the Asp 
residues, and hence the metal ions, completely eliminates the transferase activity [62-66]. 
Most glycosyltransferase-dependent transglycosylations involve a 2+ charged cation as 
cofactor (typically Mg2+ or Mn2+), and the enzymes tend to be most active in the pH range 
of 5.0 to 7.0, which reflects pH values found in various parts of the ER-Golgi-plasmalemma 
pathway. GTs typically exhibit Michaelis-Menten constants (KM) for nucleotide sugar 
substrates in the low micromolar range, when assayed in vitro. In general, KM values for 
acceptor substrates observed in vitro can vary dramatically for different enzymes, ranging 
from low micromolar values to low millimolar values [18]. However, in vitro assays are not 
likely to faithfully represent circumstances found in the subcellular compartments of the 
ER-Golgi pathway, in vivo function of these enzymes [18]. Moreover, these assays often 
utilize acceptor analogs composed of only a small portion of the physiological substrate. 
For these reasons, in vitro acceptor KM data in the literature may not reflect actual affinities 
for the natural substrates [67]. For most GTs, specific recognition of the acceptor covers 
only one or a few monosaccharide units or another residue, such as a lipid or an amino 
acid [14,68,69]. 
The catalytic sites of most GTs face the lumen of various compartments in the Golgi 
apparatus, and the low-molecular-weight sugar nucleotide-donors are made in the cytosol 
[34]. Several factors can regulate the action of each Golgi GT, including the intraluminal 
concentration of the sugar nucleotide donor resulting from donor transport, the presence of 
specific sugar nucleotide degrading enzymes, competition by other GTs for the same 
donors or acceptors, the intraluminal concentration of the acceptors, the intraluminal pH, 
and the time taken for passage of the acceptor molecule through a given Golgi 
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compartment. In an intact cell, many or all of these factors may affect the final structures of 
the glycans synthesized on a given glycoconjugate that is passing through the Golgi 
apparatus [17,34]. 
Concerning the mechanism of GTs catalytic reaction, there are two mechanisms proposed 
for the GTs using sugar nucleotides as a donor substrate. Based on the stereochemistry of 
the glycosidic bond formed at the C1 position of the sugar donor, two types of GTs can be 
distinguished: inverting and retaining stereochemistry at the anomeric center (Figure 1.3) 
[31]. 
 
O O
UDP
B- B
+ UDP
RETAINING
A-A-
O O
O
B- B
A-A
H O
RH R
 
Figure 1.3 The two mechanisms proposed for glycosyl transfer from sugar nucleotides. (a) In the 
inverting mechanism, a single nucleophilic substitution at the anomeric carbon of the donor leads 
to the formation of a β-linkage from an α-linked donor; ROH represents the acceptor, and B 
represents the catalytic base. (b) The retaining mechanism involves the transient formation of a 
glycosyl enzyme complex and a subsequent substitution by the acceptor. The two nucleophilic 
substitutions at the sugar anomeric carbon result in the formation of an α-linkage from an α-linked 
donor; ROH represents the acceptor, A represents the catalytic base, and B represents the 
nucleophile [31]. 
 
Retaining GTs result in glycosidic bonds with stereochemistry identical to that of the 
glycosyl donor, whereas inverting enzymes produce glycosidic bonds of the opposite 
stereochemistry [28,31]. Among the GTs analyzed, catalysis necessarily takes place by an 
“inversion” mechanism, as the donor substrates used in these reactions are α-linked sugar 
nucleotides (e.g., UDP-glucose, UDP-N-acetylglucosamin etc.) from which the sugar is 
transferred to the acceptor molecule forming a β-linked product. Concerning our work, next 
b a 
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H
O
R
B- B
H
INVERTING
+ UDP
 
 11
chapter will be related to one of the inverting enzymes, i.e. sialyltransferase. 
1.2.8 Sialyltransferases 
Sialyltransferases (STs) are a family of glycosyltransferase that use CMP-NeuNAc as the 
activated sugar donor to catalyze the transfer of sialic acid residues to terminal non-
reducing positions of oligosaccharide chains of glycoproteins and glycolipids [70,71]. Each 
of the sialyltransferase genes is differentially expressed in a tissue-, cell type-, and stage-
specific manner to regulate the sialylation pattern of cell’s glycoconjugates. These 
enzymes differ in their substrate specificity, tissue distribution and various biochemical 
parameters. Enzymatic analysis conducted in vitro with recombinant enzyme revealed that 
one linkage can be synthesized by multiple enzymes [23]. 
The mammalian sialyltransferase family consists of more than 20 Golgi membrane-bound 
sialyltransferases, 15 of which have been cloned in human [23]. They are Type II 
transmembrane glycoproteins with a short 3-11 amino acid NH2-terminal cytoplasmic 
domain, which is not essential for catalytic activity, a 16-20 amino acid transmembrane 
(signal anchor) domain, a 30-200 amino acid extended stem region, followed by large 300-
350 residue COOH-terminal catalytic domain [13]. These enzymes have been shown to be 
topologicaly restricted to trans cisternae and the trans Golgi network of the Golgi 
apparatus [72], although catalytically active soluble forms can be generated in vivo by 
proteolytic cleavage at the stem region, e.g. serum soluble ST6Gal I produced by 
proteolytic cleavage at the stem domain [32]. 
Even though eukaryotic sialyltransferases share the same sugar donors and recognize 
identical acceptor substrates, they do not exhibit similar protein structure except of the 
three short and conserved consensus sequences present in the catalytic domain (Figure 
1.4 a) [26,73]. 
 
Catalytic domain L
T
M
D
S VSNH2
Cytoplasm Golgi lumen
Stem
COOH
 
a 
 12
Sialyl motif L Residues
ST3Gal I RCAVVGNSGNLKDSSYGPEIDSHDFVLRMNKAPTGG–FEADVGSRD (138-182)
ST6Gal I RCAVVSSAGSLKNSQLGREIDNHDAVLRFNGAPTDN–FQQDVGTKT (180-224)
ST6GalNAc I TCAVVGNGGILNDSRVGREIDSHDYVFRLSGAVIKG–YEQDVGTRT (292-336)
ST8Sia I KCAVVGNGGILKMSGCGRQIDEANFVMRCNLPPLSSEYTRDVGSKT (136-181)
Sialyl motif S Residues
ST3Gal I PSTGILSIIFSIHICDEVDLYGF (264-286)
ST6Gal I PSSGMLGIIIMMTLCDQVDIYEF (318-340)
ST6GalNAc I PTTGALLLLTALQLCDKVSAYGF (447-469)
ST8Sia I LSTGLFLVSAALGLCEEVSIYGF (272-294)
Sialyl motif VS Residues
ST3Gal I TGVHDGDFEYNIT (309-321)
ST6Gal I GAYHPLLFEKNMV (363-374)
ST6GalNAc I YINHDFRLERMVW (492-503)
ST8Sia I SGYHAMPEEFLQL (304-316)  
Figure 1.4 (a) Schematic structure of sialyltransferase showing the relative positions of sialyl motif 
L, S and VS. TMD corresponds to the transmembrane domain. (b) Amino acid sequences of sialyl 
motif L, S, and VS in four sialyltransferases. Conserved amino acid residues in the all 
sialyltransferases are shown in bold red letters. 
 
The L (large, 50 amino acids)-, S (small, 23 amino acids)- and VS (very small, 6 amino 
acids) sialyl motifs appear to be specific for eukaryotic enzymes, as they are not present in 
any of the cloned prokaryotic STs that catalyze similar reactions [74-77]. In all of the 
known ST sequences, the number of invariant residues in L-, S- and VS- sialyl motif is 7, 2 
and 2, respectively, with one cysteine residue being conserved in each region (Figure 1.4 
b). The functional significance of the sialyl motifs has been investigated by site-directed 
mutagenesis, using ST6Gal I as a model enzyme. The replacement of the most conserved 
residues by alanine showed that sialyl motif L is mainly involved in donor substrate 
binding, whereas mutation in the sialyl motif S affected both, donor and acceptor binding 
[27,78]. The mutation of the two conserved cysteine residues generates inactive enzymes. 
This supports the hypothesis that these residues are involved in disulfide bond formation, 
the presence of which is required for the formation of the active conformation [26]. 
 
b 
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1.2.8.1 Donor and acceptor substrate of the sialyltransferase 
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Figure 1.5 Molecular structure of an activated nucleotide-N-acetylneuraminic acid (CMP-NeuNAc). 
Activated sialic acid is shown in red. 
 
Sialic acids (Figure 1.5), ubiquitous components of mammalian glycoproteins and 
glycolipids, are a family of closely related neuraminic acids found at the non-reducing 
terminal positions of glycoconjugates. Because of their terminal position and their negative 
charge at physiological pH, sialylated oligosaccharide sequences have long been 
predicted to be information – containing molecules and critical determinants, e.g. in cell-
cell recognition processes, cell-matrix interactions and maintenance of serum 
glycoproteins in the circulation [79,80]. The cell surface sialic acid residues have been 
known to act as receptors for the influenza virus [81]. They often function in the “anti-
recognition” or masking of the carbohydrate groups they terminate [80]. 
More than 36 derivatives of the sialic acid molecule have been identified [82,83]. The C-5 
position commonly bears a N-acetyl group (NeuNAc) or a hydroxyl group forming 2-keto-3-
deoxy-d-glycero-d-galactonononic acid (KDN). The 5-N-acetyl group can also be 
hydroxylated, giving N-glycolylneuraminic acid (NeuNGc) or occasionally de-N-acetylated, 
giving neuraminic acid (Neu) (Figure 1.5). These four molecules (NeuNAc, NeuNGc, KDN, 
and Neu) have the potential for additional substitutions at the hydroxyl groups on the 4-, 7-
, 8-, and 9-carbons (O-acetyl, O-methyl, O-sulfate, and O-phosphate groups). Sialic acids 
are glycosidically linked to either the 3- or 6-hydroxyl group of a galactose residue (Gal), or 
to the 6-hydroxyl group of N-acetylglucosamin (GlcNAc) or N-acetylgalactosamine 
(GalNAc) residues. They can form polysialic chains via their 8-hydroxyl group and 
R: 
O
H3C NH Sialic acid (NeuNAc) 
O
NH
HO
 NeuNGc 
NH2  Neuraminic acid (Neu) 
OH  KDN 
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terminate with a sialic acid branched via the 8- or 9-hydroxyl group [71]. 
NeuNAc and KDN are believed to be the metabolic precursors for all other sialic acids. 
They are derived by the condensation of ManNAc-6-P (for NeuNAc) or Man-6-P (for KDN) 
with activated forms of pyruvate. Following dephosphorylation, the free sialic acid is 
activated into the nucleotide donor CMP-NeuNAc (Figure 1.6) [80]. 
 
Figure 1.6 Life cycle of sialic acids. The general pathways for biosynthesis, activation, transfer, 
and recycling of the common sialic acid (NeuNAc). The asteriks indicate the pathways considered 
to be the major sources of sialic acids for CMP-NeuNAc synthesis. 
 
Polysialic acid (PSA) is a homopolymeric structure made of sialic acid molecules joined by 
α-2,8 glycosidic bonds, which is found only in a few animal glycoproteins, e.g. the N-CAM 
molecules, and also in the capsules of neuroinvasive bacteria [84]. The predominant 
building units of PSA in mammals are NeuNAc and KDN. PSA chains form large, 
negatively charged and highly hydrated structures, and the expression of these “space 
filling” carbohydrate chains attenuates cellular interactions and increases motility. 
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Figure 1.7 Molecular structure of GQ1bα ganglioside. The α-2,3 and α-2,8 sialic acid are red 
colored. 
 
The minimal motif that defines the glycosphingolipids (glycolipids) is a monosaccharide, 
e.g. glucose or galactose attached directly to a ceramide unit, e.g. glucosylceramide or 
galactosylceramide [85]. Ganglioside biosynthesis is achieved by the sequential addition of 
a carbohydrate unit to an existing glycolipid acceptor and is catalyzed by specific 
glycosyltransferases acting in parallel pathways. The most complex of the 
glycosphingolipids, the gangliosides (Figure 1.7), contain oligosaccharides with one or 
more sialic acid residues, which give gangliosides a net negative charge. Those complex 
molecules are usually synthesized by several sialyltransferases such as ST3Gal V (GM3 
synthase), ST6GalNAc V (GD1α synthase), ST6GalNAc VI (GD1α, GT1aα, GQ1bα 
synthase), ST8Sia I (GD3 synthase) and ST8Sia V. Gangliosides are most abundant in the 
plasma membrane of nerve cells, e.g. in the central nervous system (CNS), where they 
constitute 5 10% of the total lipid mass. The levels and types of gangliosides change 
during neural differentiation and development [11,18,86]. Gangliosides are also thought to 
function in cell-recognition processes, in which membrane-bound carbohydrate-binding 
proteins (lectins) bind to the sugar groups on both glycolipids (gangliosides) and 
glycoproteins [87]. More than 40 different gangliosides have been identified and named 
 16
according to the system suggested by Svennerholm [88]. The ganglioside GM1 for 
example, acts as a cell-surface receptor for the bacterial toxin that causes the debilitating 
diarrhea of cholera. Cholera toxin binds to and enters only those cells that have GM1 on 
their surface, including intestinal epithelial cells [89]. Furthermore, MAG, a member of the 
Siglec family of sialic acid binding lectins, binds to sialoglycoconjugates on axons, and 
particularly to gangliosides GD1a and GT1b, which may mediate some of MAG’s inhibitory 
effects, i.e. inhibition of the neurite otgrowth. Obviously, it was important to clone 
sialyltransferases in order to understand the biosynthetic pathway of sialoglycoconjugates. 
 
1.2.8.2 Cloning of mammalian sialyltransferases 
The ST6Gal I from rat is the second GT and the first sialyltransferase to be cloned in 1987 
by Weinstein et al. [32]. In 1990, Grundmann et al. have cloned the first human 
sialyltransferase (ST6Gal I) [90]. The enzymes were cloned using a traditional approach 
involving purification of native sialyltransferase and screening of the lambda library. This 
method was replaced by an RT-PCR method, which took an advantage of conserved sialyl 
motifs to create degenerate synthetic primers. This allowed the cloning of cDNAs of 
additional sialyltransferase family members [18]. Because of the fact that unique 
sialyltransferase genes cloned from the same species typically exhibit <50% homology, 
the majority of the known sialyltransferase cDNAs were identified by this approach [91]. 
 
1.2.8.3 Regulation of the sialyltransferase gene expression and functionality 
With only a few exceptions, a single sialic acid structure can be synthesized by more than 
one sialyltransferase. Strict development and tissue-specific programs govern the 
expression of the individual sialyltransferase genes [92-95]. 
The relative expression of sialyltransferases influences the expression of sialylated 
compound at the cell surface and contributes to the definition of the glycosylation pattern 
of normal and tumor cells. Sialyltransferase expression appears to be regulated mainly at 
the level of transcription with a strong correlation between mRNA expression levels and 
enzyme activity levels. Because sialyltransferases are expressed in most cells and tissues, 
where their function can be different, evolution of distinct promoters provide additional 
ways to modulate their expression. Post-translational modifications of sialyltransferase 
proteins may also modulate enzymatic activity [23]. 
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1.2.8.4 Sialyltransferase classification and nomenclature 
Sialyltransferases can be divided into three broad classes according to the glycosidic 
linkage of sialic acid formed with the acceptor substrate. Under the nomenclature 
proposed by Tsuji et al. [91] these broad classes are designated ST3, ST6 and ST8 to 
denote the glycosidic bond formed on the 3rd, 6th and 8th carbon on the acceptor sugar, 
respectively.  
 
1.2.8.5 Sialyltransferase family 
α-2,3 sialyltransferase (ST3Gal-) subfamily 
All known ST3 enzymes transfer sialic acids to C-3 of galactose residue in acceptor 
glycans. Six different ST3 enzymes are cloned from different species. Two α-2,3 
sialyltransferases (ST3Gal I and ST3Gal II) mediate the transfer of sialic acid residues to a 
Gal residue of terminal Galβ(1,3)GalNAc oligosaccharide (Type III) found on glycolipids or 
glycoproteins [96,97]. The ST3Gal I in vivo predominantly sialylates O-linked chains, while 
ST3Gal II is a dominant enzyme in ganglioside biosynthesis. Gangliosides containing 
NeuNAcα(2,3)Galβ(1,3)GalNAc (e.g., GD1a, GT1b) are ligands for MAG (myelin-
associated glycoprotein), a member of the Siglec family of sialic acid-binding receptors 
[98,99]. The ST3Gal II, because of its high, pronounced expression in neuronal tissues 
and preference for glycolipid acceptors is likely the enzyme utilized in vivo for the 
synthesis of MAG ligands. Human Galβ(1,3/4)GlcNAc α-2,3 sialyltransferase (hST3Gal III) 
cloned by Kitagawa and Paulson [100] preferentially acts on Type I chain and is therefore 
the candidate for the synthesis of the sialyl-Lewisa epitope, in vivo. The ST3Gal III 
catalyzes the sialylation of Type II chains but with lower catalytic efficiency. The ST3Gal III 
gene has been shown to be highly expressed in skeletal muscle but not in placenta. The 
human ST3Gal IV, which has been cloned independently from human placenta [96] and 
from the human Burkitt lymphoma cell line Namalwa [101] uses either glycolipids or 
glycoproteins containing Galβ(1,4)GlcNAc (Type II) or Galβ(1,3)GalNAc (Type III) 
sequences. Human ST3Gal IV transcripts are higly expressed in placenta. Recently, 
human ST3Gal V (GM3 synthase) cloned by Ishii et al. [102] uses only lactosylceramide 
(GA3, i.e. Galβ(1,4)Glcβ-Cer) as acceptor substrate, leading to the synthesis of GM3 
(NeuNAcα(2,3)Galβ(1,4)Glcβ-Cer), whereas the purified rat liver enzyme exhibited a 
broader specificity utilizing both galactosylceramide (Galβ-Cer) and asialoganglioside GA2 
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(GalNAcβ(1,4)Galβ(1,4)Glcβ-Cer) as well as lactosylceramide (Galβ(1,4)Glcβ-Cer) 
[103,104]. The human ST3Gal V gene was found to be expressed in a tissue-specific 
manner with predominant expression in brain, skeletal muscle and testis while very low 
levels of ST3Gal V mRNA were found in the liver. Human ST3Gal VI utilizes almost 
exclusively Galβ(1,4)GlcNAc (Type II) on glycoproteins and glycolipids [105]. Among 
glycolipid acceptors, ST3Gal VI preferres polylactosamine Type II chains thus generating 
glycolipids containing NeuNAcα(2,3)Galβ(1,4)GlcNAc structures including sialyl-
paragloboside, a precursor of sialyl-Lex on ceramide. Predominant expression of the 
ST3Gal VI gene was found in placenta, liver, heart and skeletal muscle. 
 
α-2,6 sialyltransferase (ST6Gal-, ST6GalNAc- and ST6GlcNAc-) subfamily 
Biosynthesis of the α-2,6-sialyl linkage to Gal, GalNAc, or GlcNAc is mediated by the α-2,6 
STs. ST6Gal I mediates the transfer of sialic acid residues with an α-2,6 linkage to the 
terminal Gal residue of a Type II disaccharide. The disaccharide can be found as a 
terminal N-acetyllactosamine unit of an N- or O-linked oligosaccharide. The ST6Gal I is 
unable to use Type I and Type III structures as acceptor substrates (Table 1.1, p2). 
Three distinct enzymes (ST6GalNAc I, II, IV) are known to catalyze the formation of α-2,6 
linkages onto GalNAc residues O-glycosidically linked to Ser/Thr, and three other STs 
(ST6GalNAc III, V, VI) catalyze the addition of sialic acid residues onto gangliosides [106]. 
Human ST6GalNAc I exhibits a broadest tolerance for the following structures: Tn antigen, 
T antigen and sialyl-T antigen (Table 1.1) [107,108]. The human ST6GalNAc II gene is 
expressed at low levels in heart, skeletal muscle, kidney and liver. The mouse ST6GalNAc 
III and human ST6GalNAc IV exhibit the most restricted substrate specificity utilizing only 
the sialyl-T antigen structure found on either O-glycoproteins or ganglioside GM1b, 
suggesting that they do not discriminate between α- and β-linked GalNAc [93,109]. The 
mouse ST6GalNAc V, expressed only in the brain, seems to be specific for only GM1b 
[110,111], while mouse ST6GalNAc VI [106] is expressed in a wide range of mouse 
tissues such as colon, liver, heart, spleen and brain. ST6GalNAc VI eppears to be specific 
for glycolipid acceptors and can synthesize all α-series gangliosides. The α-2,6 sialylation 
of Tn blocks all further modification of the glycan chain. The sialyl-Tn epitope is heavily 
expressed in embryonic chick brain [108], whereas in adult human tissue it is mostly 
absent. In humans, expression of sialyl-Tn antigen is limited to adenocarcinomas and 
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certain malignant tumors [112]. 
A third class of α-2,6 STs is composed of one or more enzymes that catalyze the transfer 
of sialic acid to GlcNAc in N-glycans. Though the activity has been described in a number 
of species, the enzyme(s) responsible for this activity have not been yet identified 
[113,114]. 
 
α-2,8 sialyltransferase (ST8Sia-) subfamily 
α-2,8 sialyl linkages are present in glycolipids as well as in glycoproteins. In glycoproteins, 
α-2,8-linked sialic acids exist as long homopolymers (i.e., polysialic acids) in a small set of 
molecules, e.g. in the embryonic form of neural cell adhesion molecule (N-CAM) [115]. 
Polysialylation alters the homophilic binding properties of N-CAM and has been thought to 
influence normal changes in cellular adhesion during embryonic brain development [116]. 
The presence of polysialic acids on N-CAM correlates with expression of 
polysialyltransferase and promotes neoblastoma cell growth [117]. The human α-2,8 
sialyltransferase (hST8Sia I) strongly prefers GM3 as a substrate to catalyze the synthesis 
of GD3 (NeuNAcα(2,8)NeuNAcα(2,3)Galβ(1,4)Glcβ1-O-Cer) [118]. Nakayama et al. found 
that GD3 and GT3 (NeuNAcα(2,8)NeuNAcα(2,8)NeuNAcα(2,3)Galβ(1,4)Glcβ1-O-Cer) 
structures were synthesized by the same enzyme, ST8Sia I, whereas minimal 
sialyltransferase activity was found towards glycoproteins [119]. The GD3/GT3 synthase 
gene is expressed at very low level in fetal brain and fetal lung. The 
NeuNAcα(2,3)Galβ(1,4)GlcNAc-R α-2,8 sialyltransferase (ST8Sia II or STX) has been 
described as the initiating enzyme which transfers the first sialic acid residue to the 8-
hydroxyl of NeuNAc residues, which are linked to the terminal position of N-linked glycans. 
Such glycans are the predominant form found attached to the N-CAM molecules [96,120]. 
This enzyme did not show any activity towards glycolipids including GM3 structure. The 
hST8Sia II gene is expressed in fetal brain and kidney but also in adult heart, thymus and 
brain. A third human α-2,8 sialyltransferase (ST8Sia III) was isolated from a brain cDNA 
library. It shows in vitro a high catalytic activity of sialic acid residue transfer to intact fetuin. 
Murine recombinant enzyme synthesizes oligomeric the α-2,8-sialic acid-linkage on N-
glycans and to a minor extent on glycolipids, but does not form polysialic acid [119]. 
Corresponding transcripts of ST8 Sia III were expressed in fetal and adult brain and liver. 
A fourth α-2,8-sialyltransferase (ST8Sia IV or PST-1) showed polysialic acid synthase 
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activity in vitro towards N-CAM [121]. The human ST8Sia IV gene has been found to be 
expressed in fetal brain, kidney and lung, and in adult spleen, thymus, heart, small 
intestine and leukocyte. Both polysialyltransferases, ST8Sia II and ST8Sia IV were 
sufficient to add PSA to α-2,3 or α-2,6 monosialylated complex oligosaccharides on N-
CAM [122,123]. They differ in their affinity for variable N-CAM isoforms and PSA chains 
synthesized by ST8Sia IV were found to be longer than those synthesized by ST8Sia II [6]. 
Kim et al. [124] reported the cloning and expression of a fifth type of human α-2,8-
sialyltransferase (ST8Sia V). As previously shown for the mouse ST8Sia V, the 
recombinant enzyme exhibited in vitro activity towards gangliosides, GM1b, GD1a, GT1b 
and GD3. Human ST8Sia V is expressed in both human fetal and adult brain, but also in 
adult heart and skeletal muscle. 
 
The investigation of protein glycosylation in eukaryotes gave a relatively detailed insight 
into the complex molecular mechanisms of protein glycosylation, and elucidated the 
coordinate a participation of various cell organelles in this process. In the last decades, 
accumulating evidence for glycosylated bacterial proteins has overthrown the almost 
dogmatic belief that glycosylation of proteins occurs exclusively in eukaryotes. 
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1.3 Prokaryotic glycosylation 
In prokaryotes (archaea and (eu)bacteria), the earliest examples of protein glycosylation 
have been found in archaea, which are able to present glycosylated surface layer (S-layer) 
proteins [125]. Mescher and Strominger [126] characterized the first archaeal S-layer 
glycoprotein of Halobacterium halobium (salinarum) that accounts for 50% of the cell 
envelope proteins. In 1976, Sleytr and Thorne identified the presence of S-layer 
glycoprotein in bacteria Clostridia [127]. In recent years non-S-layer glycoproteins have 
been found increasingly in insect and important mammalian bacterial pathogens [128]. 
Non-S layer glycoproteins can be found either membrane-associated (e.g., plasma 
membrane glycoproteins, outer membrane proteins), surface-associated (e.g., flagellins, 
pili), as secreted glycoprotein and exoenzymes (e.g., cellulases, endoglycosidase, 
phytotoxin), or as a group of non-classified glycoproteins (e.g., platelet aggregation-
associated protein, crystal toxin). The glycosylation process in prokaryotes leads to a 
much greater diversity of glycan compositions, linkage units, and glycosylation sequences 
on polypeptides than in eukaryotic glycoproteins. The glycosylated amino acids in 
prokaryotic glycoproteins are not restricted to those known from eukaryotes, i.e. 
asparagine in tripeptide consensus sequence Asn*-Xaa-Ser/Thr (* indicates glycosylated 
amino acid) for N-glycosidic linkages, and threonine, serine, hydroxyproline or 
hydroxylysine for O-glycosidic linkages, but also include tyrosine as a potential 
glycosylation site [129]. The requirements for O-glycosylation are less defined. It may take 
place in proline-rich domains, but also in several distinct consensus sequences, such as 
Asp-Ser*, Asp-Thr*-Thr [130] and Val-Tyr* [131]. As prokaryotic cells lack cellular 
compartments, the biosynthetic pathway of their glycan chains has to follow routes 
different from those described for eukaryotes. Similar mechanisms such as the utilization 
of sugar nucleotides for the assembly of the oligosaccharide chain, the occurrence of 
trimming reactions and the existence of lipid-bound intermediates have been observed 
during prokaryotic glycoprotein biosynthesis [132]. In contrast, the occurrence of 
nucleosidediphosphate-linked oligosaccharides is a remarkable difference between pro- 
and eukaryotic protein glycosylation, the function of which is not completely understood 
[133]. 
Thus far the glycosylation machinery has been identified only for a few examples. Some 
glycoproteins are modified by enzymes of a general glycosylation system, such as in 
Campylobacter, which show similarities to enzymes involved in protein glycosylation in 
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other species, such as Neisseria subspecies [134]. Others have acquired their own 
glycosylation mechanism, potentially by horizontal gene transfer mechanisms. In addition 
to general glycosylation system, prokaryotes express specific GTs for the modification of 
some proteins where glycosylation plays an important role for their maturation and 
function, e.g. the TibA and the AIDA system in E. coli [135-137]. 
Synthesis of polymeric cell surface carbohydrates takes place at the inner membrane [138] 
or in the periplasm via lipid-linked intermediates. For capsular antigens, a cell wall 
spanning synthesis-translocation complex has been suggested [139]. In the case of 
bacterial protein glycosylation, the organization and localization of components of the 
general glycosylation system is not known. The presence of protein-specific bacterial GTs 
(e.g., E. coli AAH heptosyltransferase) in the cytoplasm might indicate that protein 
glycosylation takes place in the cytoplasm [140]. 
 
1.3.1 Possible role of protein glycosylation in pathogenic bacteria 
In analogy to the various functions of carbohydrate modification in eukaryotic 
glycoproteins, bacterial glycoproteins can have important roles in maintenance of protein 
conformation, enhancing stability, protection against proteolytic degradation, surface 
recognition, cell adhesion or immune evasion [134]. Currently, bacterial glycoproteins can 
be divided into two groups: one group in which carbohydrate modifications directly affect 
protein function (e.g., subunit interactions and/or assembly of flagellins and pili 
(Campylobacter, Neisseria) and adherence to host cells (E. coli). A function of the 
carbohydrate moiety has been shown in C. jejuni, in which the defects in protein 
glycosylation result in impaired intestinal colonization [141]. In the second group, 
glycosylation influences the interaction with the host immune system and has an important 
role in pathogenesis. The carbohydrate moieties rather than amino acid epitopes appear to 
represent an antigenic determinant [142]. 
 
1.3.2 Bacterial glycosyltransferases 
Continuing microbial genome analysis and progress in screening and cloning techniques 
have allowed the cloning of various bacterial glycosyltransferase genes (Table 1.2), mainly 
from pathogenic bacteria. Most of these genes can be expressed as soluble active 
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proteins in E. coli. 
Table 1.2 Representation of distinct bacterial glycosyltransferase families [143]. 
Family Enzyme Source Reference
GalT    
 β-1,4 galactosyltransferase Neisseria gonorrhoeae, N. meningitidis [144-146]
 β-1,4 galactosyltransferase Helicobacter pylori [147,148]
 β-1,4 galactosyltransferase Streptococcus pneumoniae [149] 
 β-1,4 galactosyltransferase Streptococcus agalactiae [150] 
 β-1,3 galactosyltransferase Campylobacter jejuni [151] 
 β-1,3 galactosyltransferase Streptococcus agalactiae [152] 
 α-1,4 galactosyltransferase Neisseria gonorrhoeae, N. meningitidis [144,145]
GlcNacT    
 β-1,3 GlcNAc transferase Neisseria gonorrhoeae, N. meningitidis [144,145]
 β-1,4 GlcNAc transferase Campylobacter jejuni [151] 
GalNAcT    
 β-1,3 GalNAc transferase Neisseria gonorrhoeae, N. meningitidis [144,145]
 β-1,3 GalNAc transferase Campylobacter jejuni [151] 
SiaT    
 α-2,3 sialyltransferase Neisseria gonorrhoeae, N. meningitidis [153] 
 α-2,3 sialyltransferase Campylobacter jejuni [151] 
 α-2,3 sialyltransferase Haemophilus influenzae [154,155]
 α-2,3 sialyltransferase Haemophilus ducrey [156] 
 α-2,3 sialyltransferase Streptococcus agalactiae [157] 
 α-2,3/8 sialyltransferase Campylobacter jejuni [151] 
 α-2,6 sialyltransferase Photobacterium damsela [77] 
 α-2,8/9 sialyltransferase Escherichia coli [158] 
FucT    
 α-1,3 fucosyltransferase Helicobacter pylori [159,160]
 α-1,2 fucosyltransferase Helicobacter pylori [161] 
 α-1,3/4 fucosyltransferase Helicobacter pylori [162] 
 
The charbohydrate structures similar to the eukaryotic type have been found and 
characterized in many prokaryotic species. The following chapter will be related to the 
glycoconjugates expressed by the pathogenic C. jejuni. 
 
1.3.3 Campylobacter jejuni 
Campylobacter jejuni is a microaerophilic, gram-negative, non-spore-forming, flagellate 
bacterium with a characteristic S-shaped or spiral morphology, similar to the related gastric 
pathogen Helicobacter pylori [163].  
 24
 
Figure 1.8 Schematic representation of the cell wall of gram-negative bacteria [164]. 
 
Since the late 1970s, the mucosal pathogen C. jejuni has been recognized as an important 
cause of acute gastroenteritis in human [165], and has been shown to have variable cell-
surface carbohydrates, which are associated with virulence [166,167]. The core 
oligosaccharide of low molecular weight lipo-oligosaccharides (LOS) expressed on the cell 
surface of many C. jejuni strains (Figure 1.8) has been shown to exhibit molecular mimicry 
of the carbohydrate moieties of distinct gangliosides. The presence of NeuNAc in C. jejuni 
discovered by Moran et al. [168] was surprising, as it is not usually found in prokaryotes. 
Terminal regions of the core oligosaccharide containing α-2,3 NeuNAc linkages to D-Gal 
residue resemble the GM1a, GM2, GM3, GD1a, GD1c, GD3 and GT1a gangliosides 
purified from the brains of vertebrates [169]. These ganglioside-like structures have all 
been found in various C. jejuni strains. An example of GD1c-like structure is shown in 
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Figure 1.9. The molecular mimicry of host gangliosides by the oligosaccharide portion of 
the LOS molecule is considered to be a virulence factor of various mucosal pathogens, 
and play an essential role in neuropathological autoimmune diseases like Miller-Fisher 
syndrome (MFS) and Guillain-Barré syndrome (GBS). The GBS is a form of neuropathy 
(neuromuscular paralysis), and is the most common cause of generalized paralysis [170-
172]. Using mimicry mechanism, pathogens can evade the immune response and trigger 
autoimmune mechanisms to C. jejuni epitopes, eliciting cross-reactive anti-ganglioside 
antibodies that target neural cells and tissues bearing gangliosides [142,173]. 
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Figure 1.9 Outer core carbohydrate moiety of LOS structure expressed by the ATCC43438 C. 
jejuni strain as a mimic of GD1c ganglioside molecule. Kdo indicates ketodeoxy octulosonic acid, 
Hep describes heptose and PEA denotes for O-phosphoethanolamine [174]. 
 
1.3.3.1 Lipo(oligo)polysaccharides (LOS/LPS) 
Lipopolysaccharides are an abundant surface component of the outer membrane of gram-
negative bacteria. The LPS molecules consist of three distinct regions (Figure 1.10). 
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Figure 1.10 Schematic diagram of LOS/LPS molecule structure. 
 
The hydrophobic lipid A moiety, considered as the endotoxic part [175] of LPS molecule, is 
anchored in the outer membrane. Attached to the lipid A is the core, a branched-chain 
oligosaccharide linked to a ketodeoxy octulosonic acid (Kdo) molecule, which contains an 
inner and outer part. Specific to the inner core is the presence of a Kdo and a heptose 
residue. These structures were not found in the outer core. Extending from the cell surface 
is the O-antigen, a repeat of 10-30 oligosaccharides composed of 1-5 sugar residues each 
[176]. The bacterial O-antigen protects the organism against complement and other serum 
components [177,178]. Comparing to the LPS molecule, the LOS molecule lacks the O-
antigen polymer and is considered as a variant of the LPS. The C. jejuni strains mainly 
synthesize LOS molecules, whereas some strains possess polysaccharide repeats (Figure 
1.11) [179]. Aspinall et al. [169,180,181] and Nam Shin et al. [174] determinated the LOS 
outer core structures of representative C. jejuni reference strains of the Panner serotyping 
system. The Panner serotyping system is based on heat-stable antigens, and it was 
suggested that the specificity is due to the capsular polysaccharides rather than to the 
LOS and/or LPS molecules. Serotyping of C. jejuni is based upon differences in the 
saccharide structure of the bacterial heat-stable antigens, and strains have been 
designated as either “O”, Penner (e.g. O:10) or heat-stable (HS) serotypes [182]. Because 
of the fact that strains having the same Panner type could express different LOS outer 
core structures, C. jejuni was named with the specific identification number (e.g., 
ATCC43438, OH4384) as well as with the Panner type (e.g., O:10, O:19). 
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Figure 1.11 Known structures of core molecules and O-antigen-like polysaccharides from O:10 
[172] and O:19 [169,181] Campylobacter jejuni strains. The “n” indicates that the oligosaccharide is 
repeated, forming an O-antigen like polysaccharide whereas “P” denotes a phosphate group [175]. 
The identification of the LOS structures of C. jejuni reveaeled the presence of α-2,3- and 
α-2,8- sialic acid bond structures. 
 
1.3.3.2 Bifunctional α-2,3/2,8 sialyltransferase (Cst-II) 
The Campylobacter sialyltransferase II (cst-II) gene encoding a bifunctional α-2,3/2,8 ST 
(Cst-II) is one of the genes responsible for the biosynthesis of the ganglioside mimics in C. 
jejuni. This membrane-associated inverting enzyme in general catalyzes the formation of a 
α-2,3 sialic acid-linkage to a β-galactose acceptor sugar, and uses this product as an 
acceptor substrate in a second, α-2,8 sialyltransferase enzymatic reaction (Figure 1.12) 
[151]. 
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Figure 1.12 Enzymatic reaction catalyzed by α-2,3/2,8 bifunctional sialyltransferase (Cst-II). The 
bonds created in the monofunctional and bifunctional reactions are highlighted by a green circle 
[183]. 
 
Several versions of cst-II genes from different strains of C. jejuni have been found. Despite 
very high sequence identity (97.3%) between these enzymes, some of them showed α-2,3 
monofunctional (e.g., Cst-IIO:19) and some α-2,3/2,8 bifunctional (Cst-IIOH4384, Cst-
IIATCC43438) sialyltransferase activity. The Cst-II enzyme expressed in the OH4384 C. jejuni 
strain differs by only eight amino acids from the same enzyme expressed in the 
ATCC43438 strain of C. jejuni. 
The GQ1bα molecules, which are highly expressed in CNS, contain sialic acids linked to 
the galactose residue by α-2,3, α-2,6 and α-2,8 glycosidic bond. Because of the very 
specific α-2,3/2,8 bifunctional sialyltransferase activity, this enzyme was considered as a 
powerful tool for the chemo-enzymatic synthesis of the GQ1bα-like molecule. 
 
 29
1.4 Enzymes for chemical synthesis 
Recent demonstrations that oligosaccharides play important roles in diverse biological 
events have resulted in renewed interest in the synthesis of oligosaccharides and their 
analogs. The availability of such molecules can facilitate the studies on carbohydrate-
protein recognition and help to elucidate molecular mechanisms of oligosaccharide-
mediated biological process [164,184] that could eventually lead to rationally designed 
carbohydrate-based therapeutics. The application of oligosaccharides as pharmaceuticals 
in the fields of the prevention of infections by pathogens, neutralization of toxins, regulation 
of inflammation, and cancer immunotherapy have been widely recognized [185]. It has 
been very difficult to synthesize oligosaccharides, and they could be obtained only in 
limited amount by extraction or chemical synthesis. This is attributed to the inherent 
chemical difficulties presented by this class of molecules. Each monosaccharide carries at 
least three hydroxyl groups that must be protected and deprotected during synthesis. Also, 
glycosylation generates new stereocenter at the anomeric carbon, and there are no 
general methods for the introduction of all types of glycosidic linkage in a manner that is 
both stereo-controlled and high yielding. The chemical synthesis of oligosaccharides is 
therefore very time-consuming. 
In Nature, glycosyltransferase enzymes accomplish the construction of diverse and 
complex oligosaccharide. As mentioned before, these ezymes catalyze the transfer of a 
monosaccharide from a glycosyl donor to a glycosyl acceptor in a regio- and stereospecific 
manner. Such a biosynthetic pathway was utilized in the pioneering work by Wong, Haynie 
and Whitesides on the in vitro enzymatic synthesis of N-acetyllactosamine with in situ 
regeneration of uridine 5’-diphosphogalactose (UDP-Gal) [186]. Furthermore, pioneered by 
Barker [187,188], Whitesides [186] and Augé [189] and their colleagues, enzymatic 
synthesis of oligosaccharides by glycosyltransferases opened up a new venue avoiding 
many of the problems encountered in the traditional chemical synthesis. Since then, many 
synthetic chemists are using enzymes in combination with classical carbohydrate 
chemistry, i.e. chemo-enzymatic approach to produce oligosaccharides on a gram or even 
kilogram scale [190]. In the chemo-enzymatic synthesis, the most enzymes operate at 
room temperature, under neutral aqueous conditions, and in the absence of functional-
group protection. In organic synthesis, these biocatalysts can be used as the sole catalyst 
in a reaction, in combination with other enzymes, or with non-biological reagents. The 
chiral nature of enzymes results in the formation of stereo- and regiochemically defined 
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reaction products with remarkable rate acceleration (105 to 108). In addition, many 
enzymes accept unnatural substrates, and genetic engineering can further alter their 
stability, broaden their substrate specificity, and increase their specific activity. 
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1.5 Myelin-associated inhibitors of axonal regeneration in the adult 
mammalian CNS 
In the peripheral nervous system (PNS) regeneration occurs spontaneously after nerve 
injury, whereas in the central nervous system (CNS) damaged nerves do not regenerate 
after damage of the brain or spinal cord. Schwab et al. [191] were the first to discover a 
potent growth inhibitory activity in the CNS, and to show that much of this inhibitory activity 
is associated with myelin. It is now well established that the lack of regeneration in the 
CNS is due to two main obstacles, namely formation of the glial scar and presence of 
growth inhibitory molecules within the myelin [192]. The glial scar is formed by astrocytes, 
which change their morphology to present a physical barrier to growth and also upregulate 
several extracellular matrix-associated inhibitors of regeneration. However, until the scar 
fully matures, myelin seems to be the predominant source of growth inhibition. 
 
1.5.1 Myelin and myelin-associated inhibitors 
In contrast to the Schwann cells, which are responsible for the single internode formation 
of the myelin sheath around the axon in the PNS, oligodendrocytes are myelin-producing 
cells of the CNS capable of elaborating many internodes of myelin simultaneously. The 
myelin sheath acts as an axon insulator and greatly increases the rate at which an axon 
can conduct an action potential (Figure 1.13). 
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Figure 1.13 (a) Representation of a myelinated axon from a peripheral nerve. Each Schwann cell 
wraps its plasma membrane concentrically around the axon to form a segment of myelin sheath 
about 1 mm long. (b) Electron micrograph of a section from a nerve in the leg of a young rat. Two 
Schwann cells can be seen: one (below) is just beginning to myelinate its axon; the other has 
formed an almost mature myelin sheath [193]. 
 
The importance of myelination is dramatically demonstrated by demyelinating diseases in 
the CNS and PNS such as multiple sclerosis and Guillain Barré syndrome [194]. The 
sheath is interrupted by regularly spaced nodes of Ranvier allowing propagation of action 
potential along a myelinated axon by a process called saltatory conduction.  
Besides its insulation function, myelin is also recognized as a major inhibitor for axonal 
regeneration for a variety of neurons both in vivo and in vitro [195-198]. Even though CNS 
and PNS myelin differ biochemically and antigenically, Shen’s study showed their similar 
inhibition of axonal regeneration [199]. There are major differences between the 
oligodendrocyte and Schwann cells behavior after the injury. In contrast to the 
oligodendrocyte, which shows slow mitotic rate and poor regenerative capacity, the 
Schwann cell responds vigorously and is engaged in an active phase of mitosis. After the 
primary demyelination, Schwann cells show the ability to phagocytose damaged myelin 
[200]. Regeneration takes place only after the myelin debris has been cleared, the 
Schwann cells have reverted into a non-myelinated phenotype, and the expression of 
myelin proteins is downregulated [192]. In contrast, oligodendrocytes continue to express 
myelin and myelin-associated inhibitors without removing myelin debris formed during 
injury. Therefore, myelin-associated inhibitors such as MAG, Nogo and Omgp, exposed in 
the damaged myelin sheath in the CNS are the main cause of the inhibition of axonal 
regeneration [201]. 
 
1.5.1.1 Myelin-associated glycoprotein 
Myelin-associated glycoprotein (MAG) was initially described in 1973 [202] as a 
glycoprotein in the CNS and PNS myelin, and was the first myelin protein characterized as 
a potent inhibitor of axonal outgrowth in culture [203,204]. As a member of the Siglec 
(sialic acid-binding immunoglobuline like lectin) family [205], MAG (Siglec-4a) contains five 
extracellular Ig-like domains. The first Ig-domain adopts an unusual conformation by 
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folding over the second Ig-domain, and cysteine disulfide bridges are formed between the 
unpaired cysteine residues (Figure 1.14). The MAG glycoprotein contains 8-9 potential N-
glycosylation sites and one-third of its molecular mass of 100 kDa is accounted for 
carbohydrates [206]. 
MAG as a transmembrane protein exists in two alternatively spliced isoforms, a large (L) 
and a small (S) form that differ in their cytoplasmic sequence [207-209]. In the CNS myelin 
sheath, MAG is located exclusively in the periaxonal oligodendrogilal membrane, while in 
the PNS it is found in the outermost layer of the myelin sheath [210,211]. 
 
Figure 1.14 Structure of the MAG glycoprotein. The MAG exists in large (L) and small (S) isoforms 
which differ only in their cytoplasmic sequences. MAG carries five Ig-like domains in its 
extracellular sequences and the first Ig-domain adopts an unusual conformation by folding over the 
second Ig-domain. The sialic acid binding site on MAG is Arg118 in the first Ig-domain [192]. 
 
Because of its localization close to the axon, it was suggested that MAG has the ability to 
maintain the normal myelination of axons and preserve axon-myelin integrity [212]. 
Depending on the age and type of neurons, MAG seems to be bifunctional, and all 
neurons that have been studied to date switch their response to MAG from promotion to 
inhibition during development [204,213].  
As a member of the Ig-super family and Siglec family, MAG is a sialic acid-binding protein 
that specifically binds sialo-glycoproteins and sialo-glycolipids (gangliosides), preferably 
when the sialic acid residue is attached in α-2,3-O-linkage, such as in GT1b [98,99,214]. 
The sialic acid-binding site on MAG maps to Arg118 in its first Ig-like domain [215]. This 
Extracellular space 
Cytoplasm 
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arginine residue is conserved in other members of the Siglec family. When Arg of MAG is 
mutated, its sialic acid-binding capability is lost. By contrast, when Arg 118-mutated MAG 
is presented to neurons through expression by recombinant cells, it inhibits neurite 
outgrowth as effectively as wild-type MAG, indication that the sialic-acid binding site on 
MAG is distinct from its inhibition site. For soluble MAG, interaction of the inhibition site 
with the neuron is completely dependent on MAG’s inherent sialic acid-binding capacity. In 
contrast, other proteins (e.g., cell adhesion molecules – CAM) in living cells can 
compensate for the MAG’s sialic acid-binding to the neuron, allowing the inhibition site to 
interact and elicit the response [215]. This is consistent with the recent findings that the 
binding of MAG to its receptor, Nogo receptor (Ngr), is sialic acid independent [216,217]. 
 
1.5.1.2 Nogo 
Although Ramon y Cajal was first suggesting that white matter could block regeneration in 
the CNS [218], in the late 1980s the work of Schwab and his colleagues confirmed this 
hypothesis with a molecular insight into the mechanism of Nogo inhibition [219,220]. The 
IN-1 monoclonal antibody, which was raised against an inhibitory fraction of myelin that did 
not support neurite extension, allowed axons to grow on myelin in culture [219] and in vivo 
[195]. Three groups independently cloned an antigen of the IN-1 antibody named Nogo for 
its inhibitory action on axonal growth [221-223]. 
Nogo belongs to the reticulon family and exists in three isoforms A, B and C (Figure 1.15) 
in the CNS but not in the PNS [222]. The Nogo-A isoform is the only one that is expressed 
in oligodendrocytes. The amino terminus of Nogo-A is unique and possess at least two 
inhibitory domains: Nogo-66 common to all three isoforms and the amino-Nogo unique to 
the Nogo-A amino terminus. Although the topology of Nogo-A is still not resolved, the 
possible topology model place Nogo-66 on an extracellular surface and amino-Nogo on an 
intracellular surface. Regardless of topology, both of these domains induce growth cone 
collapse when exposed to the axon after damage of myelin/oligodendrocyte by injury 
[192]. 
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Figure 1.15 Structure of the Nogo molecule. Nogo exist in three isoforms, Nogo-A, Nogo-B and 
Nogo-C. Sequences that are common to all three isoforms are shown in blue and green. Only 
Nogo-A is enriched in oligodendrocyte, and it carries two inhibitory domains, one in Nogo-66 that is 
common to all three isoforms and one in the amino terminus – amino-Nogo – that is unique to 
Nogo-A. The Nogo-A has been proposed to adopt two topologies depending on weather Nogo-66 
or amino-Nogo is extracellular [192]. 
 
1.5.1.3 Oligodendrocyte myelin glycoprotein 
The oligodendrocyte myelin glycoprotein (OMgp) is a glycosyl phosphatidylinositol (GPI)-
linked protein, the third myelin-associated inhibitor of axonal regeneration (Figure 1.16) 
[224]. It is expressed not only by oligodendrocytes, but also at high level in various 
neurons in the CNS and PNS [225,226]. The OMgp is a minor component of myelin and it 
is found to be expressed largely in the paranodal loops, close to the nodes of Ranvier. The 
OMgp contains a leucine-rich repeat (LLR) domain, followed by a C-terminal domain with 
Ser/Thr repeats. Like MAG and Nogo, OMgp induces growth cone collapse and inhibits 
neurite outgrowth.  
 
Extracellular space 
Cytoplasm 
Extracellular space 
Cytoplasm 
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Figure 1.16 Structure of the OMgp molecule. The OMgp is a glycosylphosphatidylinositol (GPI)-
linked protein that carries a leucine-rich repeat (LRR) region and a serine/threonine (Ser/Thr) rich 
region. 
 
1.5.2 Receptors for myelin-associated inhibitors of axonal regeneration 
An important step forward after the identification of myelin-associated inhibitors was the 
identification of the axonal receptor that transduces their inhibitory signal across the axonal 
membrane. In 2001, by screening an expression library with soluble Nogo-66, Strittmatter 
and colleagues found the Nogo receptor (NgR), a binding partner of Nogo-66 [227]. The 
NgR is expressed as a 85 kDa GPI-linked protein on the surface of various neurons [228]. 
It contains a series of eight LLRs followed by a second cluster of C-terminal LRRs. Direct 
interaction of the NgR receptor with Nogo-66 is required to induce growth cone collapse 
[227]. The most surprising discovery was that NgR is also a receptor for the MAG and 
OMgp myelin-associated inhibitors of axonal growth [216,217,224]. Although, NgR is 
essential for Nogo-66, MAG and OMgp to exert their inhibitory effects, it can not transduce 
the signal across the membrane, because it is a GPI-linked protein and therefore has no 
transmembrane or cytoplasmatic domains. It is found that the transducing partner 
interacting with NgR is the p75 neurotrophin receptor (p75NTR). p75NTR (Figure 1.17) can 
be co-precipitated by MAG, Nogo-66 or OMgp, with NgR present in the precipitate of each 
[229,230]. Neurons from p75NTR-/- mice are not inhibited by any of the three inhibitors or by 
myelin in general [192]. 
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Figure 1.17 The myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS 
interact with the same receptor complex. The Nogo-66, the Mag and the OMgp interact with the 
same glycosyl phosphatidylinositol-linked Nogo receptor (NgR) to bring about inhibition of neurite 
outgrowth. The NgR contains two regions of LRRs – a cluster of eight together, and a series closer 
to the carboxyl terminus. Interaction of the MAG with the Ngr is independent of sialic acid binding. 
However, the MAG binding to the gangliosides is sialic acid dependent. The NgR interacts with the 
p75NTR to transducer the inhibitory signal across the membrane. The receptor for amino-Nogo is 
not known. The amino-Nogo, the Nogo-66, the MAG and the OMgp activate Rho to trigger the 
inhibition. The MAG has been shown to inactivate Rac, but it is not known whether this effect is 
required for inhibition [192]. 
 
The three main myelin-associated inhibitors that have been identified to data, MAG, Nogo-
66 and OMgp, interact with the same receptor complex, NgR – p75NTR (Figure 1.17) which 
transduces the inhibitory signal across the axonal membrane to prevent axonal 
regeneration after injury. This implies that there is functional redundancy between these 
inhibitors, i.e. the presence of any one inhibitor is sufficient to prevent regeneration by 
activating an inhibitory signal through the single receptor complex. This idea of 
redundancy can explain many of the previous results of in vivo experiments in which either 
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MAG or Nogo was blocked or absent. In the MAG-/- mouse, only a small amount of 
spontaneous axonal regeneration was recorded in one study, and none at all in another 
[231,232]. Likewise an IN-1 antibody application to Nogo allowed only a small percentage 
(5-10%) of axons to regenerate [195,233,234].  
The additional inhibitory activity of amino-Nogo, which does not act through NgR – p75NTR, 
and perhaps other as yet unidentified myelin inhibitors, might make a relatively minor 
contribution since the blocking of NgR or p75NTR can substantially block the inhibitory 
effects of total myelin for the neurons tested so far. 
 
1.5.3 Gangliosides as a MAG functional ligands 
Beside the common pathway used by MAG, Nogo and OMgp to transduce the inhibitory 
signal using the NgR or p75NTR receptor complex, for a certain time it was thought that 
MAG mediates neurite growth inhibition by the interaction with gangliosides (Figure 1.17). 
This assumption was questioned after the discovery of NgR as a main binding partner of 
MAG. Although it is more likely that gangliosides potentiate and augment MAG-initiated 
inhibition by facilitating the clustering of signaling molecules, there is much evidence to 
support the hypothesis that the gangliosides expressed by nerve cells are specific 
functional ligands responsible for the MAG-mediated neurite outgrowth inhibition 
[235,236]. 
Gangliosides (see chapter 1.2.8.1) are major sialic acid-containing glycoconjugates 
expressed in the brain, on the surface of the nerve cells [237]. Brain gangliosides are 
characterized by their structural diversity which is mainly generated by variation in the 
number and linkage positions of sialic acid on the neutral sugar core. The major brain 
gangliosides are mainly responsible for maintenance of myelin stability and for the control 
of neurite regeneration. Both of these functions are assumed to be mediated through 
specific interaction with a MAG [194]. 
MAG as a member of the Siglec family (siglec-4a) (see chapter 1.5.1.1) requires α-2,3-
linked sialic acid, preferentially, NeuNAcα(2,3)Galβ(1,3)GalNAc terminus as implicated by 
an initial specificity study [236]. Direct binding studies showed that MAG binds to GD1a 
and GT1b, which are considered as major brain gangliosides, and related gangliosides 
with high specificity and affinity in vitro [98].  
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These gangliosides abound on the neuronal cell surface and along the axons, and are 
placed directly apposed to MAG in vivo [194]. The presence of the MAG binding glycan 
sequence on gangliosides, and their location on the axon surface led to the hypothesis 
that gangliosides may be endogenous ligands for MAG, and may, therefore, mediate 
MAG’s physiological functions. 
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2 Aims 
 
 
 
The work of our laboratory is focused on the Myelin-Associated Glycoprotein (MAG) and 
its physiological ligands, i.e. brain gangliosides. Among these, GQ1bα is the most potent 
natural ligand identified so far and was therefore chosen as a lead structure for the 
development of MAG antagonists. Only the sialic acid containing part of GQ1bα  was 
shown to be important for MAG binding. Therefore, we decided to use a chemo-enzymatic 
approach for the syntheses of the GQ1bα mimetics. In order to perform preparative 
chemo-enzymatic synthesis of sialylated structures, it was of great importance to set-up 
the enzymatic platform concerning distinct sialyltransferases. Hence, this involved 
expression of different enzymes having the ability to catalyze the formation of α-2,3, α-2,6 
and α-2,8 glycosidic-linkages of sialic acid. 
Consequently, the first aim was the expression, purification and biochemical 
characterization of the eukaryotic rST3Gal III, and its application in the preparative chemo-
enzymatic synthesis of GQ1bα mimetics. Furthermore, the second aim was the expression 
and characterization of eukaryotic hST6Gal I in order to have enzyme within the enzymatic 
library. The main project was cloning, expression and characterization of the prokaryotic, 
Campylobacter jejuni bifunctional α-2,3/2,8 sialyltransferase. This enzyme was initially 
targeted for the preparative chemo-enzymatic synthesis in order to produce GQ1bα 
derivatives containing α-2,8 glycosidic-linkages. 
 41
3 Materials and Methods 
 
 
 
3.1 rST3Gal III expression in baculovirus-infected cells, purification and 
characterization 
3.1.1 Insect cell culture and virus methods 
Recombinant virus DNA containing the γ-interferon export sequence fused to the soluble 
form of the rat liver Galβ(1,3/4)GlcNAc α-2,3-sialyltransferase (rST3Gal III; EC 2.4.99.6) 
was kindly received from Dr. Markus Streiff [72]. 
 
3.1.1.1 Insect cell culture 
Complete culture medium SF-900 II with L-glutamine supplemented with 10% FCS and 1% 
Penicillin/Streptomycin) at 27°C 
 
Several established insect cell lines are highly susceptible to AcNPV virus infection. In this 
work, the Sf9 cell line was used for the rST3Gal III production. The Sf9 cell line was 
originally established from ovarian tissues of Spodoptera fugiperda (Sf9) larvae. Healthy 
insect cells attach well to the bottom of the cell culture plate at 27°C, forming a monolayer 
and double every 18-24 hours. Infected cells become round, enlarged, develop enlarged 
nuclei, do not attach and stop dividing. 
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3.1.1.2 Long-term insect cell storage [238] 
The Sf9 cells were kept for long-term storage at – 80°C or in liquid nitrogen. Aliquots of 
stock cultures were frozen down periodically to provide a backup in case of contamination. 
Table 3.1 Components for long-term insect cell storage. 
Healthy cells (>98% viable) free from contamination in exponential growth 
Complete culture medium SF-900 II with L-glutamine supplemented with 10% FCS and 1% 
Penicillin/Streptomycin) at 27°C 
Trypan blue, hemocytometer, sterile cryovials (1 ml) 
Freezing medium 85% complete culture medium, 15% DMSO, sterile filtrated (0.22 
μm filter) 
 
Freezing: 
The cells were examined for health, viability (>98%), exponential growth (≈1 x 106 cells/ml) 
and signs of contamination. 
Cells were pelleted by gentle centrifugation at 1000 x g, for 5 min at 27°C, the old media 
was removed, and the pellet was resuspended in fresh media to a density of 1-2 x 107 
cells/ml. An equal volume of the freezing medium was added (1-2 ml/flask) and placed on 
ice (Table 3.1). The cell suspension was aliquoted in cryovials (1 ml) and frozen at – 20°C 
for 1 h, then kept 2 days at – 80°C and finally stored in liquid nitrogen. After 2 weeks cell-
aliquotes were thawed and checked for viability. 
 
Thawing frozen cells: 
The cell suspension was thaw at 37°C within 40 – 60 sec. The content of 1 vial (1 ml) was 
transferred to a 25 cm2 tissue-culture flask containing 10 ml of complete culture medium 
(medium with two-fold of normal FCS concentration). Cells were incubated at 27°C for 3 h, 
checked for viability and finally the culture medium was replaced with 10 ml of fresh 
complete medium. The cell culture was further incubated at 27°C for 24 h. Additionally, 7 
ml of complete medium was added to the culture flask and incubated at 27°C until the cells 
showed confluence. 
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3.1.1.3 Amplification of virus stocks [238] 
Table 3.2 Components for virus stock amplification. 
Sf9 cell (1 x 106 cells/ml) 
Complete culture medium (SF-900 II with L-glutamine supplemented with 10% FCS and 1% 
Penicillin/Streptomycin) 
35 mm and 100 mm tissue-culture plates or 200 ml spinner culture 
Purified virus stock to be amplified 
 
Cells growing in the tissue-culture plates 
First amplification of virus stock: 
Cells (1 x 106) were seeded in a 35 mm tissue-culture dish in final volume of 2 ml of 
culture medium. The cell-culture plate was kept for 1 h at 27°C ensuring the attachment of 
the cells to the bottom of the tissue-culture plate. Culture medium was aspirated and cells 
were infected with 0.5 ml of purified virus stock inoculum (Table 3.2). Cells were incubated 
at room temperature (RT) for 1 h with gentle rocking. 1.5 ml of complete culture medium 
was added and incubation was preceded for 3 days. 
Second amplification of virus stock: 
Four 100 mm tissue-culture dishes were seeded with 5 x 106 cells each in a final volume of 
10 ml of complete tissue medium. After the cells attached to the cell-culture plate, the 
culture medium was aspirated. 1 ml of the first amplification virus stock was diluted with 3 
ml complete tissue medium and added to the cell-culture plate. Cells were incubated at 
room temperature for 1 h with gentle rocking. 9 ml of additional complete culture medium 
was added and incubated further for 3 days. 
A large-scale working stock of virus was prepared repeating this procedure and using 
many tissue-culture dishes, and infecting the cells with 0.1 of multiplicity of infection (MOI) 
which is defined as plaque-forming units per number of cell (pfu/cell). 
Cells grown in suspension 
Cells were grown in 200 ml Erlenmeyer flask until they reached a density of 1 x 106 
cells/ml. They were collected by centrifugation at 1000 x g for 5 min at room temperature 
and resuspended gently in 20 ml of complete culture medium. Second amplification virus 
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stock was added to give a MOI of 0.1 (1 x 107 pfu of virus) and incubated at room 
temperature for 1 h with gentle rocking. Cells and virus were returned to an Erlenmeyer 
flask and fed with 180 ml complete culture medium. The Erlenmeyer flask was stirred at 
27°C for 3 days. The tissue-culture fluid was harvested by centrifugation to remove cell 
debris, and the supernatant was titrated and stored at 4°C. 
3.1.1.4 Determining virus titer by end-point dilution 
The determination of the virus titer by end-point dilutions (Table 3.3) involves the 
inoculation of multiple cultures with different dilutions of the virus, and estimation of the 
dilution of virus that would infect 50% of the cultures (the end-point dilution). This quantity 
of virus is known as the 50% tissue-culture infectious dose, or TCID50. Virus titers 
determined in this manner may be expressed as TCID50/ml, or converted to pfu/ml. 
Table 3.3 Components for end-point dilution analysis. 
Sf9 cells (1 x 106 cells/ml) 
Complete culture medium (SF-900 II with L-glutamine supplemented with 10% FCS and 1% 
Penicillin/Streptomycin) 
96-well tissue-culture plates 
Virus stock to be titrated 
 
Twelve-fold serial dilutions of the virus stock were prepared (10-1,10-2, 10-3, 10-4….10-12) in 
a final volume of 10 ml. Cells were diluted to a concentration of 1 x 105 cells/ml with 
complete culture medium. 100 μl of Sf9 cell suspension was seeded into a 96-well 
microtiter plate and mixed gently with 10 μl of each dilution. Four wells were seeded with 
100 μl of Sf9 cell suspension as uninfected controls. Cell-culture plates were placed with a 
damp paper towel into a plastic box to avoid dehydration, and incubated at 27°C for 5 
days. On the third day cells were checked in order to monitor their normal growth. Five 
days later each well was examined for infected cells (virus replication). Wells with signs of 
infection (one infected cell) were scored as positive. All positive and negative wells were 
counted for each dilution. 
The virus titer was calculated by the following method [239]: 
All cultures infected at a given dilution would have been infected at all lower dilutions, and 
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conversely, all cultures uninfected at that dilution would have been uninfected at all higher 
dilutions. 
B) -(A / 50) -(A  PD =  
PD – proportionate distance  
A – is the % response above 50% 
B – is the % response below 50% 
50TCID1 virus of Titer =  
ml0.69/  TCID pfu 50 ×=  
3.1.1.5 Virus storage [238] 
For short-term storage, working stocks of virus were sterile filtrated (0.2 μm) and stored in 
culture medium supplemented with 5% FCS at 4°C for optimal virus stability. Infected cells 
and cell debris were removed from the virus stock by centrifugation at 1000 x g for 5 min at 
4°C without loss in titer of virus. For long-term storage virus stock aliquots were frozen in a 
culture medium at –80°C. 
 
3.1.2 rST3Gal III expression in baculovirus infected insect cells 
Table 3.4 Components for rST3Gal III expression. 
Sf9 cell (1 x 106 cells/ml) 
Complete culture medium SF-900 II with L-glutamine supplemented with 10% FCS and 1% 
Penicillin/Streptomycin) 
2 l Erlenmeyer flasks 
Recently titrated virus stock  
 
Cells grown in tissue-culture plates. 
The soluble rST3Gal III was produced by infecting Sf9 insect cells in monolayer culture 
(Table 3.4) with the recombinant virus (MOI of 20 pfu/cell). Complete medium was 
removed from confluent cells, and the fresh medium containing 20 pfu/cell was added. 
After 1 h at room temperature incubation, inoculum was removed, fresh medium was 
added, and the culture was returned to the incubator at 27°C. Conditioned medium was 
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collected 72 h post-infection, spun, filtrated through a 0.2 μm membrane and stored at – 
20°C. 
Cells growing in the suspension 
Two liter Erlenmeyer flasks containing 500 ml of Sf9 cell suspension in serum free medium 
supplemented with antibiotics were shaken in Erlenmeyer flasks (70 rpm) at 27°C (Table 
3.4). At a cell density of 1.8 x 106 cells/ml the culture was infected with 5 ml of virus stock 
(2.2 x 1010 pfu/ml end point dilution) and incubated at room temperature for 1 h while 
gently rocking. 72 h post-infection the culture was harvested, and the cells and debris were 
removed by centrifugation at 9000 rpm for 30 min at 4°C. 
The cleared supernatant containing the rST3Gal III from 6 to 8 Erlenmeyer flasks was first 
pre-filtered through a submicron filter (Gelman preflow DCF-CFG95NG) and then 
concentrated in an Amicon Ultrafiltration cartridge (YM-30) to 300 ml. This was followed by 
addition of 300 ml 50 mM sodium-cacodylate (pH 6.5) and reconcentration to 150 ml. 
Finally, the concentrate was stored at –20°C in 50 ml aliquots. 
 
3.1.3 Analysis of the expressed rST3Gal III 
3.1.3.1 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is used to separate proteins depending on their molecular weight [240]. The 
negatively charged detergent, SDS, disrupts non-covalent bonds while mercaptoethanol, 
reduces disulfide bonds. The molecular mass can be estimated using a molecular marker. 
Under native conditions, neither SDS nor β-mercaptoethanol is added to the protein 
sample, which enables migration of proteins according to their native charge and shape 
(Table 3.5). 
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Table 3.5 Components for SDS-PAGE analysis. 
Stacking buffer 0.5 M Tris, 0.4% SDS (Bio Rad), adjusting pH to 6.7 
Separating buffer 1.5 M Tris, 0.4% SDS, adjusting pH to 8.8 
SDS-PAGE sample 
buffer (3 x reducing) 
65 mM Tris, 20% (v/v) glycerol anhydrous (Fluka BioChemika), 
10% (v/v) β-mercaptoethanol (Fluka BioChemika), 4% (w/v) 
SDS, 1 dip bromphenol blue (Bio Rad), adjusting pH to 6.75 
SDS-PAGE sample 
buffer (2 x non-reducing)
Reducing sample buffer without β-mercaptoethanol 
SDS-PAGE sample 
buffer (2 x native) 
Reducing sample buffer without β-mercaptoethanol and SDS 
Electrophoresis buffer 
(10 x) 
0.25 M Tris, 2 M glycine (Fluka BioChemika), 1% SDS adjusting 
pH to 8.3 
Low molecular weight marker (LMW) (Sigma) 
 
Table 3.6 The SDS-PAGE reaction protocol. 
Components Separating gel Stacking gel 
 12.5% 4% 
Deionized water 3.75 ml 5.67 ml 
Acrylamide 4K solution (30%) (AppliChem, 
BioChemika) 6.25 ml 1.33 ml 
Stacking gel buffer / separating gel buffer 5 ml 3 ml 
N,N,N`,N`-tetramethylethylenediamine (TEMED) 
(Serva) 30 μl 20 μl 
Ammonium persulfate (APS) (40%) (Sigma) 30 μl 20 μl 
 
The reducing SDS-PAGE: 
The components of the separating gel (12.5%) were mixed except for APS, which was 
added just before pouring the gel (Table 3.6). After polymerization of the resolution gel, the 
stacking gel was prepared, poured in the same way and the comb placed. Before samples 
were loaded on the gel, they were mixed with reducing SDS-PAGE sample buffer (3 x). 
The samples prepared with reducing buffer as well as a marker (LMW) were heated for 5 
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min at 95°C in a heated block. All the samples were centrifuged at 13 200 rpm for 1 min. 
The samples were run through the stacking gel at 75 V. When the samples entered the 
separating gel, the voltage was increased to 150 V. 
The non-reducing SDS-PAGE gel was prepared in the same way as reducing SDS-PAGE 
gel with exception of using 2 x non-reducing SDS-PAGE sample buffer. 
For the native SDS-PAGE gel, 2 x native SDS-PAGE sample buffer as well as all buffers 
without SDS and β-mercaptoethanol were used. 
3.1.3.2 SDS-PAGE staining [240] 
The Coomassie blue dye was used for 45 min to stain the gel followed by destaining 
solution (Table 3.7) until the bands were visible and the background almost decolorized. 
Table 3.7 The Coomassie blue staining solutions. 
Coomassie blue 
staining solution 
1 g Coomassie brilliant blue G250 (Bio Rad), 1 g Coomassie 
brilliant blue R250 (Bio Rad), 200 ml methanol (Riedel-de Haën), 
200 ml deionized water (Millipore), filtrated (Fluted filter, Ø 32 cm, 
Schleicher & Schuell AG) 
Coomassie blue 
distaining solution 
150 ml acetic acid glacial (Hänseler AG), 500 ml methanol, add 
2000 ml deionized water (Millipore) 
 
In order to visualize small amount of protein (as little as 10 ng), gels were treated with 
silver stain (Table 3.8) which is 100 time more sensitive than Coomassie blue.  
Table 3.8 The silver staining solutions. 
Fixation 100 ml ethanol, 25 ml acetic acid glacial, make 
up to 250 ml with deionized water 
30 min 
Sensitizing 75 ml Ethanol, glutardialdehyde (25% w/v), 
sodium thiosulphate (5% w/v), 17 g sodium 
acetate. make up to 250 ml with deionized water 
30 min 
Washing Deionized water 3 x 5 min 
Silver reaction Silver nitrate solution (2.5% w/v), formaldehyd 
(37% w/v), make up to 250 ml with deionized 
water 
20 min 
Washing Deionized water 2 x 1 min 
Developing 6.25 g Sodium carbonate, formaldehyd (37% 
w/v), make up to 250 ml with deionized water, stir 
2-5 min 
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vigorously to dissolve sodium carbonate  
Stopping (3.65 g) EDTA-Na2 x 2H2O 10 min 
Washing Deionized water 3 x 5 min 
Preserve for plastic 
backed gels 
Glycerol (87% w/w), make up to 250 ml with 
deionized water 
20 min 
 
3.1.3.3 Western blot analysis [241] 
Table 3.9 The Western blotting solutions. 
Anode buffer I 0.3 M Tris, 20% (v/v) methanol 
Anode buffer II 0.025 M Tris, 20% (v/v) methanol 
Cathode buffer 0.04 M 6-aminocaprone acid, 20% (v/v) methanol 
Ponceau S solution  0.1 Ponceau (w/v) in 5% acetic acid (v/v) (Sigma) 
Trans-Blot® Transfer Medium Nitrocellulose membrane (0.45 μm) 
Filter paper 3 mm (Whatman®) 
 
Proteins separated by SDS-PAGE can be transferred to a nitrocellulose membrane by 
semi-dry-blotting, and particular proteins can be detected by staining with a specific 
antibody. Two filter papers were soaked in anode buffer I, one filter paper in anode buffer 
II and three filter papers in cathode buffer (Table 3.9). A nitrocellulose membrane was 
placed in the anode buffer II, and the SDS-PAGE gel into cathode buffer. The assembly 
was prepared in the following way: filter papers in anode buffer I were placed on top of the 
anode followed by the filter papers in anode buffer II, the membrane and the gel. The filter 
papers in cathode buffer were added and the protein transfer was run for 1 h at 15 V. The 
membrane was stained in Ponceau S solution to verify the efficiency of the protein 
transfer. The molecular weight standards were marked and the membrane was washed 
with deionized water. 
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3.1.3.4 Immunodetection 
Table 3.10 The immundetection buffers. 
Tris-buffered saline 
(TBS) 
20 mM Tris, 500 mM NaCl (Fluka Chemika) 
Tween Tris-buffered 
saline (TTBS) 
0.05% Polyoxyethylene Sorbitan Monolaurate (Tween 20) (Sigma) in 
TBS 
Primary antibody rabbit ST6Gal I purified serum (1:500) [242], 1% BSA, 0.1% NaN3, 10 ml 
TBS 
Secondary antibody Goat anti-rabbit IgG (whole molecule) alkaline phosphatase (AP) 
conjugated (1:10 000) (Sigma), 1% BSA, 0.1% NaN3, 10 ml TTBS 
BCIP/NBT 5-bromo-4-chloro-3-indolylphosphat / Nitroblau-tetrazolium chloride 50  
mg/ml in 100% dimethylformamide (Fluka BioChemika) 
Developing buffer 100 mM Tris, 100 mM NaCl (Fluka Chemika), 5 mM MgCl2 x 6H2O 
(Fluka BioChemika), adjusting the pH to 8.8 
Bovine serum albumin (BSA) (Sigma) 
 
The immunodetection is a method based on antigen/antibody interaction. The proteins 
were transferred to the nitrocellulose membrane and the unoccupied binding sites on the 
membrane blocked with 2% BSA in TBS buffer (Table 3.10). The membrane was 
incubated for 1 h at room temperature on the shaker. In order to remove BSA, the 
membrane was washed 3 times for 5 min with TTBS buffer and incubated overnight at 
room temperature with the primary antibody that specifically binds to the protein. The 
membrane was washed 3 times for 5 min with TTBS and incubated for 2 h with the 
secondary antibody coupled to alkaline phosphatase. Finally, the membrane was washed 
twice for 5 min with TTBS buffer and 5 min with TBS buffer. 
For visualization of the reaction, the membrane was incubated with 10 ml developing 
buffer containing 40 μl NBT/BCIP until a precipitate was visible. Violet precipitation is 
caused by oxidative dephosphorylation of BCIP and the reduction of NBT under basic 
conditions (pH 8.8). The developing reaction was stopped by washing the membrane with 
deionized water. 
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3.1.4 Purification of the rST3Gal III protein [243] 
Table 3.11 Buffers for the protein purification by affinity chromatography. 
Buffer A 50 mM Na cacodylate (pH 6.5), 0.1 M NaCl 
Buffer B 50 mM Na cacodylate (pH 6.5), 1 M NaCl 
Buffer C 50 mM Na cacodylate (pH 6.5), 50 mM NaCl 
5 ml CDP-hexanolamine-agarose (10 μmol CDP/ml gel slurry), Calbiochem 
Centrifugal filter devices, Centricon YM-30 (Amicon) 
BioLogic Duo-Flow FPLC system 
 
The media containing the rST3Gal III (40 ml) was filtrated through 0.45 μm filter and 
diluted to 80 ml with 40 ml of buffer C (Table 3.11). The column was equilibrated with 1 
column volume (CV) of buffer B and 5 CV of buffer A by using the Fast Performance Liquid 
Chromatography (FPLC) system (Bio-Rad). Samples were then applied to a CDP-
hexanolamine-agarose column and after washing the column with buffer A for 10 CV, the 
column was eluted with 1 CV of buffer B. Fractions containing the rST3Gal III enzyme 
were pooled and concentrated using centrifugal filter devices (Centricon YM-30). 
3.1.4.1 Bradford protein assay [244,245] 
Table 3.12 Buffer components for Bradford protein determination. 
Solution A 100 mg Coomassie Brilliant Blue G-250 (Bio-Rad), 10 ml 
phosphoric acid 85% wt. (Aldrich®), 5 ml ethanol (Merck), 
add 100 ml deionized water 
Solution B 1 M NaOH (Fluka BioChemika) 
Protein standard (BSA 400 μg/ml protein) (Sigma Diagnostics) 
 
The Bradford method is used for the protein quantification. Under acidic conditions, the 
Coomassie color binds to the protein, whereby the maximal absorption of the dye is shifted 
from 465 nm to 595 nm and can be measured spectrophotometerically, which enables 
estimation of the protein concentration.  
Standard curve: a dilution series from 20 to 200 μg/ml of the protein-standard BSA was 
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prepared. 20 μl of each dilution was mixed with 50 μl of 1 M NaOH and 1 ml of solution A 
was added (Table 3.12). After incubation for 5 min at room temperature, 300 μl of the 
mixture was transferred on a test-plate and the absorbance was measured at 595 nm. 
The same reaction mixture was prepared for fractions with unknown protein 
concentrations. The absorbance was measured at 595 nm and the protein concentration 
was kept in the linear range corresponding to the standard curve. 
 
3.1.5 rST3Gal III enzyme activity assay [246] 
Table 3.13 Components for enzyme activity assay. 
Column equilibration C18 Sep-Pak 
Cartridges (Waters)  5 ml Methanol, 10 ml H2O 
IRGA-SAFE plus high flash point 
LSC-cocktail 10 ml 
Reaction buffer [247] 
100 mM Na cacodylate (pH 
6.0), 0.3% Triton X-100, 10 mM 
MgCl2 
Acceptor substrate Table 3.14 
 
The standard assay mixture (20 μl) contained 600 μM of Type II (1) acceptor substrate 
(Table 3.14), expressed rST3Gal III (0.007 mU), 0.2 mM CMP-NeuNAc (4 nmol), and 60 
000 cpm of CMP-[14C] NeuNAc in a reaction buffer (Table 3.13). After incorporation of 
[14C] NeuNAc (~10%) by incubation for 1 h at 37°C, the reaction mixture was diluted with 5 
ml of water and applied to Sep-Pak C18 cartridges. The column was washed two times 
with 5 ml of water and eluted with 6 ml of methanol. Incorporation of the [14C] NeuNAc was 
determined using liquid scintillation counting twice the same eluate. 
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This standard assay was also used to calculate the enzyme units. Taking into 
consideration that one unit of enzyme activity corresponds to transfer of 1 μmol of NeuNAc 
to Type II (1) per minute, enzyme activity was determined using the following equation: 
 
cpm blank
2
2 1count −+  
pmol 2.1×  
cpm total  
 
(min) time incubation (protein) mg ×  
 
3.1.5.1 Stability of rST3Gal III during the long-period incubation 
In order to determine the enzyme stability over a long period of incubation, as an important 
parameter for preparative syntheses, the activity of the rST3Gal III over time at 37°C was 
investigated. Enzyme incubation was performed in a reaction buffer containing 0.1 mM 
CMP-NeuNAc (2 nmol), CMP-[14C] NeuNAc (60 000 cpm) and 200 μM of Type I acceptor 
substrate at 37°C over a long period. Samples were taken after 0, 6, 9, 12, 24, 60 and 84 h 
of incubation and the activity of the sialyltransferase was determined by standard 
enzymatic assay (see chapter 3.1.5). 
 
3.1.6 Long-term enzyme storage 
Enzyme aliquots were mixed with 20% and 50% of glycerol solution and stored at 4°C and 
–20°C as well as a control-aliquot which was free of glycerol. Enzyme activity was checked 
after 2 weeks and 15 months incubating for 1 h at 37°C in the reaction buffer containing 
200 μM of Type II acceptor substrate, CMP-[14C] NeuNAc (60 000 cpm) and 100 μM non- 
labeled NeuNAc (see chapter 3.1.5). 
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3.1.7 Determination of the enzyme kinetic parameters [248] 
Table 3.14 Molecular structure of acceptor substrates used for kinetic parameters determination. 
OSE: O-(trimethylsilyl)ethyl (O-CH2CH2-Si(Me)3), OLem: O-(Methoxycarbonyl)octyl (O-
(CH2)8CO2Me), TCA: tri-chloro acetyl (COCCl3). 
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Determination of enzyme kinetic parameters of rST3Gal III was performed as described in 
the chapter 3.1.5 using different concentrations of each acceptor substrate (Table 3.14) 
ranging from 25 μM to 0.6 mM for a native, and 50 μM to 2 mM for non-native acceptor 
substrate. All acceptors were linked to either OLem or OSE aglycones to facilitate a 
product isolation using C18 columns. Relative activity for each di(tri)saccharide acceptor 
substrate was calculated as a percentage of the incorporation of [14C] NeuNAc into the D-
Gal-containing di(tri)saccharide. Under standard incubation conditions (37°C; pH 6.0) 
1 
2 
3 
4 
5 
6 
7 
8 
9
10
11
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formation of the product was shown to be linear in time. Furthermore, enzyme kinetic 
parameters were obtained from double-reciprocal plots by linear regression analysis of 
Lineweaver-Burk plots. 
 
3.1.8 Preparative syntheses [249,250] 
After determination of enzyme kinetic parameters and rST3Gal III long-period activity with 
Type I natural substrate, enzyme was used for chemo-enzymatic preparative synthesis. 
Substrates and CMP-NeuNAc were incubated with rST3Gal III for 3-5 days at 37°C in a 
mixture of 50 mM sodium cacodylate buffer (pH 6.5), 60 mM MnCl2-solution (the same 
effect as MgCl2), water containing BSA and the calf intestine alkaline phosphatase (CIAP, 
Roche; EC 3.1.3.1) used to prevent the enzyme inhibition caused by CMP [251]. After 17-
24 hours of incubation, an additional aliquot of transferase was added (except for the 
natural substrates Type I and Type II). The reactions were monitored by TLC (silica gel, 
DCM/MeOH/H2O 10:4:0.8). 
3.1.8.1 A synthesis of NeuNAcα(2,3)Galβ(1,4)GlcNAc-β-OLem (7) product 
Disaccharide 1 (3.0 mg, 5.4 μmol) and CMP-NeuNAc (5.3 mg, 8.1 μmol) were dissolved in 
a mixture of 50 mM sodium cacodylate-buffer pH 6.5 (0.6 ml), 60 mM aqueous MnCl2 (0.6 
ml) and deionized water (0.4 ml) containing BSA (0.4 mg, Fluka). The mixture was 
incubated at 37°C with CIAP (2 U) and recombinant rST3Gal III (0.6 mU). After 3 d TLC 
(silica gel, DCM/MeOH/H2O 10:4:0.8) indicated complete consumption of 1. The turbid 
solution was centrifuged and the supernatant passed over a RP-18 column which was 
washed with water before the product was eluted with MeOH. After evaporation of 
methanol, the residue was chromatographed on silica gel (DCM/MeOH/H2O 10:4:0.4, then 
6:4:1) to yield trisaccharide 7 (3.5 mg, 76%) as colorless powder after a final lyophilization 
from water. The spectroscopic data of 7 were in accordance to those reported [252]. 
3.1.8.2 A synthesis of NeuNAcα(2,3)Galβ(1,3)GlcNAc-β-OLem (8) product 
According to the procedure described for the synthesis of 7, compound 2 (3.0 mg, 5.4 
μmol) was incubated with CMP-NeuNAc (5.3 mg, 8.1 μmol) and rST3Gal III (0.45 mU). 
Reaction control by TLC (silica gel, DCM/MeOH/ H2O 10:4:0.8) indicated complete 
consumption of 2 after 3 d. After work-up, the crude product was purified on RP-18 
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(H2O/MeOH gradient 1:0 to 1:1) to yield trisaccharide 8 (4.1 mg, 90%) as colorless powder 
after a final lyophilization from water. The spectroscopic data of 8 were in accordance to 
those reported [253]. 
3.1.8.3 A synthesis of NeuNAcα(2,3)Galβ(1,3)GalNAc-β-OSE (9) product 
Disaccharide 3 (10.0 mg, 20.6 μmol) and CMP-NeuNAc (20.4 mg, 31.1 μmol) were 
dissolved in a mixture of 50 mM sodium cacodylate-buffer pH 6.5 (2 ml), 60 mM aqueous 
MnCl2 (2 ml) and deionized water (1.3 ml) containing BSA (2.0 mg). The mixture was 
incubated at 37°C with CIAP (2 U) and recombinant rST3Gal III (1.5 mU). After 1 d, 
additional rST3Gal III (0.75 mU) was added and the incubation continued for 4 d. The 
turbid solution was centrifuged and the supernatant passed over a RP-18 column which 
was washed with water before the crude product was eluted with MeOH. After evaporation 
of the solvent, the residue was chromatographed on RP-18 (H2O/MeOH gradient 1:0 to 
1:1) to yield trisaccharide 9 (9.0 mg, 56%) and starting material 3 (4.4 mg, 44%) as 
colorless powders after a final lyophilization from water. 
3.1.8.4 A synthesis of NeuNAcα(2,3)Galβ(1,3)GalNHTCA-β-OSE (10) product 
According to the procedure described for the synthesis of 9, compound 4 (12.0 mg, 20.4 
μmol) was incubated with CMP-NeuNAc (20.2 mg, 30.1 μmol), BSA (2.1 mg), CIAP (2 U) 
and rST3Gal III (1.5 mU). After 1 d additional rST3Gal III (0.75 mU) was added and the 
incubation continued for 3 d. After work-up, the residue was chromatographed on silica gel 
(DCM/MeOH/H2O 10:4:0.4, then 6:4:1) to yield starting material 4 (7.5 mg, 62%) and 
trisaccharide 10 (6.4 mg, 36%) as colorless powders after a final lyophilization from water. 
3.1.8.5 A synthesis of NeuNAcα(2,3)Galβ(1,3)Gal-β-OSE (11) product 
According to the procedure described for the synthesis of 9, compound 5 (10.0 mg, 22.6 
μmol) was incubated with CMP-NeuNAc (22.3 mg, 33.9 μmol), BSA (2.3 mg), CIAP (2 U) 
and rST3Gal III (1.5 mU). After 1 d additional rST3Gal III (0.75 mU) was added and the 
incubation continued for 3 d. After work-up, the residue was chromatographed on silica gel 
(DCM/MeOH/H2O 10:4:0.4, then 6:4:1) to yield starting material 5 (4.0 mg, 40%) and 
trisaccharide 11 (9.7 mg, 59%) as colorless powders after a final lyophilization from water. 
3.1.8.6 A synthesis of NeuNAcα(2,3)Galβ(1,3)[NeuNAcα(2,6)]Gal-β-OSE (12) product 
According to the procedure described for the synthesis of 9, trisaccharide 6 (10.0 mg, 13.2 
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μmol) was incubated with CMP-NeuNAc (13.0 mg, 19.8 μmol), CIAP (2 U) and rST3Gal III 
(1.5 mU). in a mixture of 50 mM sodium cacodylate-buffer pH 6.5 (2 ml), 60 mM aqueous 
MnCl2 (2 ml) and deionized water (1.3 ml) containing BSA (2.0 mg). After 1 d, additional 
rST3Gal III (0.75 mU) was added and the incubation continued for 3 d. After work-up, the 
crude product was chromatographed on silica gel (DCM/MeOH/H2O 10:4:0.8) to yield 
exclusively starting material 6 (9.5 mg, 95%) as colorless powder after a final lyophilization 
from water. 
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3.2 hST6Gal I expression in BHK-21 cells, purification and 
characterization 
3.2.1 BT-hST6Gal I cloning and expression 
Using the strategy described by Grabenhorst for the construction of chimeric secreteable 
α-1,3/4-fucosyltransferase [246,254], a chimeric secretable protein (BT-hST6Gal I) was 
constructed by fusion of the full-length human β-trace protein (β-TP; EC 5.3.99.2) 
sequence to the N-terminus of the catalytic domain of human Galβ(1,4)GlcNAc α-2,6 
sialyltransferase (hST6Gal I; EC 2.4.99.1) protein [255]. 
 
3.2.1.1 Cell culture 
Table 3.15 The cell culture media and buffers. 
DME culture medium 
(Gibco) 
Dulbeccos Modified Eagle Medium; supplemented with Hepes, 
45 mM NaHCO3, 2 mM Glutamin, 65 mg/l Ampicillin and 100 
mg/l Streptomycinsulfate, pH 7.0 
Culture medium DME supplemented with 10% FCS 
Selective medium DME supplemented with 10% FCS, different Hygromycin B 
concentrations (25, 50 and 100 μg/ml) 
Production medium DME without or supplemented with 2% FCS 
PBS Phosphate-buffered saline (autoclaved) 
EP 1 mM EDTA (pH 8.0; sterile) in PBS 
TEP 0.1% Trypsin in 0.6 mM EDTA in PBS 
Freezing medium 5% DMSO in FCS 
 
Adherent baby hamster kidney (BHK-21) cells were grown in 5 ml of culture medium in a 
25 cm2 tissue-culture flask (Table 3.15). Cells were incubated in a humid 5% CO2-
containing environment at 37°C. After 2-3 days, confluent BHK-21 and CHO cells were 
washed with 5 ml of PBS buffer and detached from the bottom of the cell-culture plate 
using 0.5 ml EP or TEP solution, respectively, for several minutes at 37°C. Cells were 
resuspended in 5 ml of culture medium and 1/25 of the cell suspension was used as 
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inoculum. For long-term storage, 5 x 107cells were transferred to 1.5 ml of freezing 
medium and stored in liquid nitrogen. 
3.2.1.2 Long-term storage 
Cell freezing: 
Cells were growing in 25 cm2 culture flask until they reached 80% confluence. Culture 
medium was aspirated and cells were incubated in 0.5 ml EP solution for few minutes at 
37°C. Cells were collected in 5 ml of fresh culture medium, and centrifuged at 1000 rpm for 
5 min at 4°C. The cell pellet was resuspended in 1.5 ml of freezing medium (Table 3.15), 
kept at – 80°C for sveral days and finally, after verifying cell viability, was stored in liquid 
nitrogen.  
Thawing frozen cells: 
Cells stored in liquid nitrogen were placed in a water-bath at 37°C and thawed rapidly. 
Immediately afterwards, they were placed in culture medium (Table 3.15), the volume of 
wich depended on the size of the tissue-culture flask, e.g., 5 ml of culture medium for a 25 
cm2 flask. They were further incubated for several hours, after which the medium was 
replaced, and culturing was allowed to preced until cells reached confluence. 
3.2.1.3 Determination of cell number and viability [256] 
Trypanblue solution 2 V trypanblue (0.2%), 1 V of NaCl (4.25%) 
 
Cell suspensions (50 μl) were mixed with Trypan blue solution (50 μl), transferred to a 
hemocytometer and analyzed under a microscope. The viability of the cells (ratio between 
non-colored and colored cells > 98%) and cell counting was measured using Trypan blue 
solution. The cells were counted, the average number of cells was multiplied by 104 and 
the dilution factor, and the final number of cells was given in cell number/ml. 
3.2.1.4 Stable transfection and selection [255] 
Table 3.16 Components for stable transfection and selection. 
Substances Solution concentration Final solution 
pCR BT-hST6Gal I (β-
Trace Protein – 
0.65 g/l 10 μg 
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hST6Gal I) 
pCR Hyg (Hygromycin) 0.5 g/l 2.5 μg 
CaCl2 solution 2.5 M 25 μl 
HEBS (2 x) 40 mM Hepes, pH 7.05, 300 mM NaCl, 10 mM 
KCl, 1.4 mM Na2HPO4 
250 μl 
Sterile H2O Autoclaved 206 μl 
Solution A 1/10 CaCl2 + pCR BT-ST6Gal I+ pCR Hyg + H2O 250 μl 
Solution B HEBS (2 x) 250 μl 
 
Transfection of BHK-21 cells was performed, as described by Sambrook et al. [257], using 
a calcium phosphate precipitation method. 
For stable transfection, solution A was prepared by adding 10 μg of pCR BT-hST6Gal I 
and 2.5 μg of pCR Hyg plasmid DNA to the 250 mM CaCl2 solution (Table 3.16). The 
suspension was vortexed thoroughly and mixed with 250 μl of solution B. The transfection 
mixture of 500 μl was transferred to a 25 cm2 culture flask containing exponentially 
growing, app.1/4 confluent BHK-21 cells in 5 ml culture medium. Consequently, when 6-
well cell-culture plates were used for the transfection, DNA concentration was 
proportionally scaled down according to the surface of the tissue-culture plate. Cells were 
incubated for a further 24 h. The following day, DME culture medium was exchanged for 
the selective medium (Table 3.15) in such a way that a 1/6, 2/6 and 3/6 volume of the cells 
was growing in culture medium in the presence of 25 μg/ml, 50 μg/ml and 100 μg/ml 
Hygromycin B, respectively. Selective medium was replaced for 2-3 times over the 
following days. Hygromicin B-resistant BHK-21 cells were finally transferred to a 25 cm2 
culture flask and grown until they reached confluence. The selective medium was replaced 
with culture medium (Table 3.15) and cells were incubated for a further 2 days. 
Supernatant was finally analyzed for protein expression by Western blotting and an ST 
enzyme activity assay. 
3.2.1.5 The cell clone selection [258] 
Stably-transfected BHK-21 cells expressing sufficiently the gene of interest were highly 
diluted in order to get single cell clones (see chapter 3.2.2.3), which were each then 
transferred to a 12-well cell-culture plate. Clones were cultured in 0.5 ml selective medium 
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(Table 3.15) until they reached confluence. Selective medium was finally replaced with 0.5 
ml culture medium. Supernatant was collected 2 days later, analyzed by Western Blotting 
method and checked for hST6Gal I activity. The clones giving the strongest band intensity 
(Western blotting) and the highest enzymatic activity were chosen for further culturing. 
3.2.1.6 Optimization of the protein expression 
Positive clones were grown for 3 days in a 25 cm2 culture flask containing 5 ml production 
medium (Table 3.15). Each day a 250 μl sample was collected and centrifuged at 800 x g 
for 10 min at 4°C. After the three days, the supernatant was collected by centrifugation and 
stored at – 20°C. Cells were fed with 5 ml fresh production medium, and grown for a 
further 3 days repeating the same procedure mentioned above. Samples were examined 
by Western Blotting (see chapter 3.2.2.2) and the ST activity enzyme test. 
 
3.2.2 Analysis of the expressed BT-hST6Gal I 
BT-hST6Gal I chimeric protein was analyzed using the previously mentioned biochemical 
methods, e.g. SDS-PAGE and Western blotting (see chapter 3.1.3). In some experiments, 
described standard methods were modified as follows. 
3.2.2.1 SDS-PAGE [246] 
Reducing sample buffer (1 x) 1 ml SDS-buffer, 150 μl 0.3 M DTE, 200 μl glycerol, 
200 μl Bromphenol blue  
SDS-buffer 10 ml stacking buffer, 20 ml 10% SDS, add up to 100 ml 
with deionized H2O 
Bromphenolblau 0.05% in glycerol/H2O (1:1) 
Low molecular weight marker (LMW) (Bio Rad) 
 
Preparation of the samples: 
Collected protein samples (250 μl) were precipitated with 5 V of absolute ethanol and 
incubated either for 1 h, if used immediately for the experiment, or overnight (o/n) at – 
20°C. 
After incubation, samples were centrifuged at 13 000 rpm for 10 min at 4°C, supernatant 
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was discarded and the pellet was dried at RT until the ethanol evaporated completly. 
Samples were incubated with 20 μl of reducing sample buffer (1 x) for 5 min at 37°C and 
vortexed periodically, and finally heated for 5 min at 95°C in a heating block. The samples 
were run through the stacking gel at 75 V, and upon entering the separating gel, the 
voltage was increased to 150 V. 
Preparation of the standards: 
Different concentrations of the human β-TP (0.7 μg/μl stock solution) were produced and 
purified from BHK-21 cells, and used in SDS-PAGE and Western blotting as a standard 
protein. 
3.2.2.2 Western blot analysis [246] 
Table 3.17 Components for Western blotting. 
BSA blocking buffer 10 mM Tris, pH 7.4, 3% BSA, 0.9% NaCl, 10% 
horse serum 
Tris-buffered saline 
(TBS) 
50 mM Tris pH 7.4, 0.8% NaCl, 0.02% KCl 
Developing buffer 0.1 M Tris, pH 9.4, 0.1 M NaCl, 0.05 M MgCl2 
Stopping buffer 1 mM Tris, pH 7.5, 1 mM EDTA 
Primary antibody Rabbit anti-BT polyclonal serum (1:1000) [246] Incubation 
o/n at RT 
Secondary antibody Goat anti-rabbit immunoglobulin alkaline 
phosphatase (AP) conjugated (1:500) 
Incubation for 
2 h at RT 
 
Western blotting was done as it was described before except the BSA blocking step which 
was performed for 1 h at 42°C. 
3.2.2.3 Overlay assay 
This assay is based on Western blot and immunodetection analysis of the particular 
protein transferred to the nitrocellulose membrane which was placed on cells growing in 
cell culture. 
Different cell dilutions (100, 200 and 400 cells/plate) were seeded into Petri-dishes and 
grown in a DME medium for 6 days (at 37°C, 5% CO2). Medium was aspirated and cells 
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were fed with 1-2 ml of production medium (Table 3.15). An autoclaved nitrocellulose 
membrane was cut to fit the Petri-dish and placed on the cells. An additional 7 ml of 
production medium was transferred to the Petri-dish covering the membrane, the position 
of which was marked on the bottom of the Petri-dish. Cells were grown for a further 16 h 
(at 37°C, 5% CO2). The nitrocellulose membrane was analyzed by western blotting (see 
chapter 3.2.2.2) using rabbit anti-ST6Gal I purified serum (1:1000) as a primary antibody 
and goat anti-rabbit immunoglobulin-coupled alkaline phosphatase (1:500) as a secondary 
antibody in the reaction (Table 3.17). 
Clones growing in the Petri-dish were incubated for further several hours more in the 
culture medium. After the western blotting results were known, 12 clones showing 
hST6Gal I expression were carefully picked and transferred to 12 well cell culture plates 
containing 1 ml of culture medium. Clones were grown until they reached confluence, at 
which point they were checked for ST enzyme activity. Positive clones showing enzyme 
activity were transferred to 25 cm2 culture flasks containing culture medium. 
Clones which were not picked, they were allowed to continue growing in culture medium (8 
ml) until they reached confluence. These cells served as a back-up in the possible case of 
contamination. 
 
3.2.3 BT-hST6Gal I production [246] 
For the production of 0.5-1 mg of recombinant BT-hST6Gal I protein, BHK-21 cells were 
cultivated in ten tissue-culture plates (175 cm2), each filled with 50 ml of selective medium 
(Table 3.15). They were grown until they reached confluence. The selective medium was 
removed and replaced every 2 days or 3 days with 50 ml or 100 ml of production medium 
(Table 3.15), respectively. Cells were grown in the culture for a further 10 production 
cycles. Supernatant was collected by centrifugation at 800 x g, for 10 min at 4°C, analyzed 
by Western blotting (see chapter 3.2.2.2) and a ST enzyme activity assay, and stored at – 
20°C before a purification step. 
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3.2.4 Purification of recombinant BT-hST6Gal I 
Table 3.18 Buffers for protein purification by affinity chromatography. 
Buffer A 20 mM MES, pH 6.5, 0.1 M NaCl, 1 mM DTE, 0.02% Azid, 20% glycerol 
Buffer B Buffer A + 1 M NaCl 
Buffer C Buffer A + 5 mM CDP 
Buffer D Buffer A + 20 mM CDP 
 
The cell supernatant was centrifuged at 1500 rpm for 5 min at 4°C. A supernatant was 
mixed with 20% glycerol and 0.02% azid. The recombinant BT-hSTGal I protein was 
purified in a signle step from the supernatant of BT-hST6Gal I cells growing in production 
medium by CDP-hexanolamine-agarose affinity chromatography. 
Purification strategy 1 
CDP-hexanolamine-agarose column (10 ml) was first equilibrated with 10 CV of buffer A or 
PBS buffer containing 0.02% azid with a flow rate of 1.5 ml/min (Table 3.18). Supernatant 
was loaded onto the column (flow rate of 1.25 ml/min) at room temperature by using the 
FPLC system (Amersham Pharmacia Biotech). After the loading step, the column was 
washed with 10 CV of buffer A (1.5 ml/min) until the absorption baseline was stable, and 
finally the protein was eluted with 4 CV of buffer B (1.25 ml/min). 
Purification strategy 2 
In this strategy the purification was performed using 2 CV of buffer C (Table 3.18), 
followed by 2 CV of buffer D with the flow rate of 1.25 ml/min, and finally buffer B. During 
the purification step different fractions were collected: load (L), flow-through (FT), wash 
(W), and main fractions (Fr). These were stored at 4°C. The column was immediately 
regenerated for the following purification step using 10 CV of buffer A.  
The purity of the eluted fractions was analyzed by SDS-PAGE. The activity of the enzyme-
containing fraction was checked by ST activity assay after dilution (1:5) with buffer A. 
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3.2.4.1 Protein dialysis 
Table 3.19 Components for protein dialysis. 
8/32 dialysis tubes (YM-10) 30 min in 30% ethanol, 2 h in 30% 1-
propanol, 2 h x 2 in deionized water 
Storage solution 30% 1-propanol 
 
Purified protein eluted with buffer B, C and D was dialyzed against 50-fold (V) of buffer A 
(Table 3.19). 
Protein samples were dialyzed for 2 days at 4°C changing two times the same volume of 
buffer A. Dialyzed samples were checked for the activity using ST enzyme activity assay. 
3.2.4.2 Enzyme concentration [246] 
The eluate containing the enzyme was concentrated 7-fold using Diaflo YM-10 
ultrafiltration membranes (Amicon, Witten, Germany), diluted with six volumes of 20 mM 
MES, pH 6.5, and again concentrated 7-fold by ultrafiltration. 
3.2.4.3 Enzyme storage and stability 
Purified enzyme was stored at 4°C in 20% glycerol, at – 20°C in 20% and 50% glycerol, 
and after a defined time enzyme was checked for the activity using a ST enzyme assay. 
 
3.2.5 hST6Gal I enzyme activity assay [246] 
Table 3.20 Reaction mixture composition (20 μl). 
 Asialofetuin mixture Type II mixture 
Acceptor (Asialofetuin; Type II) 20 μg/μl 0.4 μg/μl 
2 mM CMP-NeuNAc 4 nmol 4 nmol 
CMP-[14C ] NeuNAc 0.1 nmol (60 000 cpm) 0.1 nmol (60 000 cpm) 
MES reaction buffer (1 x) 25 mM MES, pH 6.5, 50 mM NaCl, 10 mM MnCl2 
 
The master mix (all components except the enzyme) for 100 reactions was prepared as 
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described in Table 3.20 and stored at 4°C. The ST activity of extracts and culture 
supernatants of cells transfected with BT-hST6Gal I was tested at 37°C with up to 8 μl of 
the sample in 20 μl of reaction mixture. After this, samples were incubated for up to 3 h. 
The reaction mixtures (see Table 3.20) containing 0.4 μg/μl Type II acceptor were diluted 
with water to 0.5 ml and applied to Sep-Pak (Waters) C18 cartridges. The columns were 
washed twice with 2.5 ml of water and eluted with 1.5 ml of methanol. Transfer of [14C] 
NeuNAc was determined by liquid scintillation counting of the eluate. 
The reaction mixture (see Table 3.20) containing 20 μg/μl asialofetuin as an acceptor in 
the ST reaction mixture was precipitated with 1 ml of 0.5 M HCl containing 1% 
phosphotungstic acid (PTA) and transferred under vacuum to glass microfiber filters 
(Whatman GF/C). The filters were washed once with 4 ml of 0.5 M HCl containing 1% PTA 
and twice with 4 ml of methanol, and analyzed for radioactivity with a liquid scintillation 
counter (Beckman, LS 6000 SC). 
This standard assay was also used to calculate the enzyme units. Taking into 
consideration that one unit of enzyme activity corresponds to transfer of 1 μmol of NeuNAc 
to asialofetuin per minute. 
3.2.5.1 hST6Gal I turnover 
Table 3.21 The reaction mixture for enzyme catalytic activity. 
Acceptor Diantennary 20 nmol 
CMP-NeuNAc 200 nmol 
CMP-[14C ] NeuNAc 0.1 nmol (60 000 cpm) 
MES reaction buffer (1 x) 25 mM MES, pH 6.5, 50 mM 
NaCl, 10 mM MnCl2 
BSA 50 μg 
Purified enzyme 50 μU (1.64 mU/ml) 
Total 200 μl 
 
Reaction mix described in Table 3.21 was incubated for 12 hours at 37°C taking the 
aliquots at different time points (0, 30’, 2 h, 3 h, 6 h 12 h). Samples were purified (see 
chapter 3.2.6.1) and dried by centrifugation under vacuum. Lyophilized substance was 
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dissolved in 20 μl or 40 μl deionized water, and half of the sample was injected onto the 
CarboPac PA1 column used for high-pH anion-exchange chromatography with pulsed 
amperometric detection (HPAEC-PAD) analysis. The rest of the sample was stored at – 
20°C. 
3.2.5.2 Cell lysis [246] 
Table 3.22 Components for cell lysis method. 
Cell concentration 5 x 107 cells/ml 
Lysis buffer 20 mM MES, pH 6.5, 1% Triton X-100, 1 mM dithioerythriol (DTE), 
0.02% Azide, inhibitors 
 
In order to verify the hST6Gal I solubility, cells were lysed and cell pellets checked for the 
enzyme activity. 
Cell suspensions (1 ml) were centrifuged at 800 x g for 10 min at RT, supernatant was 
removed and the pellet resuspended in a lysis buffer (Table 3.22) to a final cell 
concentration (5 x 107 cells). The mixture was centrifuged briefly and incubated for 30 min 
at 4°C. After incubation lysed cells were centrifuged at 800 x g for 10 min at 4°C and the 
supernatant was used for the enzyme activity assay. 
 
3.2.6 Preparative (in vitro) sialylation of glycoconjugates [246] 
Table 3.23 Reaction mixture for preparative in vitro sialylation. 
Acceptor Diantennary N-acetyllactosamine type acceptor 20 mg/ml;  
MW= 1800 g/mol 
Acceptor conc. 2 nmol (0.1 mM) 
CMP-NeuNAc  10 nmol (0.5 mM)  
MES reaction buffer (1 x) 25 mM MES, pH 6.5, 50 mM NaCl, 10 mM 
MnCl2 
Enzyme 1.83 μU (0.1 mU/ml), 82 μU (1.64 mU/ml), 
supernatant 
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Diantennary Man β-(1,4)-GlcNAcβ-(1,4)-GlcNAc
α-(1,6)-Fuc
Galβ-(1,4)-GlcNAcβ-(1,2)-Manα-1
Galβ-(1,4)-GlcNAcβ-(1,2)-Manα-1 3
6
 
Asialofetuin 
Man β-(1,4)-GlcNAcβ-(1,4)-GlcNAc -N-Asn
α-(1,6)-Fuc
Galβ-(1,4)-GlcNAcβ-(1,2)-Manα-1
Galβ-(1,4)-GlcNAcβ-(1,2)-Manα-1 3
6
Galβ-(1,4)-GlcNAcβ-1 4
Galβ-(1,3)-GalNAc-O-Ser/Thr
 
 
Reducing N-glycans of the diantennary complex type were incubated at 0.1 mM 
concentrations with 0.1 U/l BT-hST6Gal I in the presence of 0.5 mM CMP-NeuNAc and 
MES buffer o/n at 37°C. Oligosaccharides were purified (see chapter 3.2.6.1) and aliquots 
of the reaction mixtures were analyzed by HPAEC-PAD and matrix-assisted laser 
desorption ionization time of flight mass spectrometry (MALDI/TOF-MS). 
3.2.6.1 Purification of glycoconjugates 
The N-oligosaccharides were separated from peptides by passing the incubation mixture 
through a 25 mg/ml graphitized carbon cartridges (HyperSep Hypercarb PGC column, 
Thermoquest) which was first equilibrated with 1 ml of 80% acetonitrile containing 0.1% 
trifluoroacetic acid (TFA), and washed four times with 1 ml deionized H2O until the pH 
reached a neutral value. The sample (20 μl) was loaded with 200 μl water onto a column 
which was washed twice with 2 ml of water. Oligosaccharides bound to the column were 
eluted with 500 μl of 40% acetonitrile containing 0.1% TFA. Elute was neutralized by 
adding 0.025% ammonium hydroxid and dried by spinning (Speed Vac) at 30°C. 
Lyophilized product was diluted in 20 μl deionized water and injected onto the CarboPac 
PA1 column used for HPAEC-PAD analysis. The rest of the purified oligosaccharide was 
stored at – 20°C. 
 
3.2.7 Mild hydrolysis of NeuNAc 
Purified oligosaccharide (20 μl) was incubated in 0.1% TFA for 1 h at 80°C and dried using 
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centrifugation under vacuum. The dried pellet was diluted in 20 μl of deionized water and 
injected onto the CarboPac PA1 column used for HPAEC-PAD analysis. 
 
3.2.8 Neuraminidase (sialidase) specific cleavage 
Oligosaccharide products obtained after incubation with purified hST6Gal I enzyme were 
checked for the α-2,6 NeuNAc glycoside linkage using neuraminidase (sialidase) enzyme 
from New Castle disease virus (NDV) hitchner B1 strain (EC 3.2.1.18). This enzyme 
specifically cleaves terminal NeuNAc linked only α-2,3 to N- or O- glycosidically bound 
oligosaccharide chains of glycoproteins and glycolipids. It also cleaves NeuNAc that is 
bound in the α-2,8 position to neuraminic acids. It is also able to cleave N-glycolyl, 4-O 
acetyl and 9-O acetylsialic acids, however it does this with a low turnover rate. 
AcNeuAc--82-AcNeu
O
N
 or -3X2-AcNeu
O
N ↓⎥⎦
⎤⎢⎣
⎡↓⎥⎦
⎤⎢⎣
⎡ αα  
Sialylated oligosaccharides were incubated overnight with 3 mU of NDV enzyme (1 U/ml) 
at 37°C. The resulting product was purified using HyperSep Hypercarb PGC column and 
injected onto the CarboPac PA1 column used for HPAEC-PAD analysis. 
 
3.2.9 High pH anion-exchange chromatography – pulse amperometric 
detection of oligosaccharides (HPAEC-PAD) [255] 
 Asialo method Oligo method 
Buffer A 0.2 M NaOH  
Buffer B 0.2 M NaOH; 0.6 M NaOAct  
Buffer C  0.1 M NaOH in deionized H2O 
Buffer D  0.1 M NaOH; 0.6 M NaOAc 
 
A Dionex Bio LC System (Dionex, Sunnyvale CA, USA), equipped with a 0.4 x 25 cm 
CarboPac PA1 column was used in combination with a pulsed amperometric detector. 
Detector potentials (E) and pulse durations (T) were E1 +50 mV, T1 480 ms; E2 +500 mV, 
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T2 120 ms; E3 – 500 mV, T3 60 ms; the output range was 500 – 1500 nA. The 
oligosaccharides were then injected onto the CarboPak PA1 column that was prior to 
injection equilibrated with 100% of solvent A or solvent C using the asialo or oligo method, 
respectively. The elution profile included an initial 5 min isocratic run with 100% buffer A or 
C, a 30 min linear gradient from 0 – 20% of solvent B or D, and finally 2 min linear gradient 
to 100% buffer B or D, each at the flow rate of 1 ml/min.  
The HPAEC-PAD was also used to prepare the total N-glycans, which were desalted on 
the graphitized carbon cartridges, for subsequent mass spectrometry. In some cases N-
glycans were desialylated prior to HPAEC-PAD analysis by dissolving in sialidase buffer 
(10 mM sodium acetat, 1 mM CaCl2, 0.02% sodium azide) and by incubating with 0.2 U/ml 
NDV neuraminidase. 
 
3.2.10 Mass spectrometry and methylation analysis of N-glycans 
The N-glycans were analyzed by matrix-assisted laser desorption ionization time of flight 
mass spectrometry (MALDI/TOF-MS). Briefly, the N-glycans were analyzed by positive ion 
MALDI/TOF-MS using Bruker REFLEX TOF instrument. One microliter of samples 
containing equal volumes of the N-glycan solution (~3-10 pmol/l) in defined conditions was 
spotted onto a stainless steel target and dried at room temperature. 
For the methylation analysis samples of the N-glycans were permethylated, hydrolyzed, 
reduced and acetylated. The resulting partially methylated alditol acetates were 
subsequently analyzed on a ThermoQuest CGQ ion trap GC/MS system.  
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3.3 α-2,3/2,8 bifunctional Campylobacter jejuni sialyltransferase (α-
2,3/2,8 ST) expression in E. coli cells 
3.3.1 Bacterial cell growth and culture 
3.3.1.1 Bacterial strains [259,260] 
Campylobacter jejuni ATCC 43438 
The strain Campylobacter jejuni ATCC 43438 (Serotype O:10) was ordered from American 
Type Culture Collection (ATCC) and cultivated by Dr. Silvia Gautsch at the Cantonal 
Laboratory in Basel. The cells were incubated in Brucella Broth (Oxoid) supplemented with 
growth factor and antibiotic (Polymyxin, Trimetoprim and Vancomycin) under 
microaerophilic conditions (7% CO2) (Anaerocult ® C, Merck KGaA, Germany) for 2 days 
at 37°C. Aliquots of 1.5 ml cell culture were centrifuged at 13`000 rpm for 2 min at room 
temperature (Eppendorf Centrifuge 5415D, Vaudaux-Eppendorf AG). The supernatant was 
discarded and the pellet stored at –20°C. 
Long-term storage: 
Using aseptic techniques, cells in the exponential growth phase (18/24 h) growing on agar 
plates supplemented with sheep blood (Biomérieux), were transferred to vials containing 
beads in cryopreservation fluid (Technical Service Consulting Ltd.), making a thick cell 
suspension. Fluid was removed and the vial was stored at – 80°C. Similarly, cells were 
transferred to 1 ml of sheep blood and several 1 ml aliquots were stored at – 80°C. 
 
Cloning strains: 
DH5α™ E. coli cells (Invitrogen)  
This is a cell strain usually used for cloning. The transformation efficacy is high and they 
can take up plasmids up to 30 kbp. In these cells, the plasmid is strongly replicated and 
can be transiently maintained. Due to the fact that even low levels of basal expression can 
disturb growth and stability of plasmids, background expression must be minimal. This is 
possible in DH5α cells, because they do not have a T7-RNA polymerase. 
JM109 E. coli cells  
Top10 E. coli cells  
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Production strains: 
The most widely used host for target gene expression. A sequence called DE3 contains 
the lacI gene, the lacUV5 promoter and the T7 RNA polymerase gene. These hosts are 
lysogens of the bacteriophage DE3. For transcription of the host T7 RNA polymerase, the 
lacUV5 promoter must be induced by isopropyl-β-D-thiogalactopyranoside (IPTG). The T7 
RNA polymerase transcribes the target DNA sequence, the target gene. 
 
E. coli expression strains Description/Application Antibiotic resistance 
AD494(DE3) (Novagen) trxB
- expression host; allows 
disulfide bond formation in E. coli 
cytoplasm 
Kanamycin (15 μg/ml) 
Rosetta-gami (DE3) 
(Novagen) 
general expression host; two 
mutations in cytoplasmic disulfide 
reduction pathway enhance 
disulfide bond formation in E. coli 
cytoplasm, provides rare codon 
tRNAs 
Tetracycline (12.5 μg/ml)  
Kanamycin (15 μg/ml)  
Chloramphenicol (34 μg/ml)
BL21(DE3) (Novagen) general purpose expression host none 
 
3.3.1.2 Growth media [257] 
The Table 3.24 describes the preparation of the culture media [257] used in this work. 
Table 3.24 Composition of cell culture growth media. 
Media Recipes for 1 l 
LB 
1% w/v Bacto Tryptone (BD), 0.5% w/v Bacto Yeast Extract (BD), 1% w/v 
NaCl (Fluka), adjust pH to 7.5 with 2 M NaOH, sterilize by autoclaving and 
store at RT 
Selective LB medium 
LB medium 
100 μg/ml Ampicillin was added just before use 
LB agar plates LB medium, 1.5% w/v Bacto agar (BD), sterilize by autoclaving, store at 4°C
Selective LB agar plates LB medium, 1.5% w/v Bacto agar (BD), sterilize by autoclaving and cool to 50°C, add 150 μg/ml Ampicillin in precooled medium, store at 4°C 
SOB 2% w/v Bacto Tryptonem, 0.5% w/v Bacto Yeast extract, 0.05% w/v NaCl, 
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2.5 ml 1 M KCl, adjust pH to 7.5 with 2 M NaOH and add H2O to 995 ml; 
sterilize by autoclaving and store at RT, before use add 5 ml sterile 1 M 
MgCl2  
SOC SOB medium with additional 20 ml of sterile 1 M D-glucose 
TB [257] 
1.2% w/v Bacto Tryptone, 2.4% w/v Bacto Yeast Extract, 4 ml glycerol, add 
H2O 900 ml; sterilize by autoclaving and add 100 ml of sterile 10 x TB 
phosphate and store at RT 
Selective TYE medium 3% w/v Bacto Tryptone, 0.5% w/v Bacto Yeast Extract, 70 μg/ml ampicillin 
Transformation medium LB medium, 10 mM MgCl2, 20 mM D-Glucose, made before use 
 
Table 3.25 Stock solutions [257]. 
TB phosphate (10 x) 
2.31 g (0.17 M) KH2PO4, 12.54 g (0.72 M) K2HPO4, dissolve 
in 90 ml H2O, adjust volume to 100 ml with H2O, sterilize by 
autoclaving and store at RT 
D-Glucose stock 1 M glucose sterilize by filtration and store at 4°C 
MgCl2 2 M MgCl2 sterilize by autoclaving and store at RT 
100 mM IPTG, Roche (isopropyl-β-D-
thiogalactopyranoside) 
2.38 g IPTG in 100 ml deionized H2O, sterilize by filtration 
and store at – 20°C 
100 mg/ml Ampicillin (sodium salt), 
(Fluka) 
Aliquots were stored at – 20°C 
100 μg/ml (cell suspension) and150 μg/ml (selective agar 
plates) was used 
 
Substances for each media and stock solution were mixed adding deionized water (Table 
3.24). For media, pH 7.5 was adjusted with 2 M NaOH. The media and stock solution was 
sterilized by autoclaving for 20 min at 121°C or by filtration (Millex®GP 0.22 μm, Millipore) 
and all additional substances described in Table 3.25 were added using aseptic 
techniques in laminar flow hood. 
 
3.3.2 Cell competence 
Normally, E. coli cells are not able to take up foreign DNA; instead they need to be treated 
under special conditions to get competent. Electroporation and heat-shock are two 
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methods for transformation. Subsequently cells are incubated in growth media and then 
plated out on Petri-dishes containing the specific antibiotic for selection [261,262]. 
 
Competent cells for heat-shock transformation 
Table 3.26 Protocol for heat-shock competent E. coli cells. 
Solution A 50 mM CaCl2, sterilize by autoclaving (Fluka), store at 4°C 
Solution B 50 mM CaCl2 (Fluka), 20% glycerol, sterilize by autoclaving and store at 4°C 
E. coli cell strain streaked out on agar plates 
LB-medium 
Selective LB-agar plates 
 
E. coli cells streaked on agar plates were grown overnight. The following day, clones were 
picked and 3 ml of LB medium was inoculated and incubated at 37°C until the culture 
entered the logarithmic phase. 1 ml of this culture was transferred to 100 ml LB medium in 
a 500 ml flask and incubated on a shaker at 37°C until the OD600 reached a value of 0.4-
0.5. The culture was placed on ice and incubated for a further 20 min. The cell suspension 
was transferred into sterile 50 ml centrifuge tubes and centrifuged at 5000 rpm for 10 min 
at 4°C. The supernatant was removed and the pellet was resuspended in 10 ml ice-cold 
solution A (Table 3.26). The cells were kept on ice for 30 min and centrifuged under the 
same conditions as mentioned before. The pellet was resuspended in 0.5 ml cold solution 
B, and aliquots of 50/100 μl were frozen rapidly in liquid nitrogen and stored at –80°C. 
Competent cells for electroporation 
Table 3.27 Protocol for electrocompetent E. coli cells. 
SOB medium 
10% Gycerol stock solution (Fluka BioChemika), sterilize by autoclaving 
and store at 4°C 
E. coli cell strain streaked out on agar plates 
Sorvall RC-5B Refrigerated Superspeed Centrifuge, GS 3 Rotor (Sorvall)
Selective LB-agar plates 
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E. coli cells streaked on agar plates were grown overnight. The following day, E. coli 
colonies were picked and 5 ml of SOB-medium free of magnesium chloride was inoculated 
for overnight pre-cultures. The pre-culture was transferred into a 1 l flask containing 250 ml 
of SOB medium (Table 3.27). The culture was grown at 37°C until an OD600 of 0.6-0.8 was 
reached. All the steps during the cell harvesting were performed on ice. Cells were 
collected by centrifugation at 5000 rpm for 10 min at 4°C. The pellet was resuspended in 
250 ml ice-cold 10% glycerol. After centrifugation under the same conditions, the collected 
cells were washed in 50 ml ice-cold 10% glycerol solution. Cells were harvested by 
centrifugation and aliquots of 50/100 μl were directly frozen in liquid nitrogen and stored at 
–80°C. 
 
3.3.3 Cell transformation 
Transformation by heat-shock 
Table 3.28 Protocol for heat-shock transformation. 
Plasmid DNA construct 1 – 1.5 μl 
Heat-shock competent cells 50 μl 
Transformation medium 
LB-medium 
Selective LB-agar plates 
 
1 μl of the plasmid DNA construct was added to 50 μl CaCl2 competent E. coli cells (Table 
3.28). The cell suspension was kept on ice for 30 min and heat-shocked at 42°C for 90 sec 
using a heating block (Thermomixer comfort, Eppendorf). After incubation for 5 min on ice, 
950 μl of transformation medium was added. The cell suspension was shaken at 500 rpm 
for 1 h at 37°C and shortly centrifuged at 13 000 rpm. Supernatant was removed and a 
pellet was resuspended in 100 μl LB medium, plated out on selective LB-agar plates and 
incubated overnight at 37°C. 
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Transformation by electroporation 
Table 3.29 Protocol for transformation by electroporation. 
Plasmid DNA construct 2 – 10 μl 
Electrocompetent cells 50 μl 
Transformation medium 
LB-medium 
Filter-paper (VSWP 02500, Type VS, 0.025 μm) 
Selective LB-agar plates 
Gene Pulser ® Cuvette (BIO RAD) 0.1 cm electrode 
 
Before electroporation, the ligation mixture had to be dialyzed to remove the remaining 
salts. The ligation solution was applied on a filter that was placed in a Petri-dish containing 
deionized sterile water and dialyzed for 45 min As the transformation efficiency decreases 
100-fold at room temperature, the following steps were carried out on ice [257] 
Electrocompetent cells were transferred into a pre-cold sterile cuvette (4°C), and 10 μl of 
the dialyzed ligation solution was added (Table 3.29). The cells were electroporated at 400 
Ω, 1.75 kV and 25 μF with time constant in the range of 6 – 8 ms. 950 μl of transformation 
medium was added and cells were further incubated in the heating block shaking at 500 
rpm for 1 h at 37°C. Furthermore, 300 μl of the electroporated cell suspension was plated 
on a selective LB-agar plate and incubated overnight at 37°C. 
3.3.3.1 Transformation efficiency test (colony forming units) 
Transformation efficiency is defined as the number of colony forming units (cfu) produced 
by 1 μg of control DNA (supercoiled plasmid DNA) and is measured by performing a 
control transformation reaction using a known quantity of DNA, typically 0.1 ng, then 
calculating the number of cfu formed per microgram DNA. 
100 μl of E. coli competent cells were transformed with 1 μl (4 ng/μl) of plasmid DNA. 100 
μl of different cell dilutions (1:10, 1:100, 1:1000) were seeded onto selective agar plates 
and incubated overnight at 37°C. The following day, cells were counted and transformation 
efficiency was calculated as follows. 
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Equation for transformation efficiency (cfu/μg): 
μg
ng  10 x 1
platedDNA   control of ng
plate control on cfu ×  
 
3.3.4 Long-term storage of E. coli strains 
Bacteria can be stored as glycerol stocks, which enable long-term storage at –80°C. 
Therefore, 0.85 ml logarithmic-phase E. coli cell culture was added to the vials containing 
0.15 ml sterilized glycerol. The vials were vortexed vigorously to ensure mixing of the 
bacterial culture and the glycerol, quickly frozen in liquid nitrogen and stored at –80°C. 
 
3.3.5 Cloning, expression and purification of α-2,3/2,8 bifunctional 
sialyltransferase using pEZZ18 vector 
C. jejuni genomic DNA isolation 
Genomic DNA isolation from the C. jejuni ATCC43438 strain was performed using a 
Wizard genomic DNA purification kit (Promega Corporation, Madison, WI, USA) as 
described by the manufacturer. 
3.3.5.1 PCR amplification and restriction enzyme digestion of cst-II gene [263,264] 
Forward primer: Tm = 67.1 
 5‘ ccg gaattc g aaa aaa gtt att att tct gga aat 3‘ 
Reverse primer: Tm = 66.5 
 5‘ cgc ggatcc tca tta ttt tcc ttt gaa ata atg 3‘ 
Internal primer: 
 5‘ acc tca gga gtc tat atg tgt gca 3‘ 
A specific DNA sequence can be amplified by PCR using cell-free conditions. This method 
comprises 3 steps: template denaturation, primer annealing and extension of the annealed 
primers by the DNA polymerase. 
3
EcoR I 
BamH I 
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A master mix of PCR reaction substances was prepared (Table 3.30) with exception of the 
genomic DNA and the DNA polymerase, which were added just before the beginning of 
the PCR reaction. The solution was kept on ice to prevent degradation of the DNA. 
Taq DNA Polymerase (Sigma) is thermostable enzyme with 5’ → 3’ DNA polymerase and 
5’ → 3’ exonuclease activity. 
Table 3.30 PCR reaction mixture for Taq DNA polymerase. 
Reagents Mixture Temperature Time Cycles Nr. 
Sterile, deH2O 39.25 μl Hold 94°C 4’  
10 mM PCR dNTPs 1 μl Denaturation 94°C 1’ 
20 mM 5‘ primer  1 μl 
20 mM 3‘ primer  1 μl 
Genomic template DNA 2.5 μl 
Annealing 52°C 1’ 
PCR buffer (10 x) 5 μl Elongation 72°C 1’ 
35 
Taq DNA Polymerase 5 U/μl 0.25 μl Final elongation 72°C 5’  
Total volume 50 μl   
 
Pfu DNA polymerase (Promega) is a thermostable enzyme. It catalyzes the DNA-
dependent polymerization of nucleotides into duplex DNA in the 5’ → 3’ direction in the 
presence of magnesium ions. The enzyme also exhibit 3’ → 5’ exonuclease (proofreading 
activity). A master mix of PCR reaction substances was prepared as described in Table 
3.31. 
Table 3.31 PCR reaction mixture for Pfu DNA polymerase. 
Reagents Mixture Temperature Time Cycles Nr. 
Sterile, deH2O 35.5 μl Hold 94°C 3’  
10 mM PCR dNTPs 2 μl Denaturation 95°C 1’ 
20 mM 5‘ primer  2 μl 
20 mM 3‘ primer  2 μl 
Genomic template DNA 2.5 μl 
Annealing 52°C 1’30’’ 
35 
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PCR buffer (10 x) 5 μl Elongation 72°C 2’ 
Pfu DNA Polymerase 3 U/μl 1 μl Final elongation 72°C 10’  
Total volume 50 μl   
 
PCR reaction was performed in Gene Amp PCR System 2400, Perkin Elmer. PCR product 
was purified using GenElute PCR Clean-up kit (Sigma) following the protocol 
recommended by the manufacturer and digested for 5 h at 37°C using EcoR I and BamH I 
restriction enzymes (Table 3.32). The digested DNA product was loaded onto a 1% 
agarose gel (see chapter 3.3.5.2), excised from the gel, extracted and eluted in 30 μl 
elution buffer using GeneElute gel extraction kit (Sigma). 
 
Table 3.32 Enzyme digestion of the cst-II gene. 
Reagent Volume 
PCR product (cst-II gene) 80 μl 
10 x New England Biolabs 2 
buffer (NEB) 9.5 μl 
EcoR I (20 000 U/ml, NEB) 2 μl 
BamH I (20 000 U/ml, NEB) 2 μl 
H2O (sterile, deionized) 1.5 μl 
Total volume 95 μl 
 
3.3.5.2 Agarose gel analysis [265] 
The agarose gel electrophoresis method was used for separation, preparative isolation 
and purification of DNA fragments. Depending on the size and shape of the DNA fragment, 
the agar concentration can be varied in order to find an optimal concentration (Table 3.33). 
An intercalating fluorescent dye, ethidium bromide, was added to the agar gel to visualize 
DNA fragments under the UV light. 
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Table 3.33 Components for agarose gel electrophoresis. 
TBE-buffer (1 x) 44.6 mM Tris, 44.6 mM Boric acid (Sigma), 1 mM EDTA (Sigma) 
Loading buffer (6 x) (Sigma) 
DNA Molecular Weight Marker X (0.07-12.2 kbp) (Roche Diagnostics GmbH) 
 
Table 3.34 The agarose gel preparation. 
1% agarose gel   
Agar (Molecular Biology Grade, Eurogent) 1 g 
TBE buffer 100 ml 
Ethidium bromide solution 1% (w/v), (AppliChem) 2 μl 
 
Preparation of the gel (Table 3.34): 
The components were mixed and heated in a microwave until the 1% agar was dissolved. 
The solution was cooled to 50-60°C and ethidium bromide was added. The agar solution 
was poured into a gel tray and after polymerization of the gel, a tank was filled with 1 x 
TBE-buffer. 
Preparation of the samples:  
The DNA samples were diluted, if necessary, with deionized water and loading buffer (6 x) 
was added. DNA molecular weight marker X, which is used as standard to compare the 
size of the DNA fragments, was prepared (Table 3.33). The samples were loaded on the 
gel, run at 80-100 V and fragments were visualized under UV light. 
3.3.5.3 pEZZ18 vector preparation [266] 
Plasmid DNA, pEZZ18 (Amersham pharmacia biotech) was amplified in the E. coli JM109 
strain and purified using the GFX Micro Plasmid Prep Kit (Amersham Pharmacia Biotech), 
according to the protocol recommended by the manufacturer. 50 μl of pEZZ18 plasmid 
DNA was digested in a total reaction volume of 60 μl, using the same protocol used for the 
digestion of PCR products (Table 3.32). After digestion for 5 h at 37°C, plasmid DNA 
vector was dephosphorylated using calf intestine alkaline phosphatase (CIAP) for 1 hour at 
37°C (Table 3.35). Enzyme activity was stopped by incubating the reaction mixture for 10 
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min at 65°C. Digested and dephosphorylated plasmid vector, pEZZ18 was loaded onto 1% 
agarose gel, excised from the gel using GeneElute gel extraction kit (Sigma), and following 
the protocol instructions recommended by the manufacturer eluted in 30 μl elution buffer. 
Table 3.35 The calf intestine alkaline phosphatase reaction mixture. 
Reagent Volume 
EcoR I/BamH I digested pEZZ18 plasmid 60 μl 
10 x CIAP buffer 7 μl 
CIAP (1U/μl, Roche) 1.5 μl 
H2O (sterile, deionized) 1.5 μl 
Total volume 70 μl 
 
3.3.5.4 DNA quantification [265] 
Plasmid DNA quantification is generally performed by spectrometric measurement of the 
absorption at 260 nm, or by agarose gel analysis. 
DNA quantification by spectophotometry 
Plasmid DNA concentration was determined by measuring the absorbance at 260 nm 
(A260) in a spectrophotometer using a quartz cuvette. For reliable DNA quantification, A260 
readings lay between 0.1 and 1.0. An absorbance of 1 unit at 260 nm corresponded to 50 
μg plasmid DNA per mililiter. 
⎥⎦
⎤⎢⎣
⎡⇒=
ml
μg50  1 A  260  
The DNA sample was diluted in Tris-HCl buffer (pH 7.0) and the absorbance at 260 nm 
was measured. Calculations were performed using the following equation: 
factor dilution*A*
ml
μg 50  c(DNA) 260⎥⎦
⎤⎢⎣
⎡=  
DNA quantification by agarose gel analysis 
Agarose gel analysis enables quick and easy quantification of DNA, especially for small 
(0.05 kb) DNA fragments. As little as 20 ng DNA can be detected by agarose gel 
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electrophoresis with ethidium bromide staining.  
The DNA sample was run on an agarose gel alongside known amounts of lambda DNA 
(25 ng – 100 ng). The amount of sample DNA loaded was estimated visually by 
densitometric measurement of band intensity and comparison with a standard curve 
generated using DNA of known concentration. 
3.3.5.5 Ligation  
Digested DNA fragments and plasmid vector were ligated using the T4 DNA ligase. This 
enzyme repairs breaks in one strand of a dsDNA molecule. The overhanging single 
stranded tails were joined resulting in new recombinant DNA plasmids.  
Ligation mixture (Table 3.36) was incubated overnight, starting the reaction at room 
temperature and subsequently decreasing to 4°C. Heat-shock DH5α E. coli competent 
cells were transformed with ligation mixture (30 μl) and bacterial clones resistant to 
ampicillin were picked and checked for cst-II gene presence. 
Table 3.36 The ligation mixture. 
Reagent  Volume 
cst-II gene (EcoR I/BamH I digested) 6 μl 
pEZZ18 plasmid vector (EcoR I/BamH I digested) 6 μl 
2 x T4 rapid ligation buffer (Promega) 15 μl 
T4 DNA-Ligase 400 U/l (BioLabs, New England) 2 μl 
Water (sterile, distilled) 1 μl 
Total volume 30 μl 
 
3.3.5.6 Analysis of pEZZ18 recombinants 
To prove the presence of the pEZZ18 plasmid-vector recombinant construct, resistant 
clones growing overnight on selective LB-agar plates were picked and used to inoculate 3 
ml selective LB medium. The cultures were grown overnight shaking at 300 rpm (37°C). 
The following day, plasmid DNA was isolated using the GFX Mikro Plasmid Prep Kit, 
(Amersham Biosciences) as recommended by the manufacturer, and checked by PCR 
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(using FW1, RW1 and internal primer) and an enzyme digestion method (Table 3.37) for 
the presence of the cst-II gene. 
All positive clones were sent for sequence analysis to Microsynth GmbH. 
Table 3.37 The restriction digestion mixture. 
Reagent Volume 
Plasmid DNA 15 μl 
10 x New England Biolabs 2 
buffer (NEB) 2 μl 
EcoR I (20 000 U/ml, NEB) 1 μl 
BamH I (20 000 U/ml, NEB) 1 μl 
H2O (sterile, deionized) 1 μl 
Total volume 20 μl 
 
DNA Molecular Weight Marker X (0.07-12.2 kbp) (Roche) 
All the components described in Table 3.37 were mixed adding the restriction enzymes 
just before starting the incubation. The reaction mixture was incubated in the heating block 
overnight at 37°C. The samples were analyzed by 1% agarose gel electrophoresis. 
Positive clones were stored at – 80°C as glycerol stocks. 
3.3.5.7 α-2,3/2,8 bifunctional sialyltransferase expression and determination [266] 
Reaction buffer 100 mM Na cacodylate (pH 7.5), 0.3% Triton X-100, 10 mM MgCl2. 
 
1 ml or 4 ml (for production) of HB101 E. coli overnight cell culture was transferred to 50 
ml or 200 ml of selective TYE medium, respectively. Cultures were shaken at 300 rpm 
overnight at 37°C. Cells were collected by centrifugation at 5000 rpm for 15 min at RT, and 
pellets stored for a short time at – 20°C. This was followed by resuspension in 5 ml of 
reaction buffer. Pellets were kept on ice and sonicated 6 x 10 sec with 10 sec of pauses at 
200-300 W (Vibra cell, Sonics and materials inc, Danbury CT USA). Lysate was 
ultracentrifuged at 21 000 rpm for 1 h at 4°C. Samples were checked for enzyme 
expression using SDS-PAGE and Western blotting analysis. Western blotting was 
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performed using mouse anti protein A IgG (1:1700) as a primary antibody (Sigma) and 
goat anti-mouse alkaline phosphatase conjugated IgG (1:30 000) as a secondary antibody 
(Sigma). α-2,3 activity was checked in a reaction with 600 μM of Type II and acceptor 3. α-
2,8 activity was determined using 600 μM of 7 acceptor substrate. Incubation was done for 
5 hours at 37°C. 
3.3.5.8 α-2,3/2,8 bifunctional sialyltransferase purification [266] 
Table 3.38 Buffers for protein purification by IgG affinity chromatography. 
Washing buffer Tris 
saline tween (TST) 
50 mM Tris (pH 7.6), 150 mM NaCl, 0.05% Tween 
20 
Binding buffer 5 mM NH4Ac (pH 5.0), pH adjusted with acetic acid 
Elution buffer 0.5 M acetic acid (pH 3.4), pH adjusted with 5 M NH4Ac 
 
Before usage, IgG sepharose affinity column was equilibrated using 3 CV of elution buffer 
as the first equilibration step, followed by 3 CV of washing buffer (Table 3.38). This 
procedure was repeated twice. The equilibrated IgG sepharose column was loaded with a 
cell soluble fraction which was preliminary filtrated (0.22 μm). The column was washed 
with 15 CV of washing buffer and 10 CV of binding buffer using a flow rate of 1.5 ml/min, 
and finally with 7.5 CV of elution buffer with a flow rate of 0.5 ml/min. Eluted fractions were 
neutralized with 2 M Tris. 
Soluble protein fraction was also purified applying to CDP-hexanolamine-agarose column 
using the protocol described previously in the chapter 3.1.4. 
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3.3.6 Cloning, expression and purification of α-2,3/2,8 bifunctional 
sialyltransferase using pET vector expression system 
3.3.6.1 PCR amplification of cst-II gene [259,264] 
The same methods which were used for the pEZZ18 expression system (see chapter 
3.3.5) were applied for the pET expression system as well. However, all modifications of 
the methods will be described. 
 
pET15b primers 
Forward primer: Tm = 59.4 
5‘ ggaattc catatg atg aaa aaa gtt att att tct 3‘ 
Reverse primer: Tm = 59.5 
5‘ cgc ggatcc tca tta ttt tcc ttt gaa ata atg 3‘ 
Reverse primer Δ32C: Tm = 64.5 
 5‘ cgc ggatcc tta att aat att ttt tga aaa ttt 3‘ 
pET21b primers 
Forward primer: Tm = 59.4 
5‘ ggaattc catatg atg aaa aaa gtt att att tct 3‘ 
Reverse primer: Tm = 70.9 
5‘ cgc ggatcc cg ttt tcc ttt gaa ata atg ctt 3‘ 
Reverse primer Δ32C: Tm = 68.3 
5‘ cgc ggatcc cg att aat att ttt tga aaa ttt 3‘ 
pET11c primers 
Forward primer: Tm = 59.4 
5‘  ggaattc catatg atg aaa aaa gtt att att tct 3‘ 
Reverse primer:  Tm = 59.5 
5‘ cgc ggatcc tca tta ttt tcc ttt gaa ata atg  3‘ 
Nde I 
BamH I 
BamH I 
Nde I 
BamH I 
BamH I 
Nde I 
BamH I 
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Primers for gene mutation: 
Forward primer (G53S): Tm = 54.3 
5’ cag tat ttt aca atc cta gtc ttt 3’ 
Forward primer (R182N): Tm = 64.8 
5‘ ggctc ctg att tta aaa atg ata act cac ac  3’ 
Forward primer (D177N; R182N):  Tm = 64.8 
5‘ ggctc cta att tta aaa atg ata act cac ac  3’ 
 
Table 3.39 The PCR reaction mixture for Pfu DNA polymerase. 
Reagents Mixture Temperature Time Cycles Nr. 
Sterile, deH2O 36 μl Hold 94°C 3’  
10 mM PCR dNTPs 1 μl Denaturation 95°C 1’ 
20 mM 5‘ primer  1 μl 
20 mM 3‘ primer  1 μl 
Genomic template DNA 
(1:10) 5 μl 
Annealing 50°C 1’30’’ 
PCR buffer (10 x) 5 μl Elongation 72°C 2’ 
35 
Pfu DNA Polymerase 3 U/μl 1 μl Final elongation 72°C 10’  
Total volume 50 μl   
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Table 3.40 The PCR reaction mixture for the PfuTurbo DNA polymerase. 
Reagents Mixture Temperature Time Cycles Nr. 
Sterile, deH2O 40 μl Hold 98°C 5’  
10 mM PCR dNTPs 1 μl Denaturation 98°C 1’ 
5‘ primer (PCR product) 2 μl 
Vector 0.5 μl 
Annealing 55°C 30’’ 
PCR buffer (10 x) 5 μl Elongation 72°C 13’ 
25 
PfuTrubo DNA Polymerase 
2.5 U/μl 1 μl Final elongation 72°C 10’ 
 
Total volume 50 μl   
 
3.3.6.2 Restriction enzyme digestion of the plasmid DNA and the gene of interest 
The cst-II gene and a plasmid DNA were digested for 5 h at 37°C with Nde I and BamH I 
restriction enzymes using BamH I reaction buffer (NEB), which was the suggested buffer 
for double digestion. Additionally, plasmid DNA was dephosphorylated for 1 h at 37°C and 
finally inactivated incubating for 10 min at 65°C. 
3.3.6.3 Ligation 
Ligation mixture (Table 3.41) was incubated overnight starting the reaction at room 
temperature and subsequently decreasing to 4°C. Electrocompetent DH5α E. coli cells 
were transformed with ligation mixture (5 μl), and bacterial clones resistant to ampicillin 
were picked and checked for cst-II gene presence. 
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Table 3.41 The ligation mixture. 
Reagent  1:2 2:2 
pET plasmid vector (Nde I/BamH I digested) 1 μl 2 μl 
cst-II gene (Nde I/BamH I digested) 2 μl 2 μl 
10 mM ATP (Sigma) 1 μl 1 μl 
10 x T4 DNA ligation buffer (NEB) 1 μl 1 μl 
T4 DNA-Ligase 400 U/l (BioLabs, New England) 1 μl 1 μl 
Water (sterile, distilled) 4 μl 11 μl 
Total volume 10 μl 20 μl  
 
3.3.6.4 Analysis of pET recombinants 
DH5α E. coli transformants were analyzed using the plasmid preparation for the PCR and 
restriction enzyme analysis described in the chapter 3.3.5.6. All positive clones were sent 
for sequence analysis to Microsynth GmbH. 
3.3.6.5 α-2,3/2,8 bifunctional sialyltransferase expression and determination 
After transformation of recombinant pET vector into the expression host, the BL21 E. coli 
cell strain (a λ DE3 lysogen), positive clones were streaked on selective agar plates and 
grown overnight at 37°C. The following day, single colonies were picked and grown 
overnight at 37°C in 3 ml of selective LB medium. 1 ml of this culture was used to inoculate 
50 ml of selective LB medium. The culture was incubated with shaking at 37°C until the 
OD600 reached 0.6. An uninduced control sample was taken, and the culture was induced 
with 1 mM IPTG solution (100 mM stock). The cell culture was further incubated for 2-3 h. 
Flasks were placed on ice for 5 min, the sample removed and cells were harvested by 
centrifugation at 5000 x g for 5 min at 4°C. Supernatant was saved for further analysis. 
The cell pellet was stored at – 20°C and treated according to the protocol.  
Determination of the expressed protein was performed using SDS-PAGE method and 
Western Blotting analysis (see chapter 3.1.3). Western blotting was performed using 
monoclonal mouse anti His Tag (1:2000) as a primary antibody (Novagen) and goat anti-
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mouse (whole molecule) alkaline phosphatase conjugated IgG (1:5 000) as a secondary 
antibody (Sigma). Enzyme was checked in the MES reaction buffer for the α-2,3/α-2,8 
activity with 600 μM of Type II substrate. The α-2,8 activity was determined using 600 μM 
of 7 acceptor substrate. 
3.3.6.6 Determination of target protein solubility [267] 
Native lysis buffer 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 10 mM 
imidazole 
Denaturing lysis buffer 10 mM Tris-HCl (pH 8.0), 8 M urea, 100 mM NaH2PO4 
 
1 ml of overnight culture was used to inoculate 50 ml of selective LB medium. Cultures 
were incubated at 37°C and induced with 1 mM IPTG when the OD600 reached 0.6. Further 
growth occurred for 16 h at 30°C and 37°C. Cells were collected by centrifugation at 10 
000 x g for 20 min at 4°C and the pellet was washed five times. This was followed by 
sonication (6 x 10’’) in Tris-HCl buffer (pH 8.0). For isolation of the soluble protein fraction, 
the pellet was resuspended, twice more sonicated and centrifuged in the native lysis 
buffer. The insoluble protein fraction was recovered by washing the pellet in denaturing 
lysis buffer. After each sonication step, a sample (100 μl) for SDS-PAGE was removed, 
resuspended in 3 x RB and stored at – 20°C. Collected samples were analyzed using 
SDS-PAGE method (see chapter 3.1.3). 
3.3.6.7 Optimization of the cell growth and enzyme production 
Growth curve [265] 
E. coli strain BL21(DE3), AD494(DE3) and RG(DE3) grown on LB agar plate  
E. coli strain BL21(DE3), AD494(DE3) and RG(DE3) with plasmid-construct grown on 
selective LB agar plate 
E. coli strain BL21(DE3), AD494(DE3) and RG(DE3) with plasmid-vector grown on 
selective LB agar plate 
LB, TB, SOB medium 
 
BL21(DE3): 3 ml LB medium was inoculated with a BL21(DE3) clone picked on a freshly 
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grown LB agar plate. The culture was incubated with shaking at 300 rpm overnight at 
37°C. Flasks containing 4 ml of different media (LB, TB, SOB) were inoculated with 40 μl 
of overnight culture. Some cultures were incubated at 37°C, and others at 30°C. The 
optical density was measured at 600 nm (OD600) over a period of 24 h. 
Cells containing the plasmid-construct: 50 ml cell cultures in selective LB, TB and SOB 
media were inoculated with 1 ml of overnight culture and incubated with shaking at 300 
rpm at 37°C until an OD600 of 0.6-0.8 was reached. The protein expression was induced 
with 1 mM IPTG. After induction, 50 ml cultures were incubated at RT, 37°C and at 30°C 
with shaking at 300 rpm. The OD600 of these cultures was also measured over a period of 
24 h. OD600 was kept in the linear range by sample dilution. 
Cells containing only the plasmid-vector (negative control): Culture-tubes containing 4 ml 
selective SOB, TB and LB-medium were inoculated with 40 μl overnight culture and 
incubated at 37°C in the shaker until an OD600 of 0.6-0.8 was reached. Further incubation 
of cultures was done at RT, 37°C, and 30°C shaking at 300 rpm. The OD600 was measured 
over the period of 24 h. 
3.3.6.8 Time course analysis [265,267] 
E. coli strain BL21(DE3) with plasmid-construct grown on selective LB agar plate 
E. coli strain BL21(DE3) with plasmid-vector grown on selective LB agar plate 
 
Cell lysis buffer 20 mM Tris, 0.3 M NaCl, 1% Triton X-100 
(Sigma), 5 mM Imidazole (Merck) 
 
The expression of proteins can be optimized with time course analyses. At different times 
after 1 mM IPTG induction, the expression of the proteins was analyzed by SDS-PAGE. 
For this assay, the same 50 ml cultures as for the growth curve were used. Over a period 
of 24 h, samples of 100 μl were removed from 50 ml cultures grown in different media that 
were incubated at RT, 30°C and 37°C. They were centrifuged for 5 min at 13 200 rpm. To 
one of the pellets 50 μl reducing buffer was added to prepare it for SDS-PAGE. The other 
pellet was resuspended in 100 μl of cell lysis buffer. After sonication over 2 min (rounds of 
10 s of sonication followed by a 10 s pause) and following centrifugation, 20 μl of 
supernatant was mixed with 10 μl of 3 x RB. For the negative control, cultures containing 
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only the plasmid-vector were induced with 1 mM IPTG. Samples were removed 
immediately after induction with IPTG and after 27 h from the cultures growing at RT, 30 
and 37°C. The samples were treated in the same way as the samples containing the 
plasmid-construct. Samples were analyzed by SDS-PAGE (see chapter 3.1.3).  
3.3.6.9 IPTG induction optimization [259] 
E. coli strain BL21(DE3) with plasmid-construct was grown on the selective LB agar plate. 
Two clones were picked and resuspended in 3 ml selective LB medium. The culture was 
incubated overnight at 37°C with shaking at 300 rpm. Nine culture tubes containing 4 ml 
selective LB medium were inoculated with 40 μl overnight culture, and incubated until an 
OD600 of 0.6-0.8 was reached. Eight of these cultures were induced with different IPTG 
concentrations in the range of 0.2 to 10 mM, except one culture which was not induced 
and which served as a negative control. After induction, the cultures were incubated for 16 
h at 30°C with shaking at 300 rpm. 100 μl of each culture was centrifuged at 13 200 rpm 
for 5 min. The pellet was resuspended in 3 x RB and analyzed using SDS-PAGE (see 
chapter 3.1.3). 
3.3.6.10 α-2,3/2,8 bifunctional sialyltransferase production  
The 250 ml culture was centrifuged at 4000 x g for 20 min at 4°C and stored overnight at –
20°C. The cell pellet of 250 ml cell culture was resuspended in 10 ml of native lysis buffer. 
Cell pellets were kept on ice and sonicated for 6 x 10 s with 10 s of pauses (80-100 W). 
The cell debris was removed by centrifugation at 21 000 rpm for 1 h at 4°C (Centrifuge 
5804 R). The supernatant was filtrated (0.22 μm). 
3.3.6.11 α-2,3/2,8 bifunctional sialyltransferase purification 
Table 3.42 Buffers for protein purification by Ni-NTA affinity chromatography. 
 Purification under native conditions Purification under denaturing conditions 
Lysis buffer 50 mM NaH2PO4, pH 8.0, 300 mM 
NaCl, 10 mM imidazole 
10 mM Tris-HCl, pH 8.0, 8 M urea, 
100 mM NaH2PO4 
Wash buffer Lysisi buffer + 30 mM imidazole Lysis buffer, pH 6.3 
Lysis buffer, pH 5.9 Elution buffer Lysis buffer + 0.5 M imidazole 
Lysisi buffer, pH 4.5 
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The FPLC purification using Ni-NTA (5/10 ml) superflow under native or denaturing 
conditions. 
The Ni-NTA column was equilibrated with 5 CV of lysis buffer (Table 3.42). Appropriate 
lysate for native or denaturing purification was applied to the column and the column was 
washed with 5 – 10 CV of lysis buffer until the A280 was stable. The column was further 
washed with 5 – 10 CV of washing buffer to monitor the stability of the baseline at A280. 
Protein elution under native conditions was performed using 5 CV of elution buffer. Finally, 
the protein elution under denaturing conditions was performed using 5 CV of elution buffer 
(pH 5.9) and, if necessary, by application of 5 CV of elution buffer (pH 4.5). 
 
3.3.7 α-2,3/2,8 ST enzyme characterization 
Table 3.43 The acceptor substrates used for determination of enzyme kinetic parameters. OSE: O-
(trimethylsilyl)ethyl (O-CH2CH2-Si(Me)3), OLem: O-(Methoxycarbonyl)octyl (O-(CH2)8CO2Me), TCA: 
tri-chloro acetyl (COCCl3). 
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O
HO
HO
OH
OH
O O
O
NHAc
OH
OLem
H
553.597 
O
HO
OH
OH
O O
O
NHAc
OH
OLem
H
O
HO2C
O
HO
AcHN
HO
OH
OH
 
844.852 
O
HO
HO
OH
OH
O O
O
OH
OH
OSE
H
442.531 
O
HO
OH
OH
O O
O
OH
OH
OSEO
HO2C
O
HO
AcHN
HO
OH
OH
 
733.785 
O
HO
HO
OH
OH
O
O
NHAc
OH
OLem
O
H 553.597 
O
HO
OH
OH
O
O
NHAc
OH
OLemO
HO2C
O
HO
AcHN
HO
OH
OH
O
H
 
844.852 
O
HO
HO
OH
OH
O
O
NHAc
OH
OSE
HO
 
483.583 
O
HO
OH
OH
O
O
NHAc
OH
OSEO
HO2C
O
HO
AcHN
HO
OH
OH
HO
 
796.819 
1 or Type II 7 
2 or Type I 8 
9 3 
1413 
 93
O
HO
HO
OH
OH
O
O
NHTCA
OH
OSE
HO
 
586.923 
O
HO
OH
OH
O
O
NHTCA
OH
OSEO
HO2C
O
HO
AcHN
HO
OH
OH
HO
 
878.172 
O
HO
HO
OH
OH
O
O
OH
OH
OSE
HO
 
442.478 
O
HO
OH
OH
O
O
OH
OH
OSEO
HO2C
O
HO
AcHN
HO
OH
OH
HO
 
733.785 
O CO2Na
O
AcHN
HO
OH
OH
O
HO
HO
OH
OH
O
O
OH
OSE
HO
HO
 
755.767  
 
 
3.3.7.1 Enzyme activity assay optimization 
Reaction buffer optimization 
Table 3.44 Reaction buffers used for enzyme activity optimisation. 
NaCaCO buffer 100 mM Na cacodylate (pH 7.5), 0.3% Triton 
X-100, 10 mM MgCl2. 
Hepes buffer 50 mM Hepes (pH 7.5), 0.3% Triton X-100, 10 mM 
MgCl2 
MES buffer 50 mM MES (pH 7.5), 0.3% Triton X-100, 10 mM 
MgCl2 
 
For the enzyme activity assay, a pellet and a supernatant of recombinant E. coli cells were 
checked for α-2,3 and α-2,8 activity using different reaction buffers (Table 3.44) in the 
presence of 600 μM of Type II and 7 acceptor substrate (Table 3.43), respectively. This 
was done under the same conditions mentioned in the chapter 3.3.7.2. 
 
Calf intestine alkaline phosphatase (CIAP) assay 
Additional 1 μl of CIAP enzyme was added to the reaction mixture containing MES buffer 
and incubated under the same conditions mentioned previously in the chapter 3.3.7.2. 
10 4 
5 11 
6 
 94
3.3.7.2 Enzyme activity assay 
Table 3.45 Standard protocol for measuring the enzyme activity. 
Reagent Volume 
MES reaction buffer, pH 7.5  14 μl 
1 mM CMP-NeuNAc (2 nmol) 10 mM 2 μl 
CMP-[14C] NeuNAc 60 000 dpm (0.1 nmol) 1 μl 
600 μM acceptor 2 μl 
Purified enzyme fraction 1 μl 
Total Volume 20 μl 
A master mix of the different components (Table 3.45), not including the enzyme, was 
prepared. The enzyme (4 mU) was added just before starting the reaction. The mixture 
was centrifuged and incubated for one hour at 25°C either in the heating block or in the 
Gene Amp PCR System 2400. Depending on the enzyme concentrations, dilutions were 
used for different purified fractions. The samples were either immediately checked for 
activity or stored at –20°C to stop the enzymatic reaction. For separating the product from 
the reaction mixture, a solid phase extraction using C18 Sep-Pak Cartridges was 
performed as it was described in the chapter 3.1.5. 
3.3.7.3 Catalytic activity 
Enzyme was incubated for 72 hours at 25°C in MES reaction buffer containing 600 μM of 
Type II acceptor substrate, CMP-[14C ] NeuNAc (60 000 dpm) and non-labeled NeuNAc. 
Samples were collected on a regular basis and checked for the enzyme activity using C18 
Sep-Pak Cartridges (see chapter 3.1.5). 
3.3.7.4 Temperature dependent activity 
The master mix (Table 3.45) was prepared without the acceptor. It was divided into 
samples of 18 μl. The mixture was preheated for 5 min at a temperature between 4°C and 
72°C either in the heating block or on a Gene Amp PCR System 2400. Then, the acceptor 
(600 μM Type I or 600 μM 7) was added and samples were incubated for 6 h. The enzyme 
α-2,3/α-2,8 and α-2,8 activity was measured using the method described in the chapter 
3.1.5. 
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3.3.7.5 pH optimization 
The enzyme activity was measured using MES buffers with a wide pH range (5.0-10.0) 
and 600 μM of Type I acceptor (Table 3.45). The samples were incubated for 6 hours at 
25°C. The enzyme was added at the start of the reaction. 
3.3.7.6 Metal ions optimization 
The MES buffer containing 10 mM of different metal cations (MgCl2, MnCl2, NiCl2, KCl, 
CuCl2, ZnCl2, FeCl3, CaCl2 and CoCl2) was prepared and the pH was adjusted after 
dissolving the cations in the reaction buffer. Buffers containing 600 μM Type I acceptor 
were used for the sample preparation (Table 3.45) in order to measure enzyme activity. 
The positive control was MES buffer with 10 mM EDTA. After incubation for 6 hours at 
25°C, enzyme activity was measured. 
3.3.7.7 Cofactor dependent enzyme activity 
The enzyme activity was measured with 600 μM Type I acceptor using MES buffers 
containing 500 μM of different cofactors (NAD, NADH, NADP, NADPH and ATP). All the 
samples were prepared as described in Table 3.45. Positive control was prepared with 
MES buffer free of metal ions or containing 10 mM of Mg2+ ions. The enzyme was added 
at the start of the reaction and the samples were incubated for 6 hours at 25°C. 
3.3.7.8 Dimethyl sulfoxid dependent enzyme activity 
The enzyme activity was measured using MES buffers containing different DMSO 
concentrations (1-80%) and 600 μM acceptor 13 (Table 3.45). The enzyme was added at 
the start of the reaction and the samples were incubated for 6 hours at 25°C. As a positive 
control, enzyme was incubated in MES buffer free of DMSO solution. 
3.3.7.9 Determination of the enzyme kinetic parameters [248] 
Enzyme kinetics was performed using the components of reaction mixture described in 
Table 3.45. Relative rates for each free di(tri)saccharide acceptor substrate were 
calculated as a percentage of the incorporation of [14C] NeuNAc into the D-Gal-containing 
di(tri)saccharide. Under standard incubation conditions, at a temperature of 25°C for α-
2,3/α-2,8 activity, and at 37°C for α-2,8 activity (pH 7.5), formation of the product was 
shown to be linear in time. 
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For the KM value determination, it was used eight to nine different acceptor substrate 
concentrations were used for each acceptor substrate presented in Table 3.43. 
Enzyme kinetic parameters were obtained from double-reciprocal plots by linear 
regression analysis of Lineweaver-Burk plots. 
 
3.3.8 Preparative synthesis 
According to the enzyme activity and the kinetic data, first preparative syntheses were 
performed by Oliver Schwardt using Type I, 4 and D-lactose-OSE as acceptor substrates 
in the reaction. 
Preparative substrate 4 Preparative substrate 13 Preparative substrate 2 
MES buffer, pH 7.5 
10 mg 4 
1.5 eq CMP-NeuNAc 
400  μl (21.6 U/l) enzyme 
fraction 
Reaction time: 6 days (d) 
MES buffer, pH 7.5 
3 mg D-Lactose-OSE 
1.5 eq CMP-NeuNAc 
300  μl (21.6 U/l) enzyme 
fraction 
Reaction time: 3 days (d) 
MES buffer, pH 7.5 
3.8 mg Type I 
2.5 eq CMP-NeuNAc 
350  μl (3.5 U/l) enzyme 
fraction 
Reaction time: 3 days (d) 
 
The preparative reaction with 4 and D-lactose-OSE was started using 200 μl of the 
enzyme fraction. After 24 h, 200 μl and 100 μl of the enzyme fraction was added and 
incubated for 6 d or 3 d, respectively. The product was monitored by TLC and analyzed by 
MS and NMR. 
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4 Results and discussions 
 
 
 
It is well known that carbohydrates from glycolipids and glycoproteins with terminal sialic 
acids linked in α-2,3, α-2,6 and α-2,8 manner are involved in a broad variety of biological 
recognition and adhesion events [268-272]. Gangliosides, a group of sialylated 
glycosphingolipids widely present in mammalian tissues, have been recognized to play an 
important role in many biological processes such as cell-cell recognition, cell growth, 
differentiation, and neural functions [11,272,273]. Thus, the gangliosides GD1a and GT1b 
have been shown to bind with high affinity to the myelin-associated glycoprotein (MAG), a 
member of the Siglec family, which is a potent inhibitor of neurite outgrowth of most 
neurons [205,215,216,235,236]. 
The most common element recognized by MAG is the terminal 
NeuNAcα(2,3)Galβ(1,3)GalNAc oligosaccharide moiety of ganglioside, suggesting a 
special importance of this trisaccharide subunit and its affinity to MAG. 
In order to investigate their binding affinity to the MAG, large numbers of natural and 
modified oligosaccharides have to be applied for broad biological screening. Although 
numerous glycosylation methods are well known, the chemical synthesis of complex 
oligosaccharides is still not a routine procedure. Difficulties often occur from time-
consuming protecting group manipulations. Finally, chemical sialylations suffer from poor 
stereoselectivity due to the lack of neighboring group assistance in the sialic acid moiety 
[274]. A convenient alternative approach is the application of glycosyltransferases 
[153,275], e.g. with α-2,3 sialyltransferases (STs) a sialic acid moiety can be transferred 
from CMP-NeuNAc donor substrate α-selectively onto the 3-OH group of a terminal D-
galactose containing acceptor substrate. 
The investigations reported here are concentrated at the expression, purification and 
characterization of the eukaryotic and prokaryotic sialyltransferases, and their utilization in 
preparative chemo-enzymatic synthesis of oligosaccharide mimetics. 
To achieve this goal, recombinant rat Galβ(1,3/4)GlcNAc α-2,3 sialyltransferase (rST3Gal 
III, EC 2.4.99.6) [276], recombinant human Galβ(1,4)GlcNAc α-2,6 sialyltransferase 
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(hST6Gal I; EC 2.4.99.1) [90] and recombinant Campylobacter jejuni α-2,3/2,8 bifunctional 
sialyltransferase (Cst-II) [264] were expressed in different expression systems and applied 
to enzymatic sialylation for several natural and non-natural acceptor substrates. 
 
4.1 rST3Gal III expression in baculovirus-infected cells, purification and 
characterization 
The Galβ(1,3/4)GlcNAc α-2,3 sialyltransferase was first purified to homogeneity from the 
rat liver by Weinstein et al. [277]. This enzyme forms the NeuNAcα(2,3)Galβ(1,3)GlcNAc 
and NeuNAcα(2,3)Galβ(1,4)GlcNAc sequence typically found to terminate complex type 
N-linked oligosaccharide chains. These sequences were also found in O-linked sugar 
chains and in glycolipids. This enzyme transferred a sialic acid moiety from CMP-NeuNAc 
regio- and α-stereoselectively onto the 3-OH group of a terminal galactose. Furthermore, it 
was demonstrated that the proteolytically sensitive stem region in vivo yielded a soluble 
catalytically active enzyme [32,47]. 
Since high-level expression and secretion of gylcosyltransferases was possible by 
truncating them to soluble form [47], as mentioned before, recombinant baculovirus DNA 
containing the γ-interferon export sequence fused to the soluble form of the rat liver 
Galβ(1,3/4)GlcNAc α-2,3 sialyltransferase (rST3Gal III; EC 2.4.99.6) was kindly received 
from Dr. Markus Streiff [72]. 
For the recombinant enzyme expression and preparative production, the powerful 
baculovirus-based expression system was used. The baculovirus expression vector 
system (BEVS) is one of the most powerful and versatile eukaryotic expression system 
available [238,278]. This system has a high integration capacity for large gene inserts. The 
proteins expressed in BEVS were, in most cases, soluble and functionally active. This 
system is capable of performing post-translational modifications. This leads to a protein 
that is similar to its native counterpart, both structurally and functionally. Several post-
translational modifications have been reported to occur in baculovirus (BV)-infected insect 
cells, including N- and O- linked glycosylation, phosphorylation, acetylation, amidation, 
carboxymethylation, isoprenylation, signal peptide cleavage and proteolytic cleavage. In 
addition, tissue- or species-specific post-translational modifications were not performed in 
the BV, unless the modifying enzyme was co-expressed. Baculovirus-expressed 
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recombinant proteins were usually localized in the same subcellular compartment as the 
authentic protein. Insect cell lines were incapable of synthesizing sialylated lactosamine 
complex-type N-glycans or sialylated core 1 O-glycans and therefore were not suitable for 
the production of recombinant pharmaceutical glycoproteins for clinical use [279-281]. 
Nevertheless, the baculovirus expression system is the preferred system when the 
production of several 100 mg of protein is required within a short time and a 
mammalian/human type of glycosylation is not of primary importance. 
 
4.1.1 rST3Gal III expression and purification 
4.1.1.1 Amplification of the virus stocks and determination of the virus titer 
In order to generate a high titer of recombinant virus stocks for maximal protein production, 
the recombinant virus was amplified and determined using the end-point dilution method. 
The basic principle of the method of Reed and Muench [239] is to assume that all cultures 
infected at a particular dilution would have been infected at all lower dilutions, and 
conversely, that all cultures uninfected at that dilution would have been uninfected at all 
higher dilutions. Considering this statement, uninfected and infected cells at certain 
dilutions (10-5, 10-6 10-7) were counted 5 days post-infection (pi). Using a given equation 
and collected cell-infected results, virus titer containing recombinant baculovirus DNA was 
amplified and estimated at the level of 3 x 107 pfu/ml [238,239]. Enzyme accumulation was 
monitored over time and a peak of activity was found approximately 72 h post-infection. 
 
4.1.1.2 Purification of the rST3Gal III 
After an optimized protein expression of approximately 128.74 mg/l of total protein (Table 
4.1), and enzyme activity of 1.85 U/l, the 72 h post-infection media of the infected Sf9 cells 
was collected. 
To purify the rST3Gal III recombinant enzyme from conditioned media produced by cells 
infected with recombinant baculovirus, the media was applied to a column of CDP-
hexanolamine-agarose (10 μmol CDP/ml agarose, Calbiochem). The FPLC 
chromatography profile demonstrated only one peak obtained with 1 M Na-cacodylate 
buffer (Figure 4.1). 
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Figure 4.1 The FPLC chromatogram of rST3Gal III purification using CDP-hexanolamine-agarose 
affinity column. The AU determine absorption unit, conductivity is displayed as mS/cm, and the FT 
describes the flow through. The arrow points the obtained peak collected in the fractions 1-3. 
 
The enzyme has revealed a loss of activity during the purification and concentration 
procedure (Table 4.1). Comparing the total activity of the enzyme measured in milliunits, a 
nearly nearly 7-fold decreased activity during the purification steps and almost 5-fold 
during concentration of Fr 2 containing partially purified enzyme was observed. One 
possible explanation for decreased enzyme activity could be the purification correlated 
loss of important enzyme cofactors other than metal ions. 
 
Table 4.1 Comparison of the starting material to the final yields of the purified and concentrated 
enzyme fraction. 
Total protein [mg/l] Total [mg] Total [mU] U/l U/g
Load 128.74 5.15 74.00 1.85 14.37
Fr 2 64.84 2.59 11.70 1.30 4.51
Fr 2 (16 x conc.) 24.29 0.97 2.12 4.24 2.18
 
 
A
U
 
Time [h] 
m
S/
cm
 
FT 
Peak: Fr 1-3 
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SDS-PAGE analysis revealed several additional signals within the eluted peak. Fr 1 
showed three weak signals, while two signals were detected in Fr 2 and 3 (Figure 4.2 a). 
Apart from the signal approximately at 66 kDa, which was shown to be recombinant 
rST3Gal III (see below), other signals might have appeared because of unspecific binding 
to the affinity column. 
The fractions were analyzed by Western blot using rabbit anti-human ST6Gal I purified 
serum as a primary antibody. This antibody was raised against the fusion-protein which 
contained human ST6Gal I with the β-galactosidase portion [282]. The presence of 
rST3Gal III with a molecular weight of approximately 66 kDa was confirmed in all three 
fractions. Fr 2 showed the strongest signal and therefore, containing the highest amount of 
the enzyme (Figure 4.2 b). Despite the impurities detected in the obtained fractions, the 
enzyme activity of 1.3 U/l non-concentrated and 4.2 U/l concentrated Fr 2 was sufficient to 
perform chemo-enzymatic preparative synthesis (Table 4.3). 
 
 
 
Figure 4.2 (a) SDS-PAGE (12.5%) analysis of the rST3Gal III purification by CDP-hexanolamin-
agarose affinity chromatography (silver staining) and (b) Western blotting. Western blot analysis 
was performed using rabbit anti-ST6Gal I purified serum as a primary antibody and goat anti-rabbit 
immunoglobulin G (IgG) alkaline phosphatase (AP) conjugated as a secondary antibody. M: low 
molecular marker; CM: collected medium; L: load; FT: flow through; W: elution with wash buffer; Fr: 
fractions collected during the chromatography. The arrow points the rST3Gal III. 
 
The ST3Gal III shares three regions of homology with other sialyltransferases 
[78,101,276]. These two peptide sequences, also called sialyl motifs, were found on all the 
M CM L FT W Fr1 Fr2 Fr3 
66 kDa 
45 kDa 
36 kDa 
29 kDa 
24 kDa 
20 kDa 
 
M CM L FT W Fr1 Fr2 Fr3 
a b 
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sialyltransferases cloned so far and seem to be characteristic for the sialyltransferase 
family [23]. Hence, the sialyl motifs are potential cross-reactive epitopes. The soluble 
recombinant rat ST3Gal III and human ST6Gal I share 18.7% homology in a global 
alignment and 24.9% in a local alignment, particularly in the L sialyl motif domain. 
Surprisingly, characterization of the expressed and purified rat ST3Gal III revealed an 
unexpected cross-reactivity of an antibody directed against the human ST6Gal I-β-
galactosidase fusion protein with the rat ST3Gal III. A very specific single band was 
obtained with a molecular weight approximately at 66 kDa (Figure 4.2 b). Due to the strong 
homology at the amino acid level between the same sialyltransferases in different species, 
interspecies cross-reactivity had already been observed. However, cross-reactivity 
between different sialyltransferases originating from distinct species has never been 
reported [72,282]. The unexpected cross-reactivity in this experiment could be explained 
on the basis of the homology between these different sialyltransferases. Another line of 
evidence showed the unspecific reaction of this antibody with β-galactosidase [72,282]. 
This was consistent with my results where the antibody reacted with β-galactosidase, one 
of the standard proteins with molecular weight of 116 kDa, present in the high molecular 
weight marker (HMW; Sigma). 
Collected fractions obtained during the protein purifications were checked for enzyme 
activity (Figure 4.3) using 200 μM of natural Type II acceptor substrate (Table 3.14). Fr 2 
exhibited 45% of the relative enzyme activity, while Fr 3 showed 11%. The relative acitivity 
of the enzyme was calculated as a percentage of incorporation of the [14C] NeuNAc radio-
labeled donor in the acceptor substrate. 
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Figure 4.3 Enzyme activity assay of CDP-hexanolamine-agarose affinity chromatography collected 
fractions. Samples were incubated with 200 μM of Type II acceptor substrate for 1 h at 37°C (L: 
load; FT: flow through; W: wash; Fr: fraction). The enzyme activity was calculated as described in 
chapter 3.1.5. 
 
4.1.2 Characterization of the rST3Gal III enzyme 
4.1.2.1 rST3Gal III catalytic activity 
In order to optimize the activity of the enzyme with natural Type II acceptor substrate 
(Table 3.14), an enzyme linearity experiment was performed. The enzyme was incubated 
for three hours at 37°C. Enzyme activity, as measured by incorporation of radioactive-
labeled NeuNAc in the Type II acceptor substrate, was determined during 180 minutes of 
incubation under standard conditions (see chapter 3.1.5). The enzyme showed highest 
activity in the first few minutes, exhibiting 18% of sialic acid incorporation, and more than 
half (57%) of the Type II acceptor substrate was labeled after 15 minutes of incubation 
(Figure 4.4). Near completion of the reaction catalyzed by rST3Gal III was already 
observed after 60 minutes, although the enzyme required as much time again to fully 
complete product formation. 
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Figure 4.4 Catalytic activity of the rST3Gal III enzyme estimated by ST enzyme activity assay. 
Samples were incubated with 200 μM of Type II acceptor substrate for 3 h at 37°C (see chapter 
3.1.5). 
 
4.1.2.2 Determination of the enzyme kinetic parameters 
The rat ST3Gal III was further characterized using natural and non-natural disaccharide 
acceptor substrates. The only difference between some of the published assays and those 
reported in Table 4.2 and Table 4.3 was that all of our acceptor sequences are attached to 
hydrophobic aliphatic aglycones such as OLem (O-(CH2)8CO2Me) and OSE (O-CH2CH2-
Si(Me)3). The acceptors were synthesized with these aglycones so that the reaction 
product of the enzymatic reaction could be conveniently isolated using a reverse-phase C-
18 Sep-Pak assay. All kinetic data as well as structures of the product that have been 
formed by the action of the rat ST3Gal III are presented in Table 4.2 and Table 4.3. 
Determination of kinetic parameters in 1982 by Weinstein et al. has revealed that 
asialoagalactoprothrombin, an acceptor substrate containing the terminal sequence 
Galβ(1,3)GlcNAc on N-linked oligosaccharides is, until now, the best acceptor substrate 
with a KM value of 6 μM and Vmax of 0.34 [277]. Using deoxygenated substrate analogs 
[283], the enzyme has been previously shown to require an intact D-galacto-3,4,6-triol 
system on the accepting galactose unit, together with some unidentified additional 
structural features, for an effective transfer of the NeuNAc residue. The KM values 
obtained in our experiment (Table 4.2) indicated that rat ST3Gal III preferentially act on 
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Type I (Figure 4.5 a) substrate acceptor exhibiting a KM of 66 μM and Vmax of 3.42, but was 
also able to catalyze the sialylation of Type II (Figure 4.5 b), albeit with lower catalytic 
efficiency (KM of 87 μM; Vmax of 3.19) [249]. 
A KM value obtained for the Type I acceptor substrate in our experiments was consistent 
with the KM published by Gosselin et al. [284]. They reported a KM value of 60 μM using 
radiochemical enzyme assay. Weinstein et al. [285] published kinetic parameters refered 
to native rat liver ST3Gal III. The KM values of Type I and Type II (0.64 mM and 2.66 mM) 
were 10- and 30-fold increased, and corresponding Vmax (1.16 and 0.75) almost 3- and 4-
fold decreased, respectively, compared to the results gained in this work. Data published 
by Wlasichuk et al. [283] using the same native rat liver enzyme, indicated a KM of 0.11 
mM and relative Vmax of 1 for Type I, whereas a KM of 0.90 mM and a relative Vmax of 0.3 
was identified for Type II. The kinetic parameters for Type II acceptor substrate determined 
in this work (KM of 87 μM) was only 1.7-fold lower than a KM value (0.15 mM) obtained for 
the same acceptor substrate using native rat liver ST3Gal III published by Hindsgual et al. 
[286]. Van Dorst et al. [287] reported that recombinant rat liver ST3Gal III exhibited a KM of 
0.49 mM and Vmax of 1.19 for Gal residue containing trisaccharide 
(Galβ(1,4)GlcNAc(1,2)Man-octyl aglicon) substrate, whereas the same enzyme was 
inhibited by all modified trisaccharide derivatives which were shown not to be substrates in 
the enzyme driven reaction. 
It should be emphasized that in order to correctly compare and explain differences and 
variations between the kinetic parameters (KM and Vmax) published so far, various enzyme 
assays (e.g. radioactive, spectrophotometric) and distinct enzyme sources (e.g. native or 
recombinant) should be taken into account. 
We considered that the catalytic activity of the enzyme is sufficient for the set up in chemo-
enzymatic reaction. Several non-natural substrates, demonstrating a part of the GQ1bα 
ganglioside mimetic, were used as acceptor substrates. Determination of the kinetic 
parameters (KM and Vmax), indicated that the activity of the rat ST3Gal III with non-natural 
substrates 3, 4 and 5 (Figure 4.5 c; d; e) was significantly reduced compared to the natural 
substrates 2 (Type I) and 1 (Type II), but still enough for preparative usage [249,250]. 
Also, the transfer efficiency Vmax/KM was much lower for these unnatural substrates. 
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Figure 4.5 Michaelis-Menten kinetics. A plot of the relative reaction activity (V) with the acceptor 
substrate (a) Galβ(1,3)GlcNAc-β-OLem 2 (Type I), (b) Galβ(1,4)GlcNAc-β-OLem 1 (Type II), (c) 
Galβ(1,3)GalNAc-β-OSE (3), (d) Galβ(1,3)GalNTCA-β-OSE (4), and (e) Galβ(1,3)Gal-β-OSE (5). 
Substrate concentration is designated as [S]. Additional graph shows data represented as a 
double-reciprocal or Lineweaver-Burk plot. 
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d c 
e 
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The enzyme kinetic data (Vmax and KM) for natural and unnatural acceptor substrates are 
summarized in the Table 4.2. 
 
Table 4.2 Determination of the enzyme kinetic parameters. OSE: O-(trimethylsilyl)ethyl (O-
CH2CH2-Si(Me)3), OLem: O-(Methoxycarbonyl)octyl (O-(CH2)8CO2Me), TCA: tri-chloroacetyl 
(COCCl3). 
Name Acceptor substrate KM [mM] Vmax ⎥⎦
⎤⎢⎣
⎡
⋅minml
nmol  Vmax/KM [10-3/min]
2 (Type I) Galβ(1,3)GlcNAc-β-OLem 0.066 3.42 51.8 
1 (Type II) Galβ(1,4)GlcNAc-β-OLem 0.087 3.19 36.7 
3  Galβ(1,3)GalNAc-β-OSE 0.995 1.11 1.1 
4  Galβ(1,3)GalNHTCA-β-OSE 0.811 0.89 1.1 
5 Galβ(1,3)Gal-β-OSE 0.990 0.43 0.43 
 
4.1.2.3 Stability of the enzyme during long-period incubation 
In order to determine optimal reaction conditions, the activity of the rST3Gal III was 
investigated over time at 37°C. The rST3Gal III reaction profile (Figure 4.6) revealed that 
the activity of the enzyme remained practically unchanged for the initial 9 h. Incubation for 
12 and 24 h, however, led to a significant decrease of activity. It is noteworthy, that even 
after 84 h of incubation at 37°C about 20% of the original enzyme activity was still 
preserved. This finding was important since our aim is the application of the produced 
rST3Gal III for preparative chemo-enzymatic synthesis of oligosaccharide mimetics. 
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Figure 4.6 Enzyme stability of rST3Gal III tested with Galβ(1,3)GlcNAc-β-OLem (Type I) at 37°C. 
 
4.1.2.4 Long-term storage of the rST3Gal III enzyme 
In order to investigate the long-term stability of purified rST3Gal III, the enzyme was stored 
at 4°C and – 20°C either in the absence or in the presence of 20% and 50% glycerol. The 
enzyme activity was then measured after 2 weeks and 15 months of storage (Figure 4.7). 
The results show that rST3Gal III stored for 15 months in the absence of glycerol was 
unstable at 4°C. The enzyme aliquots in 20% and 50% glycerol exhibited similar enzyme 
activity after 2 weeks and 15 months of storage at the aforementioned temperature. The 
purified rST3Gal III stored at –20°C in 20% and 50% glycerol as well as a sample in the 
absence of the glycerol solution showed a high degree of enzyme stability and 
preservation of the original enzyme activity. There was no enzyme activity difference 
between the sample free of glycerol and the rST3Gal III stored in 20% of glycerol solution 
at –20°C. The enzyme stored for 15 months at – 20°C showed a slight loss of activity 
when stored in 50% glycerol solution. Our findings are consistent with the reported results 
concerning enzyme stability over a long period [16]. 
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Figure 4.7 Long-term storage and stability of rST3Gal III enzyme (Gly: glycerol solution). 
 
4.1.2.5 Preparative chemo-enzymatic synthesis using rST3Gal III 
As previously mentioned, non-natural substrates (3, 4, 5, and 6), e.g. Type III derivatives 
are part of the GQ1bα mimetic molecule. This part of GQ1bα was proposed to be involved 
in the binding of the MAG. The saccharides 3, 4, 5 and 6, and, as control experiments, the 
natural substrates Type I and Type II were then incubated on a preparative scale with 
CMP-NeuNAc and recombinant rST3Gal III. As shown previously [253,288,289], the 
natural substrates Type II (1) disaccharide and Type I (2) were converted quantitatively 
into the corresponding trisaccharides 7 and 8 (entries 1 and 2 in Table 4.3). Although the 
physiological enzymes for the sialylation of terminal Galβ(1,3)GalNAc disaccharide are 
ST3Gal I, II and IV (see chapter 1.2.8.5), compounds 3, 4 and 5 were sialylated by 
rST3Gal III giving the trisaccharides 9-11 in acceptable yields. Although the reaction was 
supplemented after 17-24 hours with additional aliquot of rST3Gal III and CMP-NeuNAc, 
the yield did not increase. In all cases, unreacted starting materials could be recovered 
almost completely (Table 4.3). Trisaccharide 6 was not tolerated as substrate by the rat 
ST3Gal III, probably due to the bulky substituent in the 6-hydroxyl position of galactose as 
we reported [249,250]. 
Comparative NMR investigations (COSY, HSQC and TOCSY) of the starting sugars and 
the isolated products confirm the transfer of a sialic acid residue. Additional signals in the 
13C NMR spectra at approximately 100 ppm and 40 ppm are characteristic for the C-2 and 
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C-3 atoms of an α-linked sialic acid. Simultaneous down-field shifts (~4 ppm) of the 
galactose C-3 atom in the 13C NMR spectra and about 0.6 ppm of the galactose H-3 in the 
1H NMR spectra confirm the introduction of sialic acid onto the 3-OH group of the 
galactose moiety [249,250]. 
Isolated yields, recovered starting material and kinetic data (Vmax and KM) are summarized 
in (Table 4.3). 
Table 4.3 Isolated yields and kinetic data of the enzymatic sialidations. 
Entry Acceptor Product Isolated 
Product 
[%] 
Recovered 
Acceptor 
[%] 
Vmax 
⎥⎦
⎤⎢⎣
⎡
⋅minml
nmol
Km 
[µM] 
1 
O
HO
HO
OH
OH
O O
O
NHAc
OH
OLem
H
21
O
HO
OH
OH
O O
O
NHAc
OH
OLem
H
23
O
HO2C
O
HO
AcHN
HO
OH
OH
76 - 3.19 87.61 
2 
O
HO
HO
OH
OH
O
O
NHAc
OH
OLem
22
O
H
 
O
HO
OH
OH
O
O
NHAc
OH
OLem
24
O
HO2C
O
HO
AcHN
HO
OH
OH
O
H
 
90 - 3.42 66.08 
3 
O
HO
HO
OH
OH
O
O
NHAc
OH
OSE
13
HO
 
O
HO
OH
OH
O
O
NHAc
OH
OSE
25
O
HO2C
O
HO
AcHN
HO
OH
OH
HO
 
56 44 1.11 995.55
4 
O
HO
HO
OH
OH
O
O
NHTCA
OH
OSE
11
HO
 
O
HO
OH
OH
O
O
NHTCA
OH
OSE
26
O
HO2C
O
HO
AcHN
HO
OH
OH
HO
 
36 62 0.89 811.64
5 
O
HO
HO
OH
OH
O
O
OH
OH
OSE
16
HO
 
O
HO
OH
OH
O
O
OH
OH
OSE
27
O
HO2C
O
HO
AcHN
HO
OH
OH
HO
 
59 40 0.43 990.51
6 
O CO2Na
O
AcHN
HO
OH
OH
O
HO
HO
OH
OH
O
O
OH
OSE
20
HO
HO
 
no reaction (12) - 95 - - 
6 
11 5 
4 10 
3 9 
8 2 
7 1 
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4.2 hST6Gal I expression in BHK-21 cells, purification and 
characterization 
 
4.2.1 BT-hST6Gal I cloning and expression 
In the present study, as it was described in the chapter 3.2.1, the BHK-21 cells producing 
β-trace protein (β-TP) were stably transfected with a vector encoding a recombinant 
soluble form of human ST6Gal I (BT-hST6Gal I). The catalytic domain of ST6Gal I (543 
amino acids) was fused to the C terminus of the full-length β-TP (168 amino acids). 
Moreover, a mammalian host cell line expressing β-TP and recombinant sialyltransferase 
was used for the in vitro ST6Gal I enzyme specificity. Figure 4.8 shows the four day and 
one month old BHK-21 cells which stably express the human β-TP and BT-hST6Gal I. 
 
  
Figure 4.8 Production of BT-hST6Gal I enzyme. BHK-21 cell clone 3 in the culture after (a) 4 days 
and (b) one month. 
 
Many human N-glycosylated serum glycoproteins contain terminal NeuNAc with either α-
2,6-linkage to Galβ(1,4)GlcNAc-R, or both an α-2,6- and α-2,3-linkage in different ratios, 
e.g. AT III, β-TP protein or transferrin. The most frequently used mammalian hosts for the 
production of recombinant human pharmaceutical glycoproteins are BHK-21 and CHO 
cells which do not express a Galβ(1,4)GlcNAc-R α-2,6 sialyltransferase [290,291]. 
Carbohydrate structural analysis of their N-linked glycans has revealed that NeuNAc is 
exclusively attached in α-2,3-linkage to Galβ(1,4)GlcNAc-R [290-293]. Specificity of the 
a b 
 112
sialyltransferase in vivo can only be achieved by structural analysis of the cellular 
product(s). Alternatively, an in vitro assay of sialyltransferases with small acceptor 
substrates may yield some preliminary information about acceptor substrates properties 
recognized by the enzyme. 
The human Golgi apparatus Galβ(1,4)GlcNAc α-2,6 sialyltransferase (ST6Gal I; EC 
2.4.99.1) was cloned in 1990 by Grundmann [90]. This enzyme is involved in the terminal 
sialylation of complex type asparagine-linked oligosaccharides of glycoproteins. The 
complete protein consists of 406 amino acids having a molecular weight of 46.6 kDa and 
two potential N-glycosylation sites. The enzyme itself exists in solution as a monomer. 
Enzymatic properties showed that the enzyme is active between pH 5 and pH 8 with an 
optimum of pH 6.5 to pH 7.0. No metal requirement has been reported, and the enzyme is 
equally active in the presence and absence of nonionic detergents (1% Triton X-100) and 
reducing agents (10 mM 2-β-mercaptoethanol) [16].  
 
4.2.1.1 Overlay assay and Western blotting 
With the Western blot based overlay assay it was possible to locate the recombinant cells 
expressing the BT-hST6Gal I protein. The protein was transferred to the nitrocellulose 
membrane and immunodetected using rabbit anti-ST6Gal I purified serum as a primary 
antibody. The BHK-21 clones 1 and 2 were used as a negative control because of the very 
weak enzyme expression signal. The clones 3-12 were randomly chosen from the clone 
mixtures and considered as positive clones because of immunodetected BT-hST6Gal I 
expression (Figure 4.9). 
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Figure 4.9 Overlay assay: Clones were immunodetected using rabbit anti-ST6Gal I purified serum 
(1:1000) as a primary antibody and goat anti-rabbit immunoglobulin coupled to alkaline 
phosphatase (1:500) as a secondary antibody. (a) 200 cells and (b) 400 cells seeded onto tissue 
culture dishes (red color refers to the clones considered as a negative-control). 
 
In order to performe Western blot analysis and identify the clones, the supernatant 
medium of cultivated clones was collected and run on 12.5% SDS-PAGE. Transferred and 
immunodetected proteins revealed four different major bands (Figure 4.10) corresponding 
to a molecular weight of 43.7 kDa, 52.5 kDa, 66.2 kDa and 98 kDa. The 66.2 kDa 
polypeptide corresponded to partially glycosylated BT-hST6Gal I, which is in agreement 
with a theoretical molecular weight of 61.6 kDa for the deglycosyalated protein as 
calculated by Expasy protein engine tool. Because of the four potential N-glycosylation 
sites, the molecular weight of 98 kDa was expected to be a completely mature 
recombinant BT-hST6Gal I. This conclusion was confirmed with data obtained by enzyme 
purification (see chapter 4.2.2). Two other signals, 43.7 kDa and 52.5 kDa could represent 
partially degraded BT-hST6Gal I, which still maintained potential epitopes for polyclonal 
antibody recognition. Clone mixtures of transfected BHK-21, grown for 3 and 5 days in 
culture, showed very weak immunodetection signals (Figure 4.10; lane 2 and 3) which 
corresponded to the extremly low BT-hST6Gal I expression. All isolated positive BHK-21 
clones (Figure 4.9) showed the same expression pattern detected by Western blot and 
almost the same concentration of the enzyme expression estimated at 0.5 mg/l. 
a b 
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Figure 4.10 Western blot analysis of BT-hST6Gal I. Protein was blotted using rabbit anti-ST6Gal I 
purified serum (1:1000) as a primary antibody and goat anti-rabbit immunoglobulin coupled to 
alkaline phosphatase (1:500) as a secondary antibody in the reaction (M: low molecular weight 
marker; d: day; n.c.: negative control). Lane 1: LMW; Lane 2 and 3: clone mix after 3 and 5 d; Lane 
4: clone 2 (n.c.); Lane 5-7: Clone 3 batch 1-3; Lane 8 and 9: Clone 4 batch 1 and 2; Lane 10 and 
11: LMW; Lane 12 and 13: Clone 12 batch 1 and 2. 
 
4.2.1.2 Enzyme activity of BT-hST6Gal I expressed by BHK-21 isolated clones 
Although, all positive clones detected by Western blot showed similar expression of BT-
hST6Gal I, only a cell supernatant of clone 3, 4 and 12 exhibited high and almost identical 
enzyme activity (Figure 4.11). The catalytic activity of the enzyme expressed by those 
three clones correlated with the incubation time. The negative control, particularly for clone 
2, exhibited low enzyme activity. This finding was not surprising since we could confirm by 
Western blot analysis very low BT-hST6Gal I expression of clone 2 (Figure 4.10; lane 4). 
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Figure 4.11 The activity measurement of the BT-hST6Gal I expressed by different BHK-21 clones. 
The BT-hST6Gal I produced by different BHK-21 clones (72 h) was checked with asialofetuin 
protein (20 μg/μl) used as an acceptor substrate. Enzyme activity was performed under standard 
conditions (37°C, for 30 and 60 minutes, pH 6.5). Cl designates the cell clone. 
 
4.2.2 Purification of recombinant BT-hST6Gal I enzyme 
The produced BT-hST6Gal I was purified by performing CDP-hexanolamine-agarose 
affinity chromatography [16]. BT-hST6Gal I was eluted from the column with elution buffer 
containing 5 mM and 20 mM CDP. The final purification step, performed with 1 M of NaCl, 
washed out some additional proteins (Figure 4.12 a), which were unspecifically bound to 
the column. Coomassie stained SDS-PAGE as well as Western blot analysis revealed one 
major band with a molecular weight of 98 kDa. This signal corresponded to the fully 
glycosylated BT-hST6Gal I (Figure 4.12 a). The remaining BT-hST6Gal I, as well as one 
additional, very weak band was detected by Western blot in the fraction eluted with 1 M 
NaCl (Figure 4.12 b). The additional signal corresponded to a molecular weight of 
approximately 52.5 kDa. The same signal was observed when the supernatant of different 
clones was analyzed by Western blot (Figure 4.10). Since this short protein was not eluted 
with the more specific-CDP containing buffer, but instead together with other unspecifically 
bounded proteins, we concluded that this could be the result of partial BT-hST6Gal I 
degradation. Probably, the antibody recognition epitopes of the truncated protein were not 
affected. 
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Figure 4.12 SDS-PAGE (12.5%) analysis (Coomassie staining) of the BT-hST6Gal I purified by (a) 
CDP-hexanolamine-agarose affinity chromatography and (b) Western blotting which was 
performed using rabbit anti-ST6Gal I purified serum (1:500) as a primary antibody, and goat anti-
rabbit immunoglobulin alkaline phosphatase conjugated (1:10 000) as a secondary antibody. Lane 
1: LMW marker; Lane 2: 5 mM CDP dialyzed eluate; Lane 3: 10 mM CDP dialyzed eluate; Lane 4: 
1 M NaCl dialyzed eluate. Arrows point at proteins at approximately 98 kDa and 52.5 kDa. 
 
Immediately after the purification, measurement of enzyme activity in the CDP and NaCl 
eluted fractions showed impairment of enzyme activity towards asialofetuin, as measured 
in U/l. The enzyme fraction eluted with 5 mM CDP revealed 0.6 U/l whereas the elution 
with 20 mM CDP showed more than 6-fold less active enzyme (0.09 U/l). Specifically, 
activity of enzyme eluted with 1 M NaCl exhibited 0.19 U/l, which was twice more than the 
enzyme activity measured with the 20 mM CDP eluate. The same fractions dialyzed 
against 25 mM MES reaction buffer (pH 6.5) recovered the enzyme activity 3-fold (elution 
with 5 mM CDP and 1 M NaCl) and 11-fold (elution with 20 mM CDP), and enable the BT-
hST6Gal I to produce radioactive-labeled fetuin product (Table 4.4). The inhibition of 
enzyme activity with CDP and high molarities of salt was not surprising because it was 
consistent with previously observed and published data [16,294,295]. Furthermore, as 
early as 1979 Rearick et al. [296] reported that the CTP and acceptor, observed by 
noncompetitive patterns, can bind either to free enzyme, or to enzyme in complex with the 
first substrate. It was confirmed that CMP, as a side product of the sialyltransferase 
reaction, inhibits the forward sialyltransferase reaction with a Ki of approximately 50 μM. 
CDP was about 10-fold a more potent inhibitor than is CMP. The sialyltransferase is 
116 kDa 
80 kDa 
52.5 kDa 
 
 
34.9 kDa 
29.9 kDa 
1 2 3 4 1 2 3 4 
a b 
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reversibly inhibited by increasing ionic strength, i.e. sialyltransferase was inhibited roughly 
50% by 40 mM NaCl, and 80% by 0.2 M NaCl [16]. 
The purified enzyme exhibits a high degree of specificity for acceptor substrates that 
contain the terminal disaccharide sequence Galβ(1,4)GlcNAc (N-acetyllactosamine), which 
is commonly found in glycoproteins. Asialoglycoproteins, such as asialofetuin, containing 
N-acetyllactosaminyl linkage at the nonreducing ends of the oligosaccharides prosthetic 
groups are the best acceptor substrates [297,298]. Thus, one can presume that the in vivo 
role of the ST6Gal I is to form the sequence NeuNAcα(2,6)Galβ(1,4)GlcNAc, which 
commonly terminates the complex type asparagine-linked oligosaccharides of 
glycoproteins. 
 
Table 4.4 The BT-hST6Gal I inhibition in CDP and high salt eluted fractions and its recovered 
activity in MES buffer dialyzed fractions. Enzyme activity was measured with asialofetuin used as 
an acceptor substrate in the ST activity assay. 
Fractions Asialofetuin acceptor 5 mM CDP  20 mM CDP 1 M NaCl 
U/l 0.60 0.09 0.19 
N
on
-
di
al
yz
ed
  
Total mU 16.82 2.54 7.22 
Volumen [ml] 28 27 37.5 
U/l 2.25 1.07 0.63 
Total protein amount [mg] 0.28 0.216 0.075 
mg/l 10 8 2 
U/mg 0.225 0.133 0.315 
D
ia
ly
ze
d 
 
Total mU 62.98 28.80 23.65 
 
The BT-hST6Gal I was checked for the activity using the Type II acceptor substrate. 
Substrate affinity of BT-hST6Gal I for Type II in different dialyzed fractions was decreased 
for almost 20-fold (Table 4.5) when compared with the activity measured with asialofetuin 
acceptor substrate (Table 4.4). This was not surprising, since it is known that less effective 
acceptor substrates include lactose (Galβ(1,4)Glc) and other disaccharides with galactose 
β-linked  to the penultimate sugar [298]. The specificity of the ST6Gal I for the Type II 
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structure was explained by the requirement of a specific substrate rearrangement which 
involves polar groups on both the βGal and the GlcNAc residues [283]. However, 
glycosyltransferases may recognize more extended portions of the natural acceptor, which 
can explain the higher affinity of the recombinant BT-hST6Gal I for the asialofetuin protein 
compared to Type II substrate acceptor. 
 
Table 4.5 The enzyme activity with Type II acceptor substrate. 
Dialyzed fractions 
Type II acceptor 
5 mM CDP 20 mM CDP 1 M NaCl 
U/l 0.13 0.053 0.032 
Total mU 3.9 1.43 1.2 
In order to increase the enzyme concentration essential for the preparative in vitro 
glycosylation approach, the BT-hST6Gal I expressed and secreted in the BHK-21 cell-
medium was 20-fold concentrated, maintaining an extremely high degree of enzyme 
activity (35.47 U/l). 
 
Table 4.6 Cell-culture medium concentration increases enzyme. 
Culture medium (20 x conc.) 
Asialofetuin acceptor 
Non-dialyzed Dialyzed 
U/l 35.47 19.27 
Total mU 709.4 385 
 
4.2.3 Characterization of the BT-hST6Gal I enzyme 
4.2.3.1 BT-hST6Gal I catalytic activity 
The dialyzed fraction containing enzyme, which was eluted with the 5 mM CDP buffer, was 
incubated with 20 nmol of diantennary N-acetyllactosamine type acceptor substrate over a 
period of 12 hours (Figure 4.14). As expected, the results obtained by HPAEC-PAD 
analysis demonstrated slow but very clear appearance of one monosialylated peak which 
was proportional to the incubation time of the enzyme (Figure 4.14; filled arrow). 
Conversly, the peak corresponding to the diantennary N-acetyllactosamine acceptor 
substrate (Figure 4.13) proportionally disappeared during the incubation time (Figure 4.14; 
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dotted arrow). As predicted, this observation correlated with the BT-hST6Gal I transfer 
efficiency towards aformentioned acceptor substrate. This peak, revealed by MALDI/TOF-
MS, corresponded to the formation of the mono α-2,6 sialic-acid glycosidic bond. 
Man β-(1,4)-GlcNAcβ-(1,4)-GlcNAc
α-(1,6)-Fuc
Galβ-(1,4)-GlcNAcβ-(1,2)-Manα-1
Galβ-(1,4)-GlcNAcβ-(1,2)-Manα-1 3
6
 
Figure 4.13 Structure of diantennary N-acetyllactosamine type acceptor substrate. 
 
Recent studies have revealed a more detailed specificity of the enzyme for N-linked 
oligosaccharides of glycoproteins. The Galβ(1,4)GlcNAc sequences on the different 
branches of di-, tri- and tetraantennary N-linked oligosaccharides are not equally good 
acceptors, resulting in an ordered pattern of sialylation [297,299]. Indeed, the branch 
containing the sequence Galβ(1,4)GlcNAcβ(1,2)Manα(1,3)Man in di- and triantenary 
glycopeptides is almost fully α-2,6 sialylated before significant incorporation into other 
branches is observed [299]. 
 
 
Figure 4.14 The chromatogram of a BT-hST6Gal I catalytic activity with diantennary N-
acetyllactosamine type acceptor substrate obtained by HPAEC-PAD analysis. 1: negative control 
(0 min); 2 and 3: incubation for 30 min; 4: incubation for 2 h; 5: incubation for 3 h; 6: incubation for 
6 h; 7: incubation for 8 h; 8: diantennary N-acetyllactosamine type acceptor substrate. The filled 
arrow points to the monosialylated peak, while the dotted arrow designates the peak of diantennary 
N-acetyllactosamine acceptor. nC designates nanocoulombs. 
nC
 
Time [min] 
Monosialylated product 
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Mild hydrolysis of NeuNAc was another line of evidence which confirmed the previously 
mentioned time-dependent peak appearance associated with the formation of the 
monosialylated glycosidic bond (Figure 4.14). Mild hydrolysis of the monosialylated 
product formed after 12 h of incubation with BT-hST6Gal I (Figure 4.15; black arrow), was 
correlated with complete loss of the same peak (Figure 4.15; red arrow). As expected, 
under acetic conditions and temperature of 80°C, the previously formed monosialylated 
diantennary product (Figure 4.14) was hydrolyzed. Consequently, the peak which 
corresponds to diantennary N-acetyllactosamine type acceptor substrate was recovered 
(Figure 4.15; dotted arrow). Using HPAEC-PAD and MALDI/TOF-MS analysis, the 
detected peak was attributed to the formation of the α-2,6-monosialylated glycosidic bond. 
 
 
Figure 4.15 Comparison of the sialylated product with its hydrolyzed form. The results were 
obtained by HPAEC-PAD analysis. 1: monosialylated product obtained after 12 h of incubation with 
BT-hST6Gal I; 2: hydrolyzed BT-hST6Gal I monosialylated product; 3: diantennary N-
acetyllactosamine; 4: CMP-NeuNAc. The black arrow designates the monosialylated product, the 
red arrow points to the hydrolyzed product (peak disappearance) and the dotted arrow shows peak 
corresponding to the diantennary N-acetyllactosamine acceptor substrate. nC designates 
nanocoulombs. 
 
4.2.3.2 Neuraminidase specific cleavage 
In order to confirm the formation of α-2,6-monosialylated glycoside, the enzymatically 
synthesized monosialylated diantennary product (Figure 4.14) was incubated with a 
nC
 
Time [min] 
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Newcastle disease virus (NDV) neuraminidase enzyme. This enzyme specifically cleaves 
the terminal NeuNAc linked only α-2,3 to N- or O- glycosidically bound oligosaccharide 
chains of glycoproteins and glycolipids. It also cleaves NeuNAc that is bound in the α-2,8 
position to neuraminic acids. It is able to cleave N-glycolyl, 4-O acetyl and 9-O acetylsialic 
acids, however with a low turnover rate. 
Upon analyzing the HPAEC-PAD chromatogram profile, it can be seen that the NDV 
neuraminidase remained inactive during the incubation with the monosialylated 
diantennary N-acetyllactosamine type acceptor substrate (Figure 4.16; red arrow). This 
observation suggested the formation of a α-2,6-monosialylated glycosidic bond, which was 
not, as was predicted, a cleavage sequence and therefore substrate acceptor for the NDV 
neuraminidase. Thus, the peak-profiles obtained by HPAEC-PAD analysis maintained the 
original shape before (Figure 4.16; black arrow) and after (Figure 4.16; red arrow) the 
incubation of specific NDV neuraminidase with monosialylated diantennary acceptor 
substrate. In addition, the NDV neuraminidase incubation was performed with only 50% of 
starting material, therefore the detected peak had half the size as the peak of starting 
material. 
 
 
Figure 4.16 The chromatogram of Newcastle disease virus (NDV) neuraminidase activity with α-
2,6 sialylated N-acetyllactosamine acceptor obtained by HPAEC-PAD analysis. 1: monosialylated 
product obtained after 12 h of incubation with BT-hST6Gal I; 2: product obtained with NDV 
neuraminidase incubation. nC designates nanocoulombs. 
nC
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A control reaction showing NDV neuraminidase activity and specificity was performed 
using α-2,3 sialylated N-acetyllactosamine of O-glycosylated acceptor substrate. Initially, 
the O-glycosylation specific α-2,3 ST enzyme was used for the production of α-2,3 
sialylated product, which served as a acceptor substrate in the control reaction. The 
control reaction verified the NDV neuraminidase specific activity with the α-2,3 sialylated 
acceptor substrate. Monitoring by HPAEC-PAD analysis revealed almost complete loss of 
the α-2,3 sialylated peak (Figure 4.17; red arrow) when compared to the original untreated 
sample (Figure 4.17; black arrow). Since the NDV neuraminidase did not complete the 
reaction, it was still possible to detect a small signal corresponding to the α-2,3 sialylated 
substrate (Figure 4.17; red arrow). Hence, an efficient NDV neuraminidase activity towards 
α-2,3 sialylated substrate was confirmed (Figure 4.17). 
 
 
Figure 4.17 The chromatogram of Newcastle disease virus (NDV) neuraminidase activity with α-
2,3 sialylated N-acetyllactosamine unit of O-linked oligosaccharide acceptor. 1: α-2,3 sialylated N-
acetyllactosamine unit of O-linked oligosaccharide acceptor; 2: product obtained with NDV 
neuraminidase incubation. nC designates nanocoulombs. 
 
4.2.3.3 Preparative in vitro sialylation of glycoconjugates 
In order to characterize the affinity of the purified soluble BT-hST6Gal I for different 
branches of a diantennary substrate acceptor, the enzyme was applied for the preparative 
in vitro sialylation of glycoconjugates. The diantennary N-acetyllactosamine type acceptor 
nC
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substrate was sialylated and initially analyzed with HPAEC-PAD to obtain preliminary 
assignment by comparison of their elution times to those of N-glycan standards. Different 
fractions (17-19) of one peak containing monosialylated diantennary N-acetyllactosamine 
type acceptor substrate (3.7 nmol) were obtained after incubation with purified enzyme 
(Figure 4.18). Samples were collected and sent for negative ion MALDI/TOF-MS and 
methylation analysis. Based on the MALDI/TOF-MS signals and methylation analysis one 
peak, obtained after incubation with purified BT-hST6Gal I, corresponded to the 
monosialylated derivative of the diantennary N-acetyllactosamine type product (Figure 
4.18; arrow). The monosialylated product analyzed by MALDI/TOF-MS and methylation 
showed specific α-2,6-monosialic acid-linkage created with the terminal galactose residue 
of only one branch. 
 
 
Figure 4.18 The HPAEC-PAD chromatogram of preparative in vitro sialylation of diantennary N-
acetyllactosamine obtained with purified BT-hST6Gal I enzyme. nC designates nanocoulombs. 
 
In adition, the diantennary N-acetyllactosamine type acceptor substrate (12 nmol) was 
incubated with 20-fold concentrated and dialyzed culture medium. The culture medium, 
used for the preparative sialylation, contained BT-hST6Gal I. Two different peaks (Figure 
4.19; black and red arrow) corresponding to mono- and disialylated diantennary N-
acetyllactosamine type acceptor substrate, were collected in different fractions. 
nC
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Figure 4.19 The HPAEC-PAD chromatogram of preparative in vitro sialylation of diantennary N-
acetyllactosamine obtained with concentrated and dialyzed culture medium (20 x) containing BT-
hST6Gal I enzyme. nC designates nanocoulombs. 
 
Collected fractions containing the same peak were pooled (Figure 4.20; black and red 
arrow) and analyzed further by MALDI/TOF-MS and methylation. Signals based on 
MALDI/TOF-MS obtained from the reduced and permethylated native diantennary glycan, 
and methylation data revealed specific α-2,6-mono (Figure 4.19; black arrow) and α-2,6-
disialylated (Figure 4.19; red arrow) derivatives of the diantennary oligosaccharides. The 
obtained product contained a mono- and disialic acid α-2,6 glycosidically linked to the 
terminal galactose residue in both Man-3 and Man-6 antennae. In vivo investigations of 
ST6Gal I activity showed the specific enzyme activity with diantennary acceptors, creating 
asialo, α-2,6-mono and α-2,6 disialylated derivatives of the diantennary oligosaccharides. 
Taking advantage of BHK-21A cells, which were producing GalNAcβ(1,4)GlcNAc-R 
branches, its efficient recognition as a substrate for the ST6Gal I was confirmed in vivo 
[254]. 
 
nC
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Figure 4.20 The HPAEC-PAD chromatogram presenting isolated fractions of mono- and 
disialylated diantennary N-acetyllactosamine acceptor obtained using concentrated and dialyzed 
culture medium (20 x) containing BT-hST6Gal I enzyme. 1: fractions 17-19 containing 
monosialylated diantennary N-acetyllactosamine (black arrow); 2: fractions 32-34 containig 
disialylated diantennary N-acetyllactosamine (red arrow); 3: mono- and disialylated diantennary N-
acetyllactosamine. nC designates nanocoulombs. 
 
The purified enzyme and enzyme concentrated from the supernatant exhibited different 
affinities towards the same diantennary type acceptor substrate. Although it is well known 
that a higher degree of branching of the acceptors leads to a decrease in the rate of 
sialylation, and that the presence of a Man-6 branch strongly inhibits the rate of transfer of 
both sialic acids [300], the enzyme in the supernatant expressed affinity for the sialylation 
of both antennae in the α-2,6 sialic acid manner. In contrast, the purified enzyme showed 
exclusive preference for the α-2,6 NeuNAc attachment to the Man-3 branch in vitro. Our 
finding was in agreement with in vitro results reported by Joziasse et al. [300] on the 
branch specificity of the bovine colostrum ST6Gal I, which were obtained with 
glycopeptides and oligosaccharides as substrates. The same finding was already 
observed before in in vivo experiments, in which the human ST6Gal I had a high 
preference for the Man-3 branch of oligosaccharides [254]. Due to the competition with 
endogenous α-2,3 sialyltransferases in vivo, the final products contained mixtures of α-
2,3/2,6-sialylated oligosaccharides. Almost 60% of the diantennary oligosaccharides in 
vivo were disialylated derivatives, composed of a mixture of α-2,3 and α-2,6 sialic acids in 
which the α-2,6 was glycosidically linked to the Man-3 branch. In the present work, it was 
Time [min] 
nC
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not clear why the same enzyme behaved differently in preparative in vitro sialylation of the 
N-glycoconjugate. One proposed reason could be the original environment, i.e. the 
concentrated supernatant, which can provide some essential factors important for the 
enzyme specificity. 
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4.3 α-2,3/2,8 bifunctional Campylobacter jejuni sialyltransferase (α-
2,3/2,8 ST) expression in E. coli cells 
This particular project involved the cloning of the C. jejuni cst-II gene which encodes the 
Cst-II enzyme responsible for transfer of a sialic acid to the O-3 of galactose and to the O-
8 of a sialic acid α-2,3-linked to the galacose residue. The aim of the present work was the 
isolation of the cst-II gene, its functionally expression, and final sialyltrasnferase 
characterization relative to various factors important for its optimal activity. 
The cst-II gene encoding the α-2,3/2,8 bifunctional sialyltransferase (Cst-II; α-2,3/2,8-ST) 
was isolated from genomic DNA of the ATCC43438 strain of Campylobacter jejuni. The C. 
jejuni has a circular chromosome of 1 641 481 base pairs (30.6% G-C) which is predicted 
to encode 1 654 proteins and 54 stable RNA species. The average gene length is 948 bp, 
and 94.3% of the genome codes for proteins, making it the densest bacterial genome 
sequenced to date. There are two large regions of lower G-C content that correspond to 
genes within the LOS and extracellular polysaccharide (EP) biosynthesis clusters, 
respectively. The genome is unusual in that is contains very few repeated sequences, and 
no insertion sequences or phage-associated sequences [163]. 
 
4.3.1 α-2,3/2,8 ST cloning in pEZZ18 vector and its expression in E. coli 
4.3.1.1 PCR cst-II gene amplification 
In order to isolate genomic DNA, the ATCC43438 strain of C. jejuni was initially grown 
under microaerophilic conditions (7% CO2) at 37°C. Primers for the cst-II gene 
amplification were designed based on the published DNA and protein sequence [151,264], 
and used in the PCR reaction. Due to the low G-C content of genes within the LOS region 
[163], the primers had a very high content of A-T nucleotides (~80%). Therefore, the PCR 
reaction was performed at a very low (52°C) optimal annealing temperature, using 7 ng of 
genomic DNA as a template (see chapter 3.3.5). The PCR reaction was specific and 1% of 
the agarose gel analysis revealed a DNA fragment of approximately 900 bp ascertained by 
comparing to the DNA marker. Based on the construct which included the cst-II gene 
sequence and nucleotides for additional restriction sites, the predicted DNA band size was 
895 bp (Figure 4.21). DNA sequence was additionally confirmed by Microsynth DNA 
analysis. 
 128
 
 
Figure 4.21 Agarose gel analysis (1%) of PCR product of the cst-II gene. PCR was performed 
using FW1 and RW1 primers (see chapter 3.3.5) which are in the sequence presented in bold. 
Lane 1: DNA molecular weight marker X; Lane 2: PCR product of the cst-II gene. 
 
The pEZZ18 vector was used for the expression of the soluble recombinant protein. This 
vector is based on Protein A signal sequence and two synthetic IgG-binding domains (ZZ) 
of Staphylococcus aureus Protein A [301]. The soluble gene fusion product thus obtained, 
could be theoretically collected from the culture medium of Escherichia coli and rapidly 
recovered in a one-step procedure by IgG affinity chromatography [266]. Hence, this 
system was used to express a fusion protein consisting of two Z fragments, i.e. IgG 
binding domains, and the full-length α-2,3/2,8 bifunctional sialyltransferase. 
In order to obtain a good insert/vector ratio for subsequent steps in recombinant DNA 
technology, both the gene of interest and the pEZZ18 vector were digested by EcoR 
I/BamH I. Additionally, the vector was dephosphorylated and finally analyzed on an 
agarose gel (Figure 4.22). The DNA concentration for the cst-II gene and the pEZZ18 
vector was estimated by agarose gel analysis to be 5 ng/μl and 20 ng/μl, respectively. The 
insert/vector DNA ratio was taken into account for the ligation, an essential step in the 
construction of the recombinant DNA (Table 4.7). 
1636 bp 
1018 bp 
 
517/506 bp 
895 bp 
1 2 
FW1 
  1 atgaaaaaag ttattatttc tggaaatgga ccaagtttaa aagaaattga ttattcaagg 
 61 ctaccaaatg attttgatgt atttagatgc aatcaatttt attttgaaga taaatactat 
121 cttggtaaaa aattcaaagc agtattttac aatcctggtc ttttttttga acaatactac 
181 actttaaaac atttaatcca aaatcaagaa tatgagaccg aactaattat gtgttctaat 
241 tacaaccaag ctcatctaga aaatgaaaat tttgtaaaaa ctttttacga ttattttcct 
301 gatgctcatt tgggatatga tttttttaaa caacttaaag aatttaatgc ttattttaaa 
361 tttcacgaaa tttatctcaa tcaaagaatt acctcaggag tctatatgtg tgcagtagct 
421 atagccctag gatacaaaga aatttatctt tctggaattg atttttatca aaatgggtca 
481 tcttatgctt ttgataccaa acaagaaaat cttttaaaac tggctcctga ttttaaaaat 
541 gatcgctcac actatatcgg acatagtaaa aatacagata taaaagcttt agaatttcta 
601 gaaaaaactt acaaaataaa actatattgc ttatgtccta acagtctttt agcaaatttt 
661 atagaactag cgccaaattt aaattcaaat tttatcatac aagaaaaaaa taactacact 
721 aaagatatac tcataccttc tagtgaggct tatggaaaat tttcaaaaaa tattaatttt 
781 aaaaaaataa aaattaaaga aaatatttat tacaagttga taaaagatct attaagatta 
841 cctagtgata taaagcatta tttcaaagga aaataa 
   RW1
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Table 4.7 Estimated DNA concentrations. 
 
 
 
 
 
Figure 4.22 Ratio between vector (pEZZ18) and insert gene using agarose gel analysis (1%). 
Lane 1: DNA molecular weight marker X; 2: EcoR I / BamH I digested and dephosphorylated 
pEZZ18 vector; Lane 3: EcoR I / BamH I digested cst-II insert. 
 
4.3.1.2 Analysis of pEZZ18 recombinants 
The achieved ligation of pEZZ18 vector with the gene of interest led to the successful 
heat-shock transformation (see chapter 3.3.3) of the host suitable for cloning, namely the 
E. coli DH5α strain. After plasmid isolation and restriction digestion, analysis of the six 
ampicillin resistant DH5α E. coli transformants revealed the incorporation of an 
recombinant pEZZ18 vector containing the cst-II gene. The 1% agarose gel analysis 
revealed a DNA fragment of approximately ~900 bp (Figure 4.23). This DNA fragment 
corresponded to the original gene of interest, i.e. the cst-II gene with a DNA size of 895 bp. 
In addition, agarose gele analysis of all samples revealed one weak DNA signal with very 
high molecular size (~5500 bp), which corresponded to the incompletely digested 
recombinant vector (5486 bp). 
 
 
Figure 4.23 Agarose gel analysis (1%) of 6 recombinant DH5α E. coli clones. Lane 1: DNA 
molecular weight marker X (M); Lane 2 and 3: Non-digested (N) recombinant vector and EcoR I / 
BamH I digested recombinant vector (D) of clone 1; Lane 4 and 5: N and D of clone 2; Lane 6 and 
7: N and D of clone 3; Lane 8 and 9: N and D of clone 4; Lane 10 and 11: N and D of clone 5; Lane 
12 and 13: N and D of clone 6. 
 
1636 bp 
1018 bp 
517/506 bp 
1 2 3 
895 bp 
 Concentration 
C. jejuni genomic DNA  15 ng/μl 
Insert (895 bp) 5 ng/μl 
pEZZ18 vector 20 ng/μl 
M N D N D N D N D N D N D 
1018 bp 
517/506 bp 
895 pb 
 130
Six clones examined by restriction digestion were further verified by PCR. The 
amplification of the cst-II gene with a forward, internal and reverse primer was the second 
confirmation of the presence of pEZZ18 containing recombinant cst-II. Consequently, the 
fragments of amplified recombinant DNA containing the cst-II gene were approximately 
900 bp and 500 bp (Figure 4.24). This result perfectly matches the expected fragment of 
895 bp for the forward/reverse and 498 bp DNA fragment for internal/reverse amplification. 
Finally, the confirmed recombinant DNA was sequenced by Microsynth and, thus, verified 
on the DNA level. All sequenced positive clones were free of any mutation and contained 
the original cst-II gene amplified initially from the C. jejuni bacteria. 
 
 
Figure 4.24 Agarose gel analysis (1%) of PCR control. Recombinant vector of 6 positive DH5α E. 
coli clones. Lane 1: DNA molecular weight marker X (M); Lane 2: negative control (n.c.); Lane 1-6: 
clone 1-6 coamplified with FW1/RW1 primers (895 bp) and FW1/intern primers (498 bp). 
 
4.3.1.3 α-2,3/2,8 ST enzyme expression 
The recombinant pEZZ18 vector containing the cst-II gene isolated from DH5α E. coli 
clone 2 was further used for α-2,3/2,8 bifunctional sialyltransferase expression. In contrast 
to the expression host strain, DH5α E. coli cloning host strains has an extremely low 
transcriptional activity of T7 RNA polymerase. The recombinant plasmid was successfully 
transformed into the HB101 E. coli expression strain, and grown in trypton enriched TYE 
medium. As mentioned before, the selected pEZZ18 vector was suitable for the expression 
of soluble recombinant proteins [266]. Proteins were expressed as fusions with the ZZ 
peptide and secreted into the aqueous culture medium under the direction of the Protein A 
signal sequence [266,302]. Expression of the pEZZ18 vector was controlled by the lacUV5 
(Plac) and protein A promoters (Pspa). The fusion proteins, theoretically, should be easily 
purified using IgG Sepharose 6 Fast Flow to which the ZZ domain can bind tightly [266]. 
M n.c. 1 2 3 4 5 6 
1018 bp 
517/506 bp 
895 pb 
498 pb 
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The manufacturer states that due to its unique folding properties, the 14 kDa ZZ peptide 
has little or no effect on the fusion partners folding into native conformation [301]. 
Keeping in mind all the characteristics of the chosen vector, it was expected that the 
recombinant enzyme will be easily obtained using the optimized protocol for pEZZ18 
protein expression and purification. The recombinant enzyme expressed in the HB101 E. 
coli production strain was analyzed by silver stained SDS-PAGE. The result showed a very 
low expression level. None of the cell’s fractions revealed the presence of the recombinant 
protein. Since the enzyme was considered to be soluble, these findings were surprising 
especially for the samples of culture medium where its overexpression was expected. The 
overexpressed recombinant enzyme, the molecular weight of which was predicted to lie 
around 48 kDa, was not detected in the supernatant. The results obtained by silver stained 
SDS-PAGE analysis revealed overexpression of only one protein in the cell pellet fraction. 
The signal with a molecular weight of 14 kDa corresponds to the expression of the two 
synthetic IgG-binding domains (ZZ) (Figure 4.25). 
 
 
Figure 4.25 SDS-PAGE analysis (12.5%; silver staining) of α-2,3/2,8 ST enzyme expression in 
recombinant HB101 E. coli strain. Lane 1: High molecular weight marker (HMW); Lane 2: 
supernatant of clone two; Lane 3: 20 x concentrated supernatant of clone two; Lane 4: cell 
cytoplasm of clone two; Lane 5: cell pellet of clone two. 
 
4.3.1.4 α-2,3/2,8 ST enzyme activity with non-sialylated acceptors 
The supernatant and the cell cytoplasm were checked for α-2,3/2,8 sialyltransferase 
activity. Fractions were incubated with non-sialylated acceptor substrates, 600 μM Type II 
(1) and acceptor 3 (Figure 4.26). The results obtained by this enzyme activity assay only 
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confirmed the data previously obtained by SDS-PAGE. The soluble enzyme expression 
was missing in the even 20-fold concentrated supernatant fraction, and therefore no 
detectable enzyme activity was observed. Finally, the enzyme activity was observed only 
in the cytoplasmic fraction during the incubation with Type II acceptor substrate. Although, 
the enzyme exhibited some activity when compared to the negative control, this activity 
was still very low. Our findings revealed that the recombinant enzyme, although expressed 
as a fusion protein containing the Protein A signal sequence, was captured in the 
cytoplasmic membrane and therefore not able to leave the cell and enter the culture 
medium. It could be speculated that the soluble and catalytically active form of the 
sialyltransferase can be generated by proteolytic cleavage in the membrane binding 
domain of the enzyme, which is not required for the enzyme activity. This could lead to the 
formation of a catalytically active α-2,3/2,8 sialyltransferase missing two synthetic IgG-
binding domains (ZZ) and the membrane binding domain. SDS-PAGE analysis revealed 
that those domains were part of the cell pellet fraction. This type of proteolytic cleavage is 
well known and a common event frequently observed for many different eukaryotic 
sialyltransferases [32,47]. 
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Figure 4.26 The α-2,3/2,8 ST enzyme expression and activity using 600 μM of Type II (1) and 3 
acceptor for 5 h at 37°C (n.c.: negative control; S: supernatant). 
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4.3.1.5 α-2,3/2,8 ST catalytic activity 
The enzyme-containing cell cytoplasm fraction was used to obtain the information about 
the time-dependent catalytic activity of the α-2,3/2,8 sialyltransferase with 600 μM of Type 
II (1) acceptor substrate (Figure 4.27). The enzyme was incubated for 12 hours at 37°C 
and pH 7.5. The reaction with Type II (1) acceptor substrate was completed after six hours 
of incubation under standard conditions. Thus, six hours was estimated as the necessary 
time to complete the consumption of a donor substrate in the presence of acceptor 
substrate in order to form the final sialylated product. 
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Figure 4.27 Catalytic activity of the α-2,3/2,8 ST enzyme estimated by ST enzyme activity assay. 
Enzyme was incubated with 600 μM of 1 (Type II) acceptor at 37°C. 
 
Finally, the cytoplasmic fraction containing the ZZ – α-2,3/2,8 bifunctional sialyltransferase 
recombinant protein fusion was applied to the IgG Sepharose 6 Fast Flow, according to 
the recommendations by the vector’s supplier. However, with the recommended 
purification procedure it was not possible to obtain any fraction containing purified 
recombinant protein. This could be mainly due to the low protein abundance in the E. coli 
cells. As was mentioned before, the pEZZ18 expression vector was considered as not 
inducible. Since we tried to increase the protein expression by heat shock [303] and by 
raising the culture temperature to 44°C for two to six hours during the stationary phase of 
growth, without any results, consequently we decided to change the expression system. 
Taking into consideration our requirements, our new approach was base on an inducible 
expression system, which provides overexpressed recombinant protein fused to an 
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adequate tag-sequence important for facilitating purification. 
 
4.3.2 α-2,3/2,8 ST cloning in pET vector systems and expression in E.coli 
 
4.3.2.1 PCR cst-II gene amplification 
The new system of choice was the pET expression system, as the most powerful yet 
developed for the cloning and expression of recombinant proteins in E. coli [259]. Two very 
similar vector systems were chosen. The pET15b vector contained an amino-terminal 
6xHis tag sequence, whereas the pET21b vector possessed instead a carboxy-terminal 
6xHis tag sequence. All other characteristics of the two vectors were identical. The cst-II 
gene was amplified using C. jejuni genomic DNA as a template in the PCR reaction (see 
chapter 3.3.6.1), and using forward and reverse primers with integrated Nde I and BamH I 
restriction enzyme sequences. Different cst-II gene forms used for a distinct construct 
production are shown in Table 4.8. The amplified cst-II gene revealed a DNA sequence of 
901 bp when analyzed on a 1% agarose gel. Next, the amplified cst-II gene was digested 
and agarose gel purified (Figure 4.28 a; lane 3). The digested and dephosphorylated 
pET15b vector containing an amino terminal 6xHis tag sequence exhibited a high level of 
purity (Figure 4.28 a; lane 2). In order to improve the enzyme purification and α-2,8 
sialyltransferase catalytic function, we decided to produce a soluble and a mutated version 
of the cst-II gene, respectively. 
Recently, the cst-II gene isolated from the OH4384 strain of C. jejuni was truncated and 
cloned into the pET21b vector [183]. This construct provided overexpressed recombinant 
soluble enzyme which was purified with a high yield. Therefore, the same recombinant 
technology was applied for the amplification of the truncated or truncated/mutated cst-II 
gene, which, compared to the wild type gene sequence, lacks 96 nucleotides (32 amino 
acids) on the 3’ end (Table 4.8). In order to increased α-2,8 catalytic activity, the truncated 
gene was additionally mutated (Gly53→Ser; Asp177→Asn, Arg182→Asn) using site 
directed mutagenesis (see chapter 4.3.4.8). The truncated as well as mutated gene 
products with a molecular size of 801 or 802 bp (Figure 4.28 b; lane 1) were cloned into 
either the pET21b or pET15b vector. 
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Table 4.8 Different cst-II gene forms. 
PCR product (Nde I / BamH I) Size [bp] 
cst-II gene (wild type) for pET15b vector 901 
cst-II shortened, mutated gene for pET15b/ pET21b vector 802/801 
 
 
       
Figure 4.28 Agarose gel analysis (1%) of vector and insert. Lane 1: (a) DNA Molecular weight 
marker X (M); Lane 2: Nde I / BamH I digested and dephosphorylated pET15b vector (V); Lane 3: 
Nde I/ BamH I digested cst-II gene insert (I). (b) Truncated cst-II gene insert. 
 
4.3.2.2 Analysis of pET recombinants 
Randomly picked E. coli ampicillin resistant clones were tested for the presence of the cst-
II gene. Isolation of plasmid DNA and subsequent digestion with restriction enzyme 
revealed 100% successful incorporation of the target gene, either wild type or truncated, 
(mutated) into both selected vectors. In Figure 4.29 it can be seen that the only difference 
in the two cloning strategies was the length of the gene of interest. The molecular size of 
the wild type gene was 901 bp whereas the truncated and mutated was 801 or 802 bp long 
depending on the cloning vector (pET21b or pET15b, respectively). Agarose gel analysis 
of all digested pET DNA recombinants revealed a small fraction of an incompletely 
digested vector (~5.5 kbp) when compared to an untreated sample (Figure 4.29 a and 
b;.lane 2, 4 and 6). In Figure 4.29 only 3 positive clones are showed for both cloning 
strategies. Sequencing by the Microsynth confirmed that the wild type sequence was 
correct and that the truncated and additionally mutated gene sequence was altered by site 
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directed mutagenesis exactly according to our requirements. As was expected, the 
sequencing indicated a molecular size of 901 bp for the wild type gene, and 801 bp or 802 
bp for either the truncated or truncated/point mutated gene, respectively. 
 
    
Figure 4.29 Agarose gel analysis (1%) of 3 recombinant DH5α E. coli clones in (a) pET15b and (b) 
pET21b vector. Lane 1: DNA Molecular weight marker X (M); Lane 2 and 3: Non-digested 
recombinant vector (N) and Nde I / BamH I digested recombinant vector (D) of clone 1; Lane 4 and 
5: N and D of clone 2; Lane 6 and 7: N and D of clone 3. 
 
All results obtained by recombinant DNA technology were confirmed by sequencing for 
their consistency. This conclusion was important for the following experiments concerning 
the expression and the purification of the recombinant protein. 
 
4.3.2.3 Determination of target protein solubility 
For the high level production of the α-2,3/2,8 bifunctional sialyltransferase it was 
necessary to transform an adequate expression host of E. coli. A verified recombinant 
plasmid of clone 2 was transferred to the BL21 expression E. coli strains containing a 
chromosomal copy of the gene for T7 RNA polymerase. In contrast to the cloning strains, 
expression hosts are lysogens of bacteriophage DE3, a lambda derivative that has the 
immunity region of phage 21 and carries a DNA fragment containing the lacI gene, the 
lacUV5 promoter, and the gene for T7 RNA polymerase [259]. 
The first, very important step in the protein production was the determination of target 
protein solubility by SDS-PAGE analysis. For isolation of the soluble protein fraction, the 
pellet was sonicated and centrifuged in an imidazole-containing buffer. All treatments of 
the BL21 cell pellet fraction with Tris-HCl- and imidazole-containing buffers revealed the 
presence of the recombinant protein exclusively in the cell pellet fraction. The insoluble 
protein fraction was recovered by washing the pellet in the urea-containing buffer. This 
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buffer liberated the Cst-II15 protein with a molecular weight of ~36 kDa (Table 4.9) 
dissolving the cell membranes and denaturing the Cst-II15 initially combined with the pellet 
fraction (Figure 4.30; arrow). 
 
Table 4.9 Full-length and soluble (mutated) α2,3/2,8 ST enzyme expression forms in pET vector. 
α2,3/2,8 ST form Short name Theoretical protein size [kDa] 
Wilde type (full-length form) expressed in pET15b Cst-II15 36.867 
Truncated (mutated) form expressed in pET15b Δ32Cst-II15(S53N177N182) 32.903 
Truncated form expressed in pET21b Δ32Cst-II21 33.086 
 
A very small amount of protein was released with an imidazole-containing buffer during the 
cell pellet sonication procedure. Because of the very low abundance of the soluble Cst-II15 
protein, it was very difficult to perform a purification procedure using a Ni-NTA affinity 
column (see chapter 4.3.3.4). Hence, additional optimization of the enzyme expression 
was required in order to obtain an adequate amount of purified enzyme. 
 
 
 
Figure 4.30 Determination of the Cst-II15 protein solubility expressed in BL21(DE3). SDS-PAGE 
(12.5%; Coomassie staining); Lane 1 and 2: cell pellet (P) and supernatant (S) of Tris-HCl wash 1; 
Lane 3 and 13: Low molecular weight marker (M); Lane 4 and 5: P and S of Tris-HCl wash 2; Lane 
6 and 7: P and S of Tris-HCl wash 3; Lane 8 and 9: P and S of Tris-HCl wash 4; Lane 10 and 11: P 
and S of Tris-HCl wash 5; Lane 12 and 14: P and S treated with the imidazole-containing buffer 
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(ICB); Lane 14: P treated with the urea-containing buffer (UCB). P and S were separated by 
centrifugation 10 000 x g (see chapter 3.3.6.6). 
 
4.3.3 α-2,3/2,8 ST analysis and purification 
4.3.3.1 Enzyme expression and activity optimization 
As mentioned above, for the high-level production of the α-2,3/2,8 bifunctional 
sialyltransferase it was necessary to transform an adequate expression host of E. coli. A 
verified recombinant plasmid of clone 2 was transferred to the BL21, AD494 and RG 
expression E. coli strains containing a chromosomal copy of the gene for T7 RNA 
polymerase. In order to optimize α-2,3/2,8 bifunctional sialyltransferase expression, all 
mentioned strains were cultured in two different media, LB and TB, and checked for the 
enzyme expression and activity (Figure 4.31). Based on the same total protein amount, 
preliminary results detected maximal relative activity for the BL21 and the RG strain of E. 
coli when the cells were incubated in LB medium. The same activity was determined for 
the RG cells incubated in TB medium, whereas the BL21 cells in the same medium 
showed a 50% decrease in relative activity. The AD494 cells, regardless of culture media, 
exhibited very low (30%) enzyme activity, which corroborates with the low protein 
expression in the same cell strain verified by SDS-PAGE analysis. Very low enzyme 
activity (4%) compared to the induced non-transformed BL21, AD494 and RG cells (Figure 
4.31), which served in the experiment as a negative control, was detected in the DH5α E. 
coli cells. This result was not surprising, since DH5α cells have minimal background 
expression of recombinant protein. This background expression is due to the host RNA 
polymerase, which basically does not initiate from the T7 promoter, but instead a cloning 
site containing the recombinant protein in the pET plasmid can be weakly transcribed by 
read-through activity of bacterial RNA polymerase [259]. 
Preliminary results on bacterial growth, protein expression and enzyme activity suggested 
the utilization of the BL21 E. coli expression strain for the optimal scale-up of protein 
production. Thus, the BL21 cells transformed with the recombinant pET15b vector 
containing the wild type α-2,3/2,8 bifunctional sialyltransferase (Cst-II15) were cultured in 
the LB medium for all on-going studies.  
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Figure 4.31 The enzyme activity of wild type α-2,3/2,8 ST expressed (Cst-II15) in E. coli strains 
(DH5α, AD494(DE3), BL21(DE3), RG) and in LB and TB media (see chapter 3.3.6.7). Based on 
total protein amount, the enzyme was incubated with 600 μM of 1 (Type II) acceptor for 6 h at 37°C 
(see chapter 3.3.7.2). 
 
4.3.3.2 Time course analysis of the soluble protein form 
A similar strategy for assessment of enzyme solubility was applied for the truncated 
version of the recombinant enzyme, i.e. the enzyme missing the membrane-binding 
domain (Δ32Cst-II15 and Δ32Cst-II21). The majority of the truncated Cst-II protein 
(Δ32Cst-II15/21), as shown in the time course analysis, was overexpressed and released 
in the supernatant (Figure 4.32; arrow). The enzyme was released by sonication of the 
BL21 cell pellet in the imidazole containing buffer. A time course analysis revealed a 
successful release of the truncated protein with molecular weight of ~33 kDa Table 4.9) 
overexpressed from both, the pET15b and pET21b vectors. The same SDS-PAGE 
analysis gave us the possibility to estimate the optimal incubation time at 16 hours, which 
is necessary to obtain a high amount of overexpressed recombinant enzyme. 
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Figure 4.32 Time course analysis of Δ32Cst-II15/21 expression. The protein was analyzed by 
SDS-PAGE (12.5%) and Coomassie stained (see chapter 3.3.6.8). Lane 1 and 17: Low molecular 
weight marker (M); Lane 2, 3 and 4: total cell protein (T), supernatant (S) and pellet after lysis (PL) 
after 6 h of growth; Lane 5, 6 and 7: T, S and PL after 8 h of growth; Lane 8, 9 and 10: T, S and PL 
after 10 h of growth; Lane 11, 12 and 13: T, S and PL after 12 h of growth; Lane 14, 15 and 16: T, 
S and PL after 16 h of growth; Lane 18, 19 and 20: T, S and PL after 24 h of growth. 
 
4.3.3.3 The enzyme activity related to the culture grown at different temperatures  
In order to find the optimal temperature for BL21 cell growth, which would give the best 
protein production, analysis was carried out with samples collected from cell cultures 
grown at room temperature (RT), 30°C and 37°C. As it is shown in the Figure 4.33, BL21 
recombinant cells incubated at RT and 30°C expressed Cst-II15 exhibiting the same 
activity. In contrast, the Cst-II15 enzyme expressed by BL21 cells, which were grown at 
37°C, had 65% activity, 1.5-fold less comparing to expression at RT and 30°C. According 
to the obtained results, the optimal temperature for the BL21 cell culture growth was at RT 
and 30°C. The latter temperature revealed the highest expression of the recombinant 
protein. Therefore, for all on-going studies, BL21 cells containing recombinant enzyme 
were cultivated for 16 h at 30°C. 
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Figure 4.33 The Cst-II15 enzyme activity from BL21 cell cultures grown at different temperatures 
for 6 hours. Based on the same total protein amount, the enzyme activity was checked with 600 
μM of 1 (Type II) acceptor incubating at 37°C (see chapter 3.3.6.8).  
 
4.3.3.4 Purification of the recombinant α-2,3/2,8 ST enzyme 
As mentioned before, the pET vector system provides the possibility to express a protein 
as a N- or C-terminus 6xHis-tagged recombinant protein. The 6xHis affinity tag facilitates 
binding to Ni2+-nitrilotriacetic acid (Ni-NTA). It is poorly immunogenic, and at pH 8.0 the tag 
is small, uncharged and therefore does not affect compartimentalization or folding of the 
fusion protein within the cell. In most cases, the 6xHis tag does not interfere with the 
structure or function of the purified protein [267]. 
Purification of the 6xHis-tagged full length Cst-II15, truncated Δ32Cst-II15/21 or truncated 
and mutated protein by Ni-NTA affinity chromatography was performed under native 
conditions as it was suggested by the Ni-NTA affinity column supplier (Qiagen) [267]. The 
purification protocol was optimized and adapted to the fusion protein, because of the 
difficulties observed by the elution of the recombinant Cst-II15 from the column. The 
chromatography profile, after Ni-NTA affinity purification of the Cst-II15 recombinant 
protein with optimized purification protocol, showed elution of two peaks with the native 
lysis buffers containing 50 mM and 500 mM imidazole, respectively (Figure 4.34 a; 
arrows). 
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Figure 4.34 The FPLC chromatograms obtained after purification of (a) Cst-II15 and (b) Δ32Cst-
II15/21 using Ni-NTA affinity column. WB and WC designate native lysis buffer containing 50 mM 
and 500 mM imidazole, respectively. Arrows point the eluted peak obtained after purification under 
native conditions. 
 
The single step Ni-NTA affinity purification of the truncated Δ32Cst-II15/21 and the 
mutated Δ32Cst-II15S53N177N182 recombinant protein was performed using the same 
optimized protocols for the native purification. The purification chromatogram revealed two 
similar peaks eluted with native lysis buffers containing 50 and 500 mM imidazole. 
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Comparing the purification profile of the Cst-II15 to the profile obtained with truncated 
constructs, the later exhibited higher protein absorbance at 280 nm. Although the same 
quantity of starting material was used, i.e. 250 ml of BL21 cell culture grown for 16 h at 
30°C (Figure 4.34 b; arrows), the peak eluted with 50 mM imidazole containing buffer 
showed more than 10-fold higher protein absorbance. A similar chromatography 
purification profile was detected by elution of the mutated Δ32Cst-II15S53N177N182 
protein. 
The SDS-PAGE and Western blot analysis of the Ni-NTA affinity obtained fractions 
showed a very poor purification profile of the Cst-II15. These fractions contained partially 
purified Cst-II15 but the quantity of the protein was low. Western bolt analysis using the 
anti-His tag antibody revealed the presence of Cst-II15 in almost all obtained fractions. 
The same method detected one specific signal approximately at 36 kDa (Figure 4.35 b) in 
the Fr 1 which was in agreement with the theoretically calculated Cst-II15 molecular weight 
(Table 4.9). Additionally, a signal at about 24 kDa was observed in the 34-fold 
concentrated Fr 1 (Figure 4.35 b; lane 8). This finding can indicate possible unspecific 
proteolytic cleavage within the membrane-binding domain of the Cst-II15 (see later). 
 
 
  
Figure 4.35. SDS-PAGE and Western blot analysis of the Cst-II15 Ni-NTA affinity chromatography 
purification under native conditions. (a) SDS-PAGE (12.5%; silver staining); Lane 1: Low molecular 
marker (M); Lane 2: load (L); Lane 3: flow through (FT); Lane 4: wash (W); Lane 5: fraction 1 (Fr 1) 
eluted with WB buffer; Lane 6: 34 x concentrated Fr 1; Lane 7: Fr 1 eluted with WC buffer; Lane 8: 
Fr 2 eluted with WC buffer. (b) Western blot analysis which was performed using monoclonal 
mouse anti-His tag (1:2 000) as a primary antibody (Novagen) and goat anti-mouse 
immunoglobulin alkaline phosphatase conjugated (1:5 000) as a secondary antibody (Sigma); Lane 
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1: Low molecular marker (M); Lane 2: pellet after sonication (Ps); Lane 3: load (L); Lane 4: flow 
through (FT); Lane 5: wash (W); Lane 6: fraction 1 (Fr 1) eluted with WB buffer; Lane 7: 34 x 
concentrated Fr 1; Lane 8: Fr 1 eluted with WC buffer; Lane 9: Fr 2 eluted with WC buffer. WB and 
WC designate native lysis buffer containing 50 mM and 500 mM imidazole, respectively. Arrow 
points Cst-II15 enzyme. 
 
The partially purified Cst-II15 was expressed at a level of 1.69 mg/l, determined by 
Brathford protein analysis. While concentrating the main fraction for a factor of 50, enzyme 
was partially lost probably due to the protein binding to the Centricon membrane, and 
concentration (1.23 mg/l) decreased for 27% (Table 4.10). The Cst-II15 was definitely 
overexpressed since the SDS-PAGE analysis of enzyme solubility showed its high 
expression in the cell pellet (Figure 4.30; arrow). The Cst-II15 which was released to the 
supernatant was probably proteolytically cleaved in the membrane binding domain during 
its preparation. Actually, this membrane bound enzyme was not expected to be secreted, 
but it could be presumed that because of the spontaneous proteolytic cleavage it was 
forced to act as a secreted protein. In fact, this can explain the very low protein amount in 
the fraction, which was applied to the affinity chromatography column. A similar purification 
problem was observed, when the protein was expressed using pEZZ18 vector (see 
chapter 4.3.1). However, when comparing expression from pET and pEZZ18, the 
recombinant protein differed only in the protein expression level. The HB101 E. coli cells 
transformed with the recombinant pEZZ18 expressed the Cst-II15 at an extremely low 
level. In contrast, the BL21 cells containing the recombinant pET15b showed cell-
membrane overexpression. Determination of target protein solubility demonstrated 
possible inclusion body (IB) formation. With the issue of the protein insolubility in mind, the 
purification procedure was carried out under denaturing conditions as well. With this 
method it was also not possible to purify the recombinant fusion protein. Initially, the idea 
was to compare the kinetic data obtained with N-terminal His tag fusion protein, i.e. Cst-
II15 to its C-terminal His tag counterpart, the Cst-II21. In order to get the purified Cst-II21, 
full-length protein expressed using the pET21b vector was applied onto Ni-NTA column. 
The purification of Cst-II21 under native conditions did not show any positive results and 
therefore, the Cst-II21 enzyme was not used for the further enzyme characterization. A 
possible explanation could be the topology of the Cst-II21 recombinant enzyme. Since the 
LOS is assembled on the cytoplasmic face of the inner membrane and transported onto 
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the cell surface by means of the ABC transporter, the active site of the protein should be 
placed inside the cytoplasm [183]. According to that, the catalytically active domain of the 
proteolytically cleaved C-terminal His tagged protein, the Cst-II21, was released in the 
cytoplasm, whereas the membrane binding domain fused to the His tag sequence 
remained in the plasma membrane. The activity of the cytoplasmic fraction which 
contained small fraction of the proteolytically cleaved, soluble Cst-II21 was verified. The 
preliminary check of soluble Cst-II exhibited enzyme relative activity of 50%. The soluble, 
proteolytically cleaved Cst-II21 was not possible to purify comparing to the proteolytically 
cleaved Cst-II15 fusion protein which still contained N-terminal His tag sequence. The 
reason for this was that the His tag sequence, together with the membrane binding domain 
of an enzyme, remained in the plasma membrane as a part of the fusion protein. Taking all 
this together, these preliminary results partially confirmed our general concept about 
proteolytical cleavage prediction.  
The Δ32Cst-II15/21 and mutated protein showed similar Ni-NTA purification profile (Figure 
4.34 b). The SDS-PAGE and Western blot analysis revealed the single step protein 
purification. The aforementioned analysis confirmed also overexpression and revealed 
identical results for both constructs, truncated and additionally mutated. As expected, 
Western blot demonstrated the molecular weight of approximately 33 kDa which 
completely correlated with our theoretically calculated data (Table 4.9). The main fraction 
2, containing pure recombinant truncated enzyme was eluted with the native lysis buffer 
containing 50 mM imidazole (Figure 4.36; lane 8). The following fractions eluted with 500 
mM imidazole contained a small fraction of the purified enzyme as well. Therefore, 
measuring the purified protein concentration, a high variation in protein expression was 
noticed, which depended on the vector system and recombinant construct. In conclusion, 
the BL21 cells containing the Δ32Cst-II21 construct within the pET21b vector showed 
higher protein production, roughly 460 mg/l (Table 4.10). Interestingly, the same construct 
within the pET15b vector was produced at the level of 120 mg/l, which is an almost 4-fold 
difference. The mutated Δ32Cst-II15S53N177N182 construct expressed in the BL21 cells 
using the pET15b vector revealed a concentration of only 65.04 mg/l, which is 2.5-fold less 
compared to the same vector system expressing the Δ32Cst-II under the standard 
conditions. The reason for the low expression level is not clear, but since the enzyme is 
mutated, triple mutation could have had a certain influence on its folding and expression 
behavior. 
 146
 
 
     
Figure 4.36 (a) SDS-PAGE (12.5%, Coomassie staining) and (b) Western blot analysis of the 
Δ32Cst-II15/21 Ni-NTA affinity chromatography purification under native conditions. Western blot 
was performed using monoclonal mouse anti-His tag (1:2 000) as a primary antibody (Novagen) 
and goat anti-mouse immunoglobulin alkaline phosphatase conjugated (1:5 000) as a secondary 
antibody (Sigma). Lane 1: pellet (P); Lane 2: pellet after sonication (Ps); Lane 3: Low molecular 
marker (M); Lane 4: load (L); Lane 5: flow through (FT); Lane 6: wash (W); Lane 7 and 8: Fractions 
1 and 2 eluted with WB buffer; Lane 9 and 10: Fractions 1 and 2 eluted with WC buffer. WB and 
WC designate native lysis buffer containing 50 mM and 500 mM imidazole, respectively. Arrow 
points purified soluble enzyme. 
 
Table 4.10 Concentration of α-2,3/2,8 ST expressed by different pET recombinant constructs on 1 
l scale, and enzyme activity measured with 600 μM of 2 (Type I) acceptor substrate (see chapter 
3.3.7.2.). 
Cst-II15  Δ32Cst-II Type I 
acceptor Non-conc. Conc. 15 21 
Δ32Cst-
II15S53N177N182 
U/l 2.39 35.26 21.69 21.62 3.46 
U/mg 1.41 28.61 0.12 0.05 0.05 
Volumen [ml] 11.8 0.24 10.8 14.8 19.7 
mg/l 1.69 1.23 177.27 463.24 65.04 
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4.3.4 α-2,3/2,8 ST enzyme characterization 
After the high quantity expression of the soluble enzyme and its qualitative purification, it 
was very important to optimize all parameters, e.g. temperature, pH, metal cofactors etc., 
essential for the enzyme maximal performance. In order to use expressed enzyme for the 
chemo-enzymatic preparative synthesis of GQ1bα mimetics, it was of great interest to 
obtain reliable kinetic data, KM and kcat/KM, related to Type I and Type II as a natural and 
Type III derivatives as a non-natural acceptor substrates. 
 
4.3.4.1 α-2,3/2,8 ST catalytic activity 
The catalytic activity of Cst-II15 with 600 μM of 1 (Type II) acceptor substrate confirmed 
the results obtained with the full length enzyme expressed by pEZZ18 vector (Figure 4.27). 
Indeed, the maximal catalytic activity and correlated sialylated Type II production was 
accomplished after six hours of incubation under standard conditions, at 37°C and pH 7.5 
(Figure 4.37). This fact proved the enzyme stability and its independence concerning two 
completely different vector expression systems. 
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Figure 4.37 Catalytic activity of the Cst-II15 estimated by ST enzyme activity assay as described in 
the chapter 3.3.7.3. Enzyme was incubated within the incubation buffer consisting of 600 μM of 1 
(Type II) acceptor, 1 mM CMP-NeuNAc and 60 000 dpm radioactive donor substrate at 37°C and 
pH 7.5. 
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4.3.4.2 Temperature dependent enzyme activity 
Proving the temperature stability of the Δ32Cst-II15, it was found that the enzyme 
exhibited different catalytic performance concerning its α-2,3/2,8 and α-2,8 specific 
sialyltransferase activity (Figure 4.38). The enzyme exhibited slightly distinct specificity 
with non-sialylated 1 (Type II) and sialylated acceptor substrate (7) (Table 3.43), when 
incubated at different temperatures for the same time period. To isolate the product, either 
α-2,3- or α-2,3/2,8 sialylated, it was used C18 SepPak cartridges. The radioactive 
background, obtained by counting the C18 SepPak washing step, was very low (Figure 
4.38, n.c.) what eliminate a difference in enzyme activity as a product of possible 
contamination during the product isolation. The maximal α-2,3/2,8 sialyltransferase relative 
activity of the Δ32Cst-II15 was estimated at 25°C, whereas 37°C revealed the optimal 
temperature for the α-2,8 enzyme activity. Interestingly, the enzyme demonstrated 
bifunctional behavior when it was incubated within the range of 20°C to 56°C showing a 
temperature overlapping for the both catalytic activities, α-2,3/2,8 and α-2,8. The most 
surprising result was the relative α-2,3/2,8 enzyme activity of 12.5% obtained for the 
Δ32Cst-II15 incubated with Type II acceptor on ice. At the temperatures of 56°C and 60°C 
almost 6% and 3% of the α-2,3/2,8 Δ32Cst-II15 activity was preserved, whereas these 
values were more than two-fold higher for the α-2,8 activity of the Δ32Cst-II15, 
respectively. It could be speculated that two optimal temperatures as well as the 
temperature overleaping of enzyme activity could be an indication of an important role of 
the α-2,3/2,8 bifunctional enzyme activity during host infection. These differences in 
temperature might be one important factor in the C. jejuni life cycle. The bifunctionality of 
the cst-II might have an impact on the outcome of the C. jejuni infection. It has been 
suggested that the expression of the terminal disialylated epitope might be involved in the 
development of neuropathic complications such as the Guillain-Barré syndrome (GBS). In 
1996 it was published by Salloway et al. [172] that Miler-Fisher Syndrome (MFS) and GBS 
neuropathies in some patients were preceded by intestinal infections with the specific C. 
jejuni strains such as O:10, O:19. It is known that lipopolysaccharides (LPSs) from some 
strains of C. jejuni mimic the structure of human gangliosides [180], and attention has 
focused on the possibility that molecular mimicry is a factor in the pathogenesis of human 
neurological disease. The ganglioside-mimicking has been found to be located in the 
terminal regions of the core oligosaccharides (OSs) of the LPS [180,304]. Molecular 
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mimicry of host structures by the saccharide portion of LOS is considered to be a virulence 
factor of various mucosal pathogens which could use this strategy to evade the immune 
response [142,173]. The specific saccharide-containing region of LPS can act as an 
immunoantigen and play an important role in different bacterial-host recognition 
processes. It is suspected that with changes in temperature, the α-2,3/2,8 bifunctional 
sialyltransferase can synthesize in vivo variable glycosidic bonds and therefore modify the 
terminal oligosaccharide region of the LOS/LPS molecule. Consequently, this might 
influence and accelerate some processes in the host infection and in pathogenesis 
mechanisms. 
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Figure 4.38 Temperature dependent α-2,3/2,8 and α-2,8 sialyltransferase activity. The α-2,3/2,8 
ST activity was verified with 600 μM of 1 (Type II) acceptor substrate, whereas 600 μM of the 
acceptor substrate 7 was used to check the α-2,8 ST. Enzyme was incubating at indicated 
temperatures for 6 h (see chapter 3.3.7.4). Negative control (n.c.) represents the cytoplasmic 
fraction of non-recombinant BL21 cells. 
 
4.3.4.3 pH dependent enzyme activity 
For further biochemical characterizations the enzyme activity was investigated at different 
pH values. Our kinetic analysis of three different enzyme-constructs, i.e. the full length and 
the soluble forms (Cst-II15 and Δ32Cst-II15/21) with the Type I (2) acceptor substrate 
revealed that the optimal pH value lies between pH 7.0 – 10.0 (Figure 4.39). These results 
were in agreement with results published by Chiu et al. [183] who showed that the optimal 
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enzyme activity occurs around pH 8.0. It was stated that at this pH, the catalytically 
important His188 would be expected to be deprotonated as required for a general base 
catalysis. Upon proton transfer, the positive charge that develops on the histidine side 
chain could be stabilized through electrostatic interactions with the negatively charged 
phosphate and carboxylate groups of the donor sugar. Mutation of His188 to alanine 
results in loss of all detectable transferase activity, indicating its key catalytic role in the 
transferase mechanism of Cst-II. The most significant difference in enzyme activity 
between the full length and truncated enzyme occurred at pH 7.0. As described, the 
flexible lid domain of Δ32Cst-II15/21 enzyme is disordered in complex with CMP resulting 
in the absence of electrostatic interactions and hydrophobic contacts [183]. This might 
explain lower enzymatic activity of Δ32Cst-II15/21 at pH 7.0 comparing to the full length 
enzyme, where these contacts have been conserved. Testing different buffering reagents 
such as cacodylate, Hepes and MES buffer, no particular preference was observed. 
Therefore, we decided to use 50 mM MES buffer in all enzyme activity assays, consistent 
with the previously described experiments [74]. 
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Figure 4.39 pH dependent activity of α-2,3/2,8 ST. As acceptor substrate, 600 μM of 2 (Type I) 
was used in the enzymatic reaction performed for 6 h at 25°C (see chapter 3.3.7.5). For 100% of 
reaction it was converted ~20% of substrate into product. 
 
4.3.4.4 The role of metal ions on enzyme activity 
In the present work, we studied the role played by magnesium and other metals in the 
reactions catalyzed by the soluble recombinant enzyme constructs, Δ32Cst-II15 and 
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Δ32Cst-II21. They were incubated in MES buffer containing different metal cofactors and 
acceptor substrate 2 (Type I). The activity pattern of both enzymes at pH 7.5 was changed 
with a panel of distinct cations at 10 mM. Both enzymes revealed similar kinetic data with 
these cations. In fact, it was observed that the cofactors were not essential for enzyme 
activity, since the enzyme remained active in the presence of EDTA. The enzyme 
incubated in MES buffer containing divalent magnesium (Mg2+) and calcium (Ca2+) as well 
as monovalent potassium (K+) ions exhibited similar kinetic data when compared to the 
positive control (Figure 4.40). The presence of 10 mM EDTA in the Mg2+ containing 
incubation buffer did not disturb enzyme activity. Although the Δ32Cst-II15 was in general 
~20% less active than Δ32Cst-II21, they both showed similar activity, if incubated in the 
presence of the above mentioned metal cations. Since the only difference in these two 
recombinant enzymes was the His tag position, we can doubt that its placement might 
influence enzyme activity. Comparing to the positive control the Δ32Cst-II21 activity 
decreased for 1.5-fold in the presence of trivalent iron ions (Fe3+), whereas the Δ32Cst-
II15 activity decreased for one-fold. Unlike these cations, incubation with Ni2+, Zn2+ and 
Co2+ almost completely abolished enzyme activity (~85%). In the presence of Cu2+ no 
activity was detected (Figure 4.40). Surprisingly, Mn2+ ions, which are usually utilized 
instead of Mg2+ in many glycosyltransferase activity assays because of similar 
coordination [305], inhibited enzyme activity. According to that, the activity of the Δ32Cst-
II15 and the Δ32Cst-II21 was impaired 76% and 96%, respectively, compared to the 
positive control. Although those ions possess the same charge, the inhibition of the 
enzyme by Mn2+ could be explained by the fact that they are, concerning the ionic radius 
(r), bigger (r = 0.80 Å) comparing to Mg2+ (r = 0.66 Å), which could lead to inhibition due to 
the possible structural rearrangement. 
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Figure 4.40 Metal ion-dependent activity of the soluble α-2,3/2,8 ST. 600 μM of 2 (Type I) was 
used as acceptor substrate in the enzymatic reaction which was performed for 6 h at 25°C in MES 
buffer containing 10 mM indicated metal cofactors. Positive control (p.c.) represent the enzyme 
incubated in 10 mM EDTA containing MES buffer (see chapter 3.3.7.6). For 100% of reaction it 
was converted ~40% of substrate into product. 
 
A very similar experiment was done before, regarding the characterization and acceptor 
specificity of the recombinant Neisseria meningitidis α-2,3 sialyltransferase [306]. Data 
published by Gilbert et al. [74,306] demonstrated the stimulation of enzyme activity due to 
the metal cofactors. The activity was stimulated three-fold in presence of 20 mM MgCl2 
and four-fold in presence of MnCl2. We could have assumed that the metals were not 
required for the activity since the enzyme remains active in the presence of 5 mM EDTA. 
In that experiment, MnCl2 provided the best stimulatory effect only in a short-term assay 
since it caused the α-2,3 sialyltransferase precipitation during long-term incubation. 
Consequently, it was preferred to perform preparative synthesis with MgCl2. Results 
concerning the Cst-II enzyme reported by Chiu et al. [183] confirmed the previous finding 
regarding the activity enhancement due to the manganese and magnesium ions. The 
results obtained with manganese and magnesium ions showed enhancement of the 
enzyme activity by ~50%. It was also reported that they were not essential for enzyme 
catalysis since Cst-II belongs to the GTA group of enzymes. Unlike the other GTs from the 
same group, a bound metal was not observed in the active site of Cst-IIΔ32. The Cst-II 
lacks the DXD sequence motif found in a wide range of GTs. This motif is known to 
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coordinate the divalent cations involved in the binding of the nucleotide sugar through 
interaction with the diphosphate moiety [62,63]. The metal is generally considered to act 
as a Lewis acid catalyst, which stabilizes the leaving nucleoside diphosphate. Since the 
donor substrate in the case of the Cst-IIΔ32 is a nucleoside monophosphate sugar (CMP-
NeuNAc), it can be assumed that metal ions are not essential for the stabilization of the 
departing nucleoside diphosphate [183]. The divalent cations Ni2+, Zn2+, Co2+ and Cu2+, 
which show preferences for other geometries and are coordinated by ligands containing 
nitrogen and imidazole groups [307], inhibited the enzyme. Inhibition was possibly due to 
the metal coordination of amino acids essential for catalysis. Such an amino acid could be 
His-188, for which a key catalytic role in the transferase mechanism of Cst-II was observed 
[183]. This suggested that the enzyme does not require any metal ion for the catalytic 
activity. However the enzyme activity could be disturbed or completely abolished in the 
presence of metal ions preferentially co-ordinated by imidazole containing ligands. 
 
4.3.4.5 Cofactor and dependent enzyme activity 
Apart from metal cofactors, the soluble recombinant enzyme was tested for cofactor 
requirements. Compared to the positive control, the results showed very similar catalytic 
activity of the enzyme with reduced and non-reduced cofactor forms. Surprisingly, the 
enzyme incubation with 0.5 mM adenosine triphosphate (ATP) did not change the catalytic 
activity greatly. In contrast, compared to the positive control, the enzyme retained 90% of 
its original activity. It is well known that cytosine triphosphate (CTP) is a potent inhibitor of 
sialyltransferases [296]. In the study of chicken ST3Gal I [295], an inhibition of ST3Gal I by 
different nucleosides could be demonstrated in the concentration range of 50-300 μM. 
CTP together with UTP and GTP strongly inhibited chicken ST3Gal I in a competitive 
manner with respect to CMP-NeuNAc. In addition, CMP and ATP also acted as inhibitors. 
In the same study, AMP, UMP and GMP did not show inhibitory effect up to 300 μM under 
standard assay conditions. Additionally, considering the nucleosides as inhibitors of 
prokaryotic sialyltransferases, it was found that CMP as well as CDP were inhibitors. CMP 
concentration of 1 mM showed 80% inhibition, whereas CDP caused 40% inhibition under 
standard conditions [306]. Our results displayed highly efficient catalytic activity of the 
enzyme in the presence of different cofactors, especially ATP. None of them highly 
disturbed or abolished the enzyme performance; instead the enzyme maintained the 
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original catalytic efficiency. 
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Figure 4.41 Cofactor dependent activity of α-2,3/2,8 ST. Enzyme was incubated with 600 μM of 2 
(Type I) for 6 h at 25°C. Positive control (p.c.) was prepared with the MES buffer free of metal ions 
and with the MES buffer containing 10 mM Mg2+ (see chapter 3.3.7.7). 
 
4.3.4.6 Influence of dimethyl sulfoxide on enzyme activity 
Many chemically synthesized substances, especially those containing hydrophobic 
aliphatic aglycones such as OLem and OSE are not insoluble in water. In that case, the 
acceptor substrate needs to be dissolved in organic solvent such as DMSO. Therefore, it 
was necessary to check the enzyme activity in the presence of variable amounts of DMSO 
solution. The catalytic activity was checked with acceptor 13 (Table 3.43), since this 
substrate was not soluble in the water. Enzyme reaction was performed in MES buffer 
containing different concentrations of DMSO. The enzyme activity, relative to the positive 
control, revealed the same or slightly better results during the incubation of the enzyme 
within a wide range of DMSO concentrations (Figure 4.42). 20% of DMSO was estimated 
as an optimal concentration, associated with a catalytic activity of 47%. With 50% of 
DMSO, the enzyme exhibited half of the maximal activity whereas 5% of maximal activity 
was detected at 70% and 80% of DMSO. Interestingly, in pure DMSO solution the enzyme 
activity was still preserved showing 5% of maximal activity. A low enzyme activity detected 
at high DMSO concentration could be explained with the hypothesis of Khmelnitsky et al. 
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[308]. Namely, the presence of water soluble organic solvent could modify the nature of 
the catalytically active conformation of the enzyme in such a solution. Consequently, the 
enzyme could be partially inactivated and even precipitated, stopping the active site 
accessibility to substrates and acceptors [309]. 
These results clearly showed that the enzyme retained its original activity within the 
organic solvent catalyzing efficiently the product formation. 
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Figure 4.42 Dimethyl sulfoxide dependent activity of the α-2,3/2,8 ST enzyme. Enzyme was 
incubated with 600 μM acceptor substrate 13 for 6 h at 25°C. Enzyme incubated in the MES 
reaction buffer free of DMSO was used as a positive control (p.c.) (see chapter 3.3.7.8). 
 
4.3.4.7 Determination of the enzyme kinetic parameters 
After we optimized all of the important parameters, such as temperature, pH, enzyme 
activity in DMSO, metal ions, and importance of cofactor, we were able to determine the 
kinetic parameters of distinct expressed enzyme constructs relative to different acceptor 
substrates. The measurement of the kinetic parameters for the Cst-II15 revealed the best 
α-2,3/2,8 catalytic efficiency of 77.44 min-1 and KM of 0.36 mM for the acceptor 2 (Type I). 
Very similar catalytic efficiency and KM, precisely 77.06 min-1 and 0.31 mM for the same 
enzyme construct was obtained for the Type III-derivative acceptor 4 (Table 4.11). The 
reason for this substrate tolerance and very good enzyme performance with the acceptor 4 
could be an indirect influence of the acylgroup on the catalytic efficiency of the enzyme. 
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Interestingly, catalytic efficiency of the acceptor 5 was almost 1.5-fold decreased (51.83 
min-1) compared to the acceptor 4, whereas the acceptor 3 exhibited catalytic efficiency of 
72.31 min-1 and the highest Michaelis constant of 2.2 mM. The results obtained for the 
same construct concerning the α-2,8 sialyltransferase activity generally showed highly 
decreased catalytic efficiency and increased KM value, regardless of the incubation 
temperature. Namely, kinetic parameters for the α-2,8 enzyme activity were obtained at 
25°C and 37°C (Table 4.11). The best sialylated Type II enzyme acceptor, acceptor 7, 
showed a catalytic efficiency of 59.01 min-1, which was almost the same compared to the 
acceptor 8 if the enzyme was incubated at 25°C. However, if the enzyme was incubated at 
37°C the catalytic efficiency for the acceptor 7 was increased for 1.3-fold, wherease it 
changed extremely for an acceptor 8 (5.3-fold). Comparing to substrate 7 and 8, acceptor 
10 showed for 1.1-fold decreased catalytic efficiency. Acceptor 7 exhibited KM of 1.22 mM 
at 25°C and 2.02 mM at 37°C, whereas acceptor 10 showed KM of 2.06 mM at 25°C and 
2.80 mM at 37°C. A very surprising result was the KM value obtained for acceptor 
substrate 8. Namely, the KM value of 2.62 mM obtained at 25°C was extremely changed 
(17.5 mM) when the enzyme was incubated with the same acceptor at the temperature of 
37°C. This was surprising, since we were expecting that the α-2,8 catalytic function would 
indicate different temperature dependent kinetic parameters according to the above 
mentioned results. The Cst-II15 did not show any activity with the acceptor 9 and 11, i.e. 
sialylated derivatives of Type III acceptor substrate. This fact can be explained with the 
probably very high KM value of the enzyme for the particular acceptor, which was not 
accessed in the experiments. 
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Table 4.11 Determination of the enzyme kinetic parameters for the Cst-II15 and Δ32Cst-II15 (see chapter 3.3.7.9). OSE: O-(trimethylsilyl)ethyl 
(O-CH2CH2-Si(Me)3), OLem: O-(Methoxycarbonyl)octyl (O-(CH2)8CO2Me), TCA: tri-chloro acetyl (COCCl3). It was convertet ~20% of substrate. 
Acceptor
2 (Type I)
(Galβ1,3GlcN Ac-β-OLem) 77.44 25.07 0.36 0.69 216.08 36.31 26.97 37.70
4 
(Galβ1,3GalNHTCA-β-OSE) 77.06 21.62 0.31 0.59 247.38 36.55 26.83 32.50
3 
(Galβ1,3GalN Ac-β-OSE) 72.31 2.20 32.85 25.18
5 
(Galβ1,3Gal-β-OSE) 51.83 25.87 0.81 2.09 63.66 12.40 18.05 38.90
13
(D-Lactose-β-OSE) 16.74 0.47 35.35 25.16
Temperature [°C] 25 37 25 37 25 37 25 37 25 37 25 37 25 37 25 37
8
(Siaα2,3Galβ1,3GlcN Ac-β-OLem) 58.23 310.65 7.14 29.43 2.62 17.49 1.77 7.68 22.27 17.76 4.02 3.83 20.28 108.17 10.74 44.25
7
(Siaα2,3Galβ1,4GlcN Ac-β-OLem) 59.01 80.07 35.56 1.22 2.02 8.09 48.25 39.56 4.40 20.55 27.88 53.46
10 
(Siaα2,3Galβ1,3GalNHTCA-β-OSE) 51.36 56.23 2.06 2.80 24.89 20.08 17.89 19.58
14
(Siaα2,3-D- Lactose-OSE)
0.57 0.47 1.21 0.85
9
(Siaα2,3Galβ1,3GalN Ac-β-OSE) 0 0 0 0
11
(Siaα2,3Galβ1,3Gal-β-OSE) 0 0 0 0
Trunc.
α
-
2
,
3
/
2
,
8
 
S
T
α
-
2
,
8
 
S
T
Full Trunc.
Cst-II15/Δ32Cst-II15
Trunc.
k cat 
(min-1)
K M 
(mM)
k cat /K M 
(mM-1 min-1)
V max
(nmol min-1 ml-1)
Full Full FullTrunc.
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The same acceptors were used for the kinetic parameter determination of the N- and C-
His tag expressed soluble form of the Cst-II enzyme (Δ32Cst-II15 and Δ32Cst-II21). The 
soluble Δ32Cst-II15 obtained similar results concerning the α-2,3/2,8 catalytic efficiency for 
two different acceptors. To be more precise, for the acceptors 2 and 5, catalytic efficiency 
was ~25 min-1, wherease KM value for acceptor 5 was ~3-fold higher (2.09 mM) comparing 
to the acceptor 2. Acceptor 4 and 13 showed slightly decreased catalytic efficiency, 21.62 
min-1 and 16.74 min-1 but almost similar the Michaelis-Menten parameters 0.59 mM and 
0.47 mM, respectively. Comparison of the kinetic parameters obtained for the α-2,3/2,8 
catalytic activity of Δ32Cst-II15 to those of Δ32Cst-II21 revealed similarities and 
differences. For instance, catalytic efficiency of Δ32Cst-II21 was slightly better for the 
acceptor 2, 4 and 13, whereas the KM value remain almost in the same range. The 
Δ32Cst-II21 with the substrate 5 displayed ~3-fold higher catalytic efficiency and 3-fold 
higher KM value (6.18 mM) comparing to the Δ32Cst-II15. An additional acceptor 3 was 
used to obtain kinetic parameters for the Δ32Cst-II21. These results demonstrated half of 
the catalytic efficiency and enzyme affinity obtained for an acceptor 5. Taking into account 
the kinetic parameters obtained for α-2,8 catalytic activity of Δ32Cst-II15 and Δ32Cst-II21 
enzymes, similarly a low catalytic efficiency and accordingly very high Michaelis constant 
was obtained. More precisely, α-2,8 catalytic function of Δ32Cst-II21 exhibited catalytic 
efficiency of 23.03 min-1 for acceptor 7. For the same acceptor, the Δ32Cst-II15 showed a 
catalytic efficiency of 35.56 min-1. Both enzymes exhibited extremely low activity, if any, 
with acceptor 14. 
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Table 4.12 Enzyme kinetic parameters for the Δ32Cst-II21 were determined as described in 
chapter 3.3.7.9. OSE: O-(trimethylsilyl)ethyl (O-CH2CH2-Si(Me)3), OLem: O-(Methoxycarbonyl)octyl 
(O-(CH2)8CO2Me), TCA: tri-chloro acetyl (COCCl3). It was convertet ~20% of the substrate into 
product. 
Acceptor
2 (Type I)
(Galβ1,3GlcN Ac-β-OLem) 28.78 0.54 53.02 101.08
4 
(Galβ1,3GalNHTCA-β-OSE) 29.70 0.75 39.68 104.33
3 
(Galβ1,3GalN Ac-β-OSE) 31.07 3.998 7.77 109.15
5 
(Galβ1,3Gal-β-OSE) 70.51 6.18 11.41 247.68
13
(D -Lactose-β-OSE) 22.64 0.57 39.42 79.52
Temperature [°C] 25 37 25 37 25 37 25 37
8
(Siaα2,3Galβ1,3GlcN Ac-β-OLem) 6.14 4.19 1.47 21.55
7
(Siaα2,3Galβ1,4GlcN Ac-β-OLem) 7.93 23.03 1.02 3.79 7.77 6.08 27.81 80.75
14
(Siaα2,3-D- Lactose-β-OSE) 0.24 0.291 0.82 0.42
Δ32Cst-II21
α-2
,3
/2
,8
α-2
,8
 S
T
K M 
(mM)
k cat /K M 
(mM-1 min-1)
V max
(nmol min-1 ml-1)
k cat 
(min-1)
 
Comparing the results obtained in these experiments with the recently published kinetic 
data [151,183,264], it was possible to observe some variations in the enzyme’s ability to 
act in the same way with the same acceptor substrate. Thus, the published soluble Cst-II 
revealed a α-2,3/2,8 catalytic efficiency of 1.1 mM-1 min-1 and KM of 35 mM with lactose 
(13). In contrast, the α-2,8 function revealed 16-fold higher catalytic efficiency and 
therefore 10-fold decreased KM of 3.5 mM with sialylated lactose acceptor (14) [183]. In 
order to evaluate the data, it was very important to make the comparison between the 
published enzyme sequence and the enzyme sequence used in our experiments. The 
available data were obtained by the Cst-II enzyme expressed from the OH4384 C. jejuni 
strain. The Cst-II from the mentioned strain differs by eight amino acids from the enzyme 
expressed in the ATCC43438 strain of C. jejuni, which was used in our studies. This 
similarity on the DNA level and correlated primary protein structure (97.3%) enables both 
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strains to express the bifunctional activity of the Cst-II enzyme. Nevertheless, comparison 
of the reported kinetic parameters and those obtained in this study demonstrate very low 
similarity regarding the same acceptor substrates. It should be mentioned that the 
observed differences of kinetic parameters might be due to the 6-(5-fluorescein-
carboxamido)-hexanoic acid succimidyl ester (FCHASE)-labeled oligosaccharide 
acceptors and the enzyme assay used to determine the published OH4384 Cst-II activity. 
In fact, the reported enzyme exhibited much lower α-2,3 than α-2,8 sialyltransferase 
activity, while the Cst-II isolated from ATCC43438 showed exactly the opposite behavior. 
In 2002, Gilbert et al. [264] reported cloning and expression of six different Cst-II proteins 
originating from different C. jejuni strains. These E. coli-expressed Cst-II recombinant 
proteins were assayed for the α-2,3 and the α-2,8 sialyltransferase activity using 
FCHASE-labeled non-sialylated and sialylated lactose oligosaccharides, respectively, as 
acceptors. It was found that only four out of six Cst-II proteins showed bifinctional 
sialyltransferase activity, while other two demonstrated exclusively the α-2,3 catalytic 
activity. An alignment of the amino acid sequences of the various Cst-II versions indicated 
that only three residues, i.e. Asn51, Leu54 and Ile269 were specific for the bifunctional 
Cst-II versions. Using site directed mutagenesis, it was found that an Asn51→Thr 
substitution completely abolished the α-2,8 sialyltransferase acitivity in the OH4384 C. 
jejuni strain. The inversed substitution (Thr51→Asn) in the monofunctional Cst-II from 
ATCC43446 strain confirmed the importance of Asn51 within the enzyme sequence for the 
α-2,3 and the α-2,8 activities. The other two residues (Leu54 and Ile269), unique to 
bifunctional Cst-II variants, as well as the very variable residue 53, were found to affect the 
relative ratios of α-2,3 and α-2,8 sialyltransferase activities. Only Asn51 was found to be 
essential for the α-2,8 activity. The amino acid substitution Ile53→Gly increased both 
activities of the OH4384 version, which suggested that this residue has an important 
impact on the level of in vitro activity. It was noticed as well that the strains with Ser53 
have much lower α-2,3 than α-2,8 sialyltransferase activity [264]. A randomly mutated 
(I53S) and soluble form of the enzyme (Cst-IIΔ32) was generated by deletion of the 
predicted membrane spanning domain at the C-terminus (32 amino acids), and was co-
crystallized with a donor sugar CMP-3-fluoro-N-acetylneuraminic acid (CMP-3FNeuNAc) 
analog (Figure 4.43). The first structure and glycosyl transfer mechanism of 
sialyltransferase, that of Cst-II from the OH4384 C. jejuni strain was reported by Chiu et al. 
[183]. 
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Figure 4.43 (a) The overall architecture of Cst-IIΔ32. Arrangement of the Cst-IIΔ32 tetramer. Each 
monomer is colored differentially. A donor sugar analog (CMP-3FNeuNAc) is shown as a stick 
representation in magenta color, indicating the location of the catalytic center. (b) View of the Cst-
IIΔ32 monomer showing the N-terminal domain and the lid-like domain with bound donor sugar 
analog. CMP-3FNeuNAc is represented as a red stick. The N-terminus, C-terminus, individual 
strands and individual helices are labeled [183]. 
 
It was shown that the enzyme forms a tetramer in the asymmetric unit of the crystal. Each 
monomer of Cst-IIΔ32 consists of 259 residues organized in two domains. The first domain 
(residues 1 – 154, 189 – 259) create the nucleotide-binding domain in the form of the 
Rossmann fold [56]. The active site is not at the interface between monomers of the 
tetramer, suggesting that the oligomerization of the enzyme has no direct role in catalysis. 
The second, smaller domain (155-188) forms a lid-like structure that folds over the active 
site. This domain is ordered only after binding of the CMP-NeuNAc substrate, suggesting 
that the lid probably fulfills several functions in catalysis; directly liganding the donor sugar, 
creating the acceptor sugar binding site and shielding the enzyme active site from bulk 
solvent thereby minimizing side reactions such as hydrolysis of substrate, as was 
observed in other GTs [58,59]. Concerning the CMP binding, it was found that CMP binds 
to a deep cleft in the nucleotide-binding domain at the C-terminal end of the central β-
sheet. This suggests that this location of the active site at the protein-membrane interface 
facilitates transfer of the sugar onto the terminus of the LOS. The LOS is assembled on 
the cytoplasmic face of the inner membrane, and transported onto the cell surface by ABC 
transporter. The CMP is relatively buried within the active site cleft with several favorable 
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interactions formed within the active site (Figure 4.44). 
 
Figure 4.44 The active site of Cst-IIΔ32. (a) Interactions of CMP and active site residues. CMP is 
depicted in CPK coloring with carbon atoms in magenta, nitrogen atoms in blue, oxygen atoms in 
red and phosphorus atom in green. Active site residues involved in CMP binding and catalysis are 
labeled and shown with carbon atoms in beige, nitrogen in blue and oxygen in red. H2O molecules 
are shown as cyan spheres. Dotted lines indicate hydrogen bonding; (b) Interactions of CMP-
3FNeuAc and key active site residues. CMP-3FNeuAc is depicted in CPK coloring as in a with the 
fluorine atom in light blue. The Helix F is highlighted as a blue ribbon [183]. 
 
A mutation, I53S, which lies on the periphery of the acceptor sugar binding site, in a cleft 
adjacent to the NeuNAc, may promote stabilization of the Cst-IIΔ32 construct through 
interaction with the acceptor substrates. 
 
4.3.4.8 α-2,3/2,8 enzyme activity of the mutated and truncated enzyme 
According to these characteristics, regarding the very similar OH4384 Cst-II mentioned 
above, we decided to improve α-2,8 sialyltransferase activity of the Δ32Cst-II15 construct 
using site directed mutagenesis. Increased α-2,8 catalytic activity would be extremely 
helpful for the preparative chemo-enzymatic synthesis of distinct ganglioside-derivatives. 
The Cst-II enzyme of both C. jejuni strains, the ATCC43438 and the ATCC43432, naturally 
involved Gly-53. Despite the likely large impact Gly-53 was expected to have on in vitro 
activity [264], this residue was replaced with Ser-53 using site directed mutagenesis. As 
mentioned before, Ser53 was believed to promote stabilization of Cst-II enzyme, to affect 
relative ratios of α-2,3 and α-2,8 activities and to enhance α-2,8 sialyltransferase 
specificity [183,264]. In addition, in silico analysis of the X-ray structure of OH4384 Cst-II 
published by Chiu et al. [183], revealed two variable amino acids, i.e. Asn177 and Asn182 
close to the binding site. These two positions in the case of the ATCC43438 Cst-II enzyme 
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were occupied by a negatively charged Asp177 and positively charged Arg182. We 
assumed that this difference in charge might have been the reason for the very low α-2,8 
activity of the Cst-II enzyme expressed from ATCC43438 strain. The α-2,3 activity was not 
disturbed when Gly53 was substituted by Ser. In contrast, one (Asp177→Asn) or two 
additional mutations (Arg182→Asn) in the truncated Cst-II protein decreased α-2,3 and 
increased α-2,8 activity. Comparison of the results obtained with soluble wild type 
(Δ32Cst-II15) and additionally mutated Cst-II (Δ32Cst-II15S53N177N182) confirmed 
previously mentioned differences concerning α-2,3 and α-2,8 activity. Mutated enzyme 
revealed 50% decreased activity with non-sialylated Type I (2) and Type II (1) acceptor 
substrate. In contrast, α-2,8 activity was increased for 50%, when the sialylated acceptor 
substrates 8 was used for the enzyme activity test (Figure 4.45). Similar results were 
obtained for the α-2,8 activity of the mutated enzyme incubated with acceptor 7. 
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Figure 4.45 The comparison of Δ32Cst-II15 and Δ32Cst-II15S53N177N182 activity using 600 μM 
and 1 mM of 2 (Type I) and 1 (Type II), and 8 and 7, for the α-2,3/2,8 and α-2,8 ST activity, 
respectively. 
 
4.3.4.9 Preparative chemo-enzymatic synthesis using α-2,3/2,8 ST 
The successful site directed mutagenesis according to the predicted in silico data gave us 
the possibility to perform preparative chemo-enzymatic synthesis thanks to the improved 
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α-2,8 activity of Cst-II. The accomplished results, verified by NMR and MS analysis, 
demonstrated the synthesis of only monosialylated product in the case of acceptor 2 and 
13 achieving 76% and 80% of the product 8 and 14, respectively (Table 4.13). However, 
incubation of Δ32Cst-II21 with the acceptor 4 did not give any product. Mutated enzyme 
with improved α-2,8 activity was used for the synthesis of disialylated compounds using 2 
(Type I) acceptor as a starting material. Finally, mutated enzyme, which demonstrated 
50% improved α-2,8 catalytic activity compared to the wild type enzyme, was able to react 
and produce tri- and tetrasaccharide. The enzyme exhibited different affinity for the 2 
(Type I) and trisaccharide 8, showing stronger preference for the non-sialylated acceptor 
substrate. This was expected, since the enzyme should mainly produce trisaccharide 
product in order to use it as an acceptor substrate in the α-2,8 catalytic activity. Therefore, 
preparative synthesis followed by TLC indicated formation of 55% of product 8 and 13% of 
the product 15. The structure of both products were verified by NMR and MS analysis 
confirming an occurrence of the α-2,3 and α-2,8 glycosidic-linkages. The preparative 
synthesis, i.e. chemo-enzymatic reaction reproducibly gave approximately 50% of the 
product 15 using the acceptor substrate 8 as a starting material. It was observed that the 
reaction slowed down and did not proceed further, although an additional aliquot of the 
enzyme and donor substrate was added. This could be explained by the hydrolysis of the 
CMP-NeuNAc. Namely, while crystallizing the Cst-II in the presence of the donor and 
acceptor substrate, kinetic analysis showed considerable hydrolysis of the CMP-NeuNAc 
in the absence of an acceptor catalyzed by both truncated and the full-length Cst-II [183]. 
This finding was very similar to the fact observed almost 25 years ago by Beyer et al. [22]. 
These studies showed that the reactions of the β-galactoside α-2,3 sialyltransferase and 
the α-N-aceylgalactosaminide α-2,6 sialyltransferase were reversible. Thus, it was 
possible to demonstrate a CMP-dependent “neuraminidase” activity associated with these 
sialyltransferases. Under conditions used for glycosylation, the equilibrium heavily favored 
the formation of products. 
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Table 4.13 Isolated yields and kinetic data of the enzymatic sialidations. OSE: O-(trimethylsilyl)ethyl (O-CH2CH2-Si(Me)3), OLem: O-
(Methoxycarbonyl)octyl (O-(CH2)8CO2Me), TCA: tri-chloro acetyl (COCCl3). 
Entry Acceptor Product Isol. 
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5 Conclusions and Outlook 
 
 
 
Enzymes responsible for the terminal sialylation are sialyltransferases (STs), a subset of 
the glycosyltransferase (GT) family that uses CMP-NeuNAc as the activated sugar donor 
and catalyzes the transfer of sialic acid residues to terminal non-reducing positions of 
oligosaccharide chains of glycoproteins and glycolipids. Sialylated oligosaccharide 
sequences have long been predicted to be information – containing molecules and critical 
determinants, e.g. in cell-cell recognition processes, cell-matrix interactions and 
maintenance of serum glycoproteins in the circulation [79,80]. Our work was focused on 
the myelin-associated glycoprotein (MAG) and its physiological ligands, i.e. brain 
gangliosides. MAG [199,203,204,213] has been identified as one of the neurite outgrowth-
inhibitory proteins, together with Nogo-A and the oligodendrocyte myelin glycoprotein 
(OMgp) [192,201,310]. Among all physiological ligands of MAG, i.e. brain gangliosides, the 
GQ1bα is the most potent natural ligand identified so far [235,236]. Therefore, this 
ganglioside was chosen as a lead structure in our MAG project. Moreover, only the sialic 
acid containing part of the GQ1bα molecule was shown to be important for MAG binding. 
Thus, we decided to use a chemo-enzymatic approach for the syntheses of the GQ1bα 
mimetics. In order to perform preparative chemo-enzymatic synthesis of sialylated 
structures it was necessary to express distinct sialyltransferases able to catalyze the 
formation of α-2,3, α-2,6 and α-2,8 glycosidic-linkages.  
Recombinant eukaryotic rST3Gal III (EC 2.4.99.6) was expressed as a secreted protein in 
baculovirus infected insect cells and purified by CDP-hexanolamine-agarose. Enzyme 
activity was confirmed using ST enzyme activity assays. Our investigations [249,250] 
showed, in addition to previous reports [252,253,275,288,289,311], an unexpectedly high 
substrate tolerance of recombinant rST3Gal III. The kinetic data for the sialylation 
reactions indicated that the activity of rST3Gal III with the Type III derivatives was reduced 
only about 10-fold compared to its Type I and Type II natural substrates. The enzyme, 
therefore, accepted the replacement of the natural GlcNAc moiety by Gal, GalNAc and 
GalNHTCA. Thus, the preparative applicability of the sialyltransferase has been 
substantially extended.  
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Furthermore, recombinant human ST6Gal I (hST6 Gal I; EC 2.4.99.1) was expressed as a 
soluble protein in a mammalian expression system (BHK cells) and purified to 
homogeneity by CDP-hexanolamine-agarose affinity chromatography. The activity of the 
purified protein was confirmed with the ST activity assay. The BT-hST6Gal I exhibited 20-
fold higher substrate affinity towards asialofetuin than for Type II acceptor substrate. This 
observation was not surprising, since it is well known, that less effective acceptor 
substrates include lactose (Galβ(1,4)Glc) and other disaccharides with galactose β-linked  
to the penultimate sugar [298]. Preparative in vitro sialylation of diantennary substrate 
acceptor using BT-hST6Gal I showed mono- and disialylated diantennary N-
acetyllactosamine type acceptor substrate. Sialylated product analyzed by MALDI/TOF-
MS and methylation showed mono- and disialic acid α-2,6 glycosidically linked to the 
terminal galactose residue in both, Man-3 and Man-6 antennae. 
Thirdly, the main project involved recombinant prokaryotic Campylobacter jejuni α-2,3/2,8 
bifunctional sialyltransferase (Cst-II), and its cloning and expression in E. coli as a His-
tagged full length (~36 kDa) and truncated, i.e. soluble (~33 kDa) enzyme using pET 
expression systems. The enzyme overexpression and solubility was confirmed with SDS-
PAGE and Western blot using monoclonal mouse anti-His tag antibody. Estimated by 
Bradford, a soluble form of the enzyme was expressed at very high level (~460 mg/l) 
compared to its full length counterpart (~1.69 mg/l). Therefore, the N- and C-His tagged 
soluble form of Cst-II, i.e. Δ32Cst-II15 and Δ32Cst-II21, were successfully purified to 
homogeneity using Ni-NTA affinity chromatography. Enzyme activity was confirmed using 
ST activity assay. 
The enzyme exhibited slightly distinct specificity with non-sialylated and sialylated acceptor 
substrates, when incubated at different temperatures. The maximal α-2,3/2,8 
sialyltransferase relative activity of the Δ32Cst-II15 was detected at 25°C, whereas 37°C 
revealed the optimal temperature for the maximal α-2,8 enzyme activity. The kinetic data 
revealed the wide optimal pH range, i.e. pH 7.0 – 10.0. It was observed that cofactors 
were not essential for enzyme activity and the enzyme remained active in the presence of 
EDTA. The activity pattern of the both enzymes at pH 7.5, with a panel of distinct cations, 
indicated that it could be modulated by these metals, e.g. incubation with Ni2+, Zn2+ and 
Co2+ almost completely abolished the enzyme activity (~85%) or in the presence of Cu2+ 
no activity was detected. The enzyme did not require cofactors, since enzyme activity was 
not changed in the presence of these substances. Besides, the enzyme also remains 
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active within the wide range of DMSO concentrations used to dissolve water insoluble 
acceptors. A full-length and soluble enzyme constructs were used to determine enzyme 
kinetic parameters with several non-sialylated and sialylated acceptor substrates. In 
general, all enzyme constructs showed the best α-2,3/2,8 catalytic efficiency with acceptor 
2 (Type I), 4 and 13, whereas very low α-2,8 catalytic efficiency was observed with 
acceptor substrates 7 and 8. The Cst-II15 and Δ32Cst-II21 purified proteins were applied 
for preparative synthesis using 2 (Type I) and 13 acceptor substrates. The results obtained 
by synthesis and verified by NMR and MS analysis, demonstrated production of 76% and 
80% of monosialylated product 8 and 14, respectively. In order to improve α-2,8 
sialyltransferase activity of Δ32Cst-II15 construct we have mutated the enzyme using in 
silico obtained data and site directed mutagenesis method. Mutated enzyme, Δ32Cst-
II15S53N177N182 revealed 50% decreased activity with non-sialylated 2 (Type I) and 1 
(Type II) acceptor substrate. In contrast, the α-2,8 activity was increased for 50% when 
sialylated acceptor substrates 8 was used for the enzyme activity test. 
The mutated enzyme was used for preparative chemo-enzymatic synthesis of GQ1bα 
mimetics. Analysis indicated the formation of 55% of monosialylated product 8 and 13% of 
the disialylated product 15. The structure and mass of both products were verified by NMR 
and MS analysis confirming the occurrence of the α-2,3 and α-2,8 glycosidic-linkages. 
In outlook, truncated and full length form of the recombinant prokaryotic Campylobacter 
jejuni α-2,3/2,8 bifunctional sialyltransferase (Cst-II) cloned and expressed in E. coli should 
be used for the X-ray crystal structure analysis co-crystallizing with the ligand and acceptor 
substrate. Prior to these studies, Cst-II should be further purified over a CDP-
hexanolamine-agarose affinity column to isolate only a fraction containing the 
bifunctionally active enzyme. Besides, the enzyme activity towards gangliosides and many 
other chemically synthesized oligosaccharides should be first verified by determining the 
enzyme kinetic parameters. It would be important to solve the function and a possible 
influence of the metal cofactors on the enzyme catalytic efficiency. 
More data could further improve the specific activity of the enzyme and contribute to its 
successful usage for the preparative chemo-enzymatic synthesis of the sialylated GQ1bα 
mimetics. Hence, the synthesis on a milligram scale of a number of modified 
sialyloligosaccharides indicates that the sialyltransferases can be exploited as biocatalysts 
in the synthesis of interesting non-natural compounds, which is particularly valuable in 
view of the difficulties in chemical sialylation. 
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6 Abbreviations 
AcNPV Autographa californica nuclear polyhedrosis virus 
Arg Arginine 
Asn Asparagine 
Asp Aspartate 
ATP Adenosine triphosphate 
AU Absorption unit 
BHK Baby hamster kidney 
BmPV Bombyx mori polyhedrosis virus 
BSA Bovine serum albumine 
β-TP β-trace protein 
cAMP Cyclic adenosine monophosphate 
cDNA Complementary deoxyribonucleic acid 
CDP Cytidine diphosphate 
CH3CN Acetonitrile 
CIAP Calf intestine alkaline phosphatase 
CMP-NeuNAc cytidine monophosphate- N-acetyl neuraminic acid 
CRD Consensus repeat domains 
Cst-II Campylobacter jejuni sialyltransferase 
Cys Cystein 
DMSO dimethyl sulfoxid 
DTE 1,4-Dithioerythritol 
DTT Dithiothreithol 
E. coli Escherichia coli 
EDTA Ethylendiaminotetraacetic acid 
FBS Fetal bovine serum 
FCHASE 6-(5-fluorescein-carboxamido)-hexanoic acid succimidyl ester 
FCS Fetal calf serum 
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FPLC Fast protein liquid chromatography 
Fuc Fucose 
FucT Fucosyl transferase 
Gal Galactose 
GalNAc N-acetyl galactosamine 
Glc Glucose 
GlcNAc N-acetyl glucosamine 
Glu Glutamine 
GuHCl Guanidium hydrochloride 
HAB Hepes assay buffer 
His Histidine 
HMW high molecular weight marker 
HPAEC-PAD high-pH anion-exchange chromatography-pulsed amperometric detection 
HTS High throughput screening 
IFN-γ Interferon γ 
IgG Imminoglobulin G 
IMAC Immobilized metal ion affinity chromatography 
IPTG Isopropyl-β-D-Thiogalactosid 
LB Lauria Bretani 
LMW low molecular weight marker 
LPS Lipopolysaccharide 
M.O.I. Multiplicity of infection 
mAb Monoclonal antibody 
MS Mass spectrometry 
NAD β-nicotinamide adenine dinucleotide (oxidized form) 
NADH β-nicotinamide adenine dinucleotide (reduced form) 
NADP β-Nicotinamide adenine dinucleotide phosphate (oxidized form) 
NADPH β-Nicotinamide adenine dinucleotide phosphate (reduced form) 
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NBT/BCIP Nitro-blue tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate  
N-CAM Neural cell adhesion molecule 
NeuNAc N-acetylneuraminic acid 
Ni-NTA Nickel-nitrilotriacetic acid 
NMR Nuclear magnetic resonance 
OD Optical density 
OLem O-(Methoxycarbonyl)octyl (O-(CH2)8CO2Me) 
OSE O-(trimethylsilyl)ethyl (O-CH2CH2-Si(Me)3), 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
Pi post-infection 
pET expression vector His 
pEZZ18 expression vector ssZZ 
Pfu Plaque forming units 
RB reducing buffer 
RT Room temperature 
SDS-PAGE Sodium-dodecyl-sulfat polyacrylamide-gel-electrophoresis 
Sf Spodoptera frugiperda 
Sia Sialic acid 
sLea Sialyl Lewis a 
sLex Sialyl Lewis X 
TBS Tris buffered saline 
TE tris-EDTA buffer 
TEMED N,N,N’,N’-Tetramethylethylendiamine 
TFA Trifluoroacetic acid 
Tris (Hydroxymethyl)-Aminomethan 
TTBS TBS with 0.05% Tween 20 
Tyr Tyrosine 
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TYE trypton enriched medium 
ZZ two synthetic IgG-binding domains 
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